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1 . Introduct ion 
 
Chronic kidney disease (CKD) is a common disease in cats mainly affecting the elderly population.1-3 
Timely diagnosis may greatly improve life quality and expectancy; however diagnosing CKD in early 
stage of the disease process remains challenging.4 
 
Contrast-enhanced ultrasonography (CEUS) is an emerging functional imaging technique. The use 
of intravenously administered microbubbles allows non-invasive evaluation of tissue perfusion.5  
 
This introduction gives an overview of the anatomy and physiology of the feline kidney in normal 
and diseased states, imaging techniques available to study the kidney, and the current knowledge 
on the use of CEUS in renal imaging.  
 
2 . The fel ine kidney 
 
2.1. Anatomy 
 
The kidneys are paired bean-shaped organs located in the retroperitoneal space attached to the 
dorsal wall on either side of the spine. They consist of an outer cortex, an inner medulla and central 
renal pelvis, containing the renal hilus. The renal artery and vein, and ureters find their origin at 
the renal hilus.6 The functional unit of the kidney is the nephron, consisting of the renal corpuscle, 
where filtration occurs, and segments of the renal tubules, where absorption and secretion occurs, 
and collecting ducts.7 The renal corpuscle is composed of a coil of capillaries, the glomerulus and a 
surrounding capsule, Bowman’s capsule, and is located in the renal cortex. In the cortex, the 
nephrons join a complex system of tubules and collecting ducts which traverse the kidney and end 
in the medullary collecting duct (Figure 1). 
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F igure 1 .  Internal  architecture of  the kidney.  (Image courtesy of Prof. P. Simoens) (1.renal 
cortex 2.renal medulla 3.renal hilus 4.renal artery 5.interlobar artery 6.arcuate artery 7.interlobular 
artery 8.glomerulus 9.proximal tubule 10.Henle’s loop 11.distal tubule 12.papillary duct 13.renal 
papilla 14.renal pelvis 15.ureter; the arteries are accompanied by veins) 
 
The vascular system of the kidneys is rather complicated and closely related to the urine 
conducting system. The renal artery, originating from the abdominal aorta, divides at the hilus into 
the interlobar arteries, which are continued as the arcuate arteries running at the interface 
between cortex and medulla. The interlobular arteries originate from the arcuate arteries, radiate 
in a peripheral direction and mainly supply the renal cortex. The afferent arterioles, supplying the 
glomerular capillaries, arise from these interlobular arteries. Filtration takes place at the level of 
the glomerular capillaries, which are drained by the efferent arterioles. A second dense capillary 
network then arises; this contains the peritubular capillaries, which surround the cortical tubular 
elements, and the vasa recta, which continue towards the medulla. The term ‘renal 
microvasculature’ is used for the combination of the glomerular capillaries and the peritubular 
capillaries.8 Both the peritubular capillaries and vasa recta drain into the venous system. The renal 
vein finally drains into the caudal vena cava.6, 9 Anatomical variations in the renal artery and vein 
are common. The most common anatomy for the renal artery is a single artery with bifurcation just 
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before the hilus, however a single renal artery without bifurcation is seen in about 4% of the cats. A 
double renal artery is only reported for the left kidney and occurs in 7% of the feline population. 
Similarly, a single renal vein with bifurcation is seen most often. Nevertheless, double or even 
triple renal veins are relatively common for the right kidney (respectively in 37 and 3% of the cats), 
and occur rarely at the left kidney. A single renal vein without bifurcation occurs in almost 20% of 
the cats.10  Figure 2 illustrates the vascular anatomy of the kidney. 
 
 
F igure 2 .  Pattern of  distr ibution of  the renal  vessels  within the kidney. (Copyright 
2001 Benjamin Cummings, an imprint of Addison Wesley Longman, Inc) 
 
2.2. Physiology 
 
The kidneys are well-vascularized organs, receiving approximately 25% of the cardiac output.9 The 
high renal blood flow has a dual function: it provides blood for filtration and provides oxygen for 
the renal parenchyma. Therefore, a decrease in renal blood flow will cause ischemia and 
consequently alterations in renal function, as well as a decrease in glomerular filtration.7, 9  
 
In order to maintain a stable glomerular filtration rate (GFR), the kidneys have the ability to keep a 
relatively constant renal blood flow despite changes in systemic blood pressure (renal 
autoregulation system). This is achieved by modulation of the systemic blood pressure and 
intravascular volume, intrinsic control of renal blood flow and glomerular capillary pressure.  
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The renin-angiotensin-aldosterone system (RAAS) provides a major contribution in this renal 
autoregulatory mechanism.7, 9 Renin is produced by the kidney in response to a decrease in 
perfusion pressure, often caused by hypotension. Renin aids in the transformation of 
angiotensinogen to angiotensin I, which in turn is converted into angiotensin II (AT II).7 AT II is the 
active form and causes vasoconstriction both inducing systemic hypertension and a decrease in 
renal blood flow. The efferent arteriole is more sensitive to the vasoconstrictive effects of AT II 
compared to the afferent arteriole.11 Moreover, AT II stimulates the release of aldosterone and 
vasopressin, which enhances salt and water reabsorption, thereby increasing intravascular volume 
and thus improving renal perfusion.7 AT II also induces the production of vasodilative renal 
prostaglandins. The afferent arteriole is relatively more sensitive to these prostaglandins.7, 11 Both a 
systemic and a tissue-based or local RAAS system exist. The local RAAS appears to act in an 
autocrine manner to regulate organ function and is involved in pathological processes as CKD 
(discussed under 2.3). Two major receptor types for AT II are described. The type 1 receptor 
predominates and is present extra-renal as well as within the kidney. This receptor type mediates 
the classic effects of AT II, as described above. The type 2 receptor has a more limited distribution 
and generates effects opposed to those induced by the type 1 receptor.12 
The 2 main systems responsible for the intrinsic control of renal blood flow are the myogenic 
reflex and the tubuloglomerular feedback. The myogenic reflex is responsible for alterations in the 
diameter of the afferent and efferent arteriole (vasoconstriction and vasodilation) in reaction to a 
change in intravascular pressure. The tubuloglomerular feedback system changes single nephron 
GFR based on the contents of the renal tubules.7 
 
More than 90% of the renal blood flow supplies the cortex, only a minority supplies the medulla. 
Therefore, the medulla is already under normal circumstances poorly vascularized and more 
vulnerable to hypoxia.13 The kidneys tend to reduce the cortical blood flow and maintain medullary 
oxygen supply in cases of hypoxia.14  
 
2.3. Chronic kidney disease in cats 
CKD is a very common disease in cats, with an estimated prevalence of 1.6 to 50% 1, 2 in the general 
feline population, increasing up to 30% 3 or even 80% 2 in geriatric cats. It is defined as “structural 
and/or functional impairment of one or both kidneys that has been present for more than 
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approximately 3 months”.15 CKD is a multifactorial pathophysiologic process resulting in 
progressive loss of nephrons in both number and function.16  
Cats present with polyuria, polydipsia, progressive weight loss, muscle wasting, (partial) anorexia, 
halitosis and/or vomiting. These clinical signs occur when already a substantial decrease in renal 
function has occurred.4 The diagnosis is based on a combination of clinical signs, blood and urine 
exam. Azotemia, i.e. elevations in serum urea and creatinine concentrations will be noted on blood 
examination. However, these variables will only rise when approximately 70-75% of renal function 
is lost.17 A decreased urine specific gravity (USG) will be present in most cases, since the kidney 
gradually loses its ability to reabsorb water and thus concentrate the urine.4 Nevertheless, cats 
with CKD may retain their urinary concentrating ability despite being azotemic, in particular in 
early stages of the disease.18 A staging system has been proposed by the International Renal 
Interest Society (IRIS). This system is based on the patient’s serum creatinine level, presence of 
proteinuria, measured by the urinary protein:creatinine ratio (UPC), and blood pressure. The serum 
creatinine (sCr) concentration determines the IRIS stage. Cats with a sCr < 140 µmol/L, which is still 
within laboratory reference interval, but presenting with another abnormality (e.g. abnormal renal 
imaging, decreased USG, renal proteinuria) are assigned to stage 1. Stage 2 includes cats with mild 
renal azotemia (140 – 250 µmol/L), stage 3 includes cats with moderate renal azotemia (251 – 440 
µmol/L) and cats with severe renal azotemia ( > 440 µmol/L) are designed to stage 4.19 
 
GFR measurement is considered the gold standard for evaluation of renal function. It can be 
calculated from urinary or plasma clearance of a marker. Commonly used markers are iohexol and 
creatinine.20 Multiple samples must be obtained, making this technique labor-intensive, time-
consuming and stressful for the patient, thereby limiting the practical use.21 Nevertheless, to 
overcome these limitations, limited sampling strategies have been described.21, 22 
 
Recently, several new renal biomarkers have been investigated aiming to diagnose renal damage 
in early stage and to localize damage to the compartment of the kidney that is affected. Symmetric 
dimethylarginine (SDMA) is very recently introduced in veterinary medicine, and there is strong 
evidence for SDMA as an endogenous surrogate marker for GFR. More importantly, SDMA appears to 
detect a decrease in GFR prior to serum creatinine.23 Fibroblast growth factor-23  has been shown 
to be an early indicator for the development of CKD in cats.24 However, it is not available as a 
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routine diagnostic test. Cystatin C, a valuable renal marker in human medicine, has been shown to 
be a poor marker for GFR in cats.25 Similarly, neutrophil gelatinase-associated lipocalin, a promising 
renal marker in dogs, seems to be of no value in cats.26 Homocysteine, another promising marker in 
dogs, has not been evaluated in cats yet.27 
Urinary biomarkers have also been described, however only few of them have been investigated 
for the use in the diagnosis of feline CKD. Biomarkers which show potential for the diagnosis of 
CKD in cats are: albumin, retinol binding protein, Tamm-Horsfall protein, N-acetyl-beta-D-
glucosaminidase, cauxin, neutrophil gelatinase-associated lipocalin and transforming growth 
factor beta-1.26-28 
 
The pathophysiology of CKD is complex and still not completely understood. A primary, most often 
unknown insult initiates renal damage, which is followed by a sequence of functional and 
structural pathological changes finally resulting in a self-perpetuating process with progressive 
loss of functional nephrons.16 Several factors are believed to influence the occurrence of CKD in 
cats: genetic factors; other disease processes as periodontal disease, urinary tract infections, and 
infections with feline immunodeficiency virus; exposure to nephrotoxic drugs; episodes of prerenal 
azotemia or renal ischemia; previous general anesthesia; diet and vaccination.29 In a study 
investigating iatrogenic unilateral ischemia in cats, acute epithelial necrosis was followed by 
chronic fibrosis, interstitial inflammation and tubular atrophy.30 Independent of the underlying 
etiology, the most common histopathologic findings in cats with naturally occurring CKD are 
nonspecific tubulointerstitial inflammation, interstitial fibrosis and tubular atrophy.16, 29  
A reduction in functional nephrons will induce an adaptive response with elevation of the 
intraglomerular capillary pressure in order to increase the single nephron glomerular filtration 
rate of the surviving nephrons in an attempt to maintain GFR. However, this results in glomerular 
hypertrophy and intraglomerular hypertension, leading to cell injury, microaneurisms and finally 
segmental sclerosis and/or thrombosis of microvasculature.15, 16, 29 
Renal fibrosis starts in early stage of the disease process, and is correlated with renal function in 
both human and cats.31-33 Fibrosis is a normal sequel of renal injury, however the process fails to 
terminate in CKD. The excessive fibrogenic response is characterized by accumulation of 
extracellular matrix, loss of renal microcirculation, infiltration of inflammatory cells, tubular 
atrophy, dilation and mineralization.16, 29, 31 The exact mechanism remains unclear, however several 
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profibrogenic factors have been recognized: transforming growth factor-β, AT II, endothelin-1, 
hyperphosphatemia, hypoxia, proteinuria.29, 31  
The RAAS system is upregulated in early CKD.12, 34 Increased levels of plasma renin, aldosterone, 
angiotensin I and AT II have been described in cats with experimentally induced CKD.35 AT II 
concentrations are markedly higher in the kidney compared to the systemic circulation.12, 29 AT II 
plays an important role in the progression of CKD. Due to its potent vasoconstrictive action it 
causes glomerular hypertension, decreased renal blood flow and subsequent renal hypoxia. 
Moreover, it increases the permeability of the glomerular filtration barrier thereby promoting 
proteinuria and the development of glomerulosclerosis. AT II has direct fibroproliferative actions 
and stimulates the production of inflammatory and fibrogenic factors as transforming growth 
factor-β and nuclear factor-κβ. The production of aldosterone by the adrenal gland is also 
stimulated by AT II. Aldosterone induces oxidative stress, inflammation and renal fibrosis.12, 29, 31 
The combination of these processes results in microvascular rarefaction and dysfunction, which is a 
central factor in CKD in both human and cats.8, 30, 36 
 
2.4. Hyperthyroidism and kidney disease in cats 
 
Hyperthyroidism is another common disease in geriatric cats. The prevalence in a population of 
apparently healthy cats of over 9 years is reported to be 6%.37 Hyperthyroidism is caused by the 
overproduction of active thyroid hormones by abnormally functioning thyroid tissue. In the 
majority of the patients a functional adenoma or hyperplasia is diagnosed, whereas thyroid 
carcinoma is reported only in a minority of the patients.38 The underlying etiology causing 
hyperthyroidism remains currently unknown. As thyroid hormones have a broad range of effects on 
several body systems, clinical signs noticed in hyperthyroid cats are variable. The most typical 
clinical sign is weight loss with preserved to even increased appetite. Other signs include: 
hyperactivity, aggressiveness, altered behavior, muscle atrophy, polyuria/polydipsia, vomiting, 
diarrhea, tachypnea, tachycardia, heart murmurs.39 The diagnosis is usually based on compatible 
clinical signs and increased serum total thyroxine (T4). Scintigraphy, using 99mtechnetium (99mTc), is 
very useful in the work-up of hyperthyroid cats, as it provides both anatomic and functional 
information.40  
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Treatment options include administration of radioactive iodine (131I), antithyroid drugs, special diet 
and surgery (thyroidectomy).39 Radioiodine treatment is a permanent solution, which is safe and 
easy, non-invasive, and no anesthesia is required. Radioiodine treatment has been reported to be 
associated with longer survival times when compared to medical treatment.41 High success rates 
are reported after radioiodine treatment, ranging from 70% to 95%. However the definition of 
‘successful outcome’ is variable.42 In a recent study, 66.5% of the cats had a normal T4 value 6 
months after radioiodine treatment, 24% had a T4 value below reference limits and 9.5% had a T4 
value above reference intervals.43 
 
The increased levels of thyroid hormones have important systemic and renal consequences. The 
hyperthyroid state induces decreased peripheral resistance by vasodilation of the peripheral 
vasculature. In consequence, the effective circulating volume decreases thereby stimulating the 
RAAS. Activation of the RAAS in its turn leads to sodium retention with resultant increase in blood 
volume. In addition, an increased heart rate and left ventricular contractility contribute to 
increased cardiac output. Furthermore, hyperthyroidism induces increased responsiveness, and 
upregulation of β-adrenergic receptors in cardiac and renal tissue. The combination of these 
processes leads to increased renal blood flow and consequently increased glomerular filtration 
rate.44-47 
 
As both hyperthyroidism and CKD are common diseases in elderly cats, it is not surprising that both 
diseases often occur concurrently. The prevalence of concurrent CKD and hyperthyroidism prior to 
hyperthyroid treatment is approximately 14% 41, even increasing to up to 40% post-treatment of 
hyperthyroidism.48, 49 Evaluation of renal function in hyperthyroid cats is therefore important. 
However, this has shown to be problematic. Clinical signs of both diseases overlap. Moreover, 
predicting post-treatment azotemia based on pre-treatment sCr is not reliable due to the 
increased GFR, lowering sCr, and decreased sCr due to reduction in muscle mass in hyperthyroid 
cats.44 Proteinuria is often present in hyperthyroid cats but is not correlated with the development 
of azotemia after treatment.44 USG is lower in hyperthyroid cats compared to healthy cats and also 
often remains lower post-treatment.50, 51 Pre-treatment measurement of GFR has some promise in 
predicting post-treatment azotemia, however great overlap with non-azotemic cats is present.44, 45 
Whereas fibroblast growth factor 23 has shown promise for early diagnosis of CKD, it is not a good 
predictor for the development of post treatment azotemia in hyperthyroid cats.52 The use of SDMA 
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in hyperthyroid cats is currently under investigation. In conclusion, an ideal test to predict post-
treatment azotemia is not available at this moment. 
 
Treatment of hyperthyroidism results in a normalization in GFR and sCr.45, 50, 53, 54 A significant 
decrease in GFR is noted starting 1 week after 131I treatment and continuing up to 1 month after 
treatment.45, 54 Nevertheless, sCr may continue to increase up to 6 months after obtaining euthyroid 
state.46 
 
Cats developing post-treatment hypothyroidism have a higher risk of developing CKD and have 
shorter survival times, whereas no differences have been noticed in survival times between 
azotemic and non-azotemic cats obtaining euthyroid state after treatment. Iatrogenic 
hypothyroidsm may occur up to 3 to 6 months post treatment.49 It is important to differentiate 
iatrogenic hypothyroidism from euthyroid sick syndrome, in which a low total T4 occurs in patients 
with non-thyroidal illness as CKD.44, 49 The combination of low total T4 level with an elevated 
thyroid stimulating hormone (TSH) level is consistent with iatrogenic hypothyroidism, while normal 
TSH levels are present in cats with euthyroid sick syndrome.46 
 
3 . Imaging of  the kidney 
 
3.1. Radiography 
 
Abdominal radiographs are routinely made in veterinary practice. They allow assessment of renal 
size, shape and opacity. The kidneys are outlined by the retroperitoneal fat. Normal renal size in 
cats has been reported to be 2.4 to 3.0 times the length of the second lumbar vertebra. Kidneys 
should have homogeneous soft tissue opacity, however fat deposition in the renal pelvis can lead 
to a focal radiolucency. In cats with CKD, kidneys tend to be small and irregularly outlined. 
Abdominal radiographs also allow the assessment of the presence of radiopaque uroliths. 55  
Excretory urography is obtained after intravenous administration of iodinated contrast medium, 
serial radiographs are made at several time points. Three renal phases are observed: (1) angiogram 
outlining the renal vasculature, (2) nephrogram with a diffusely increasing opacity of the renal 
parenchyma, and (3) pyelogram with filling of the renal pelvis and ureter. This technique is most 
useful for evaluation of the renal pelvis and ureter. Lesions of the renal parenchyma are more 
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difficult to diagnose. A poor or absent nephrogram will be seen in patients with renal dysfunction. 
It is important to notice that renal insufficiency is an important risk factor for contrast-medium-
induced nephropathy, therefore, excretory urography is contra-indicated in these patients. 55 
 
3.2. B-mode ultrasound 
 
B-mode ultrasonography (US) is the most frequently used technique to assess the size, shape and 
internal architecture of kidneys. It has the advantages of being widely available, non-invasive and 
does not involve the use of ionizing radiation.  
Normal kidneys are bean-shaped, smoothly outlined and well defined. Ultrasound textbooks 
mention kidney measurements in healthy cats ranging between 3.0 and 4.3 cm, however reference 
intervals vary and kidney dimensions are not widely studied in large populations of healthy cats.56-
59 The normal renal cortex has a uniform echogenicity, which is hypoechoic to the spleen (left 
kidney) and hypo- or isoechoic to the liver (right kidney). However, hyperechoic renal cortices have 
been reported in healthy cats, mainly in obese male cats. The renal medulla is hypo- to anechoic. 
The renal sinus, surrounding the renal pelvis, is hyperechoic due to the presence of fat and dense 
fibrous connective tissue. The renal pelvis is sometimes visible as a thin anechoic V-shaped line of 
1-2mm wide.58 A longitudinal and transverse B-mode ultrasound image of the kidney of a healthy 
cat is presented in Figure 3.  
 
A thin hyperechoic line in the outer medulla, paralleling the corticomedullary junction, has been 
described in cats. This so called ‘medullary rim sign’ corresponds to calcium deposits in the lumen 
of the proximal tubules and has been described in healthy cats in and in conjunction with 
pathological conditions as acute tubular necrosis, pyogranulomatous vasculitis due to feline 
infectious peritonitis, chronic interstitial nephritis and renal calcification secondary to 
hypercalcemia.58 
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F igure 3 .  Longitudinal  and transverse ultrasound image of  a  normal  k idney,  
showing the cortex (1), medulla (2) and sinus (3).  
 
Typical findings in cats with CKD are small, irregularly outlined kidneys, a decrease in 
corticomedullary differentiation and poorly discernible internal architecture.58, 60 The echogencity 
of cortex and medulla may be normal or hyperechoic (Figure 4).60, 61 Small areas of mineralization 
may be observed in the renal parenchyma. These are deposits of calcium and phosphate and are 
associated with feline mineral and bone disease (previously ‘renal secondary 
hyperparathyroidism’).58, 60 Unfortunately, ultrasonographic findings do not always correlate well 
with renal function.58   
 
 
 
F igure 4 .  Ultrasound image of  a  k idney of  a  cat  with CKD.  The kidney is decreased in 
size, irregularly outlined, and several triangular hyperechoic lesions are present in the renal cortex 
(segmental cortical lesions). 
 
 
 
1	 1	2	 2	 3	3	
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3.3. Renal perfusion imaging 
 
3.3.1. Doppler ultrasound 
 
The use of pulsed-wave Doppler ultrasound of the interlobar or arcuate arteries allows the 
calculation of 2 indices: the resistive index (RI) and pulsatility index (PI). Both indices provide 
information about vascular resistance. The resistive index is the most used parameter, and is 
calculated as the ratio between the peak systolic velocity (PSV) and end-diastolic velocity (EDV); 
RI= [PSV-EDV]/PSV.60 The RI mainly depends on the systemic blood pressure, glomerular filtration 
rate and renal blood flow.62 In animals with renal disease, RI increases due to increased vascular 
resistance, which reduces diastolic blood flow to a greater degree than systolic flow.63-65 In human 
medicine, RI is associated with prognosis of CKD66, however a similar association has not been 
described in cats with CKD. Moreover, increase in RI is a non-specific finding as RI is also influenced 
by heart rate, urinary obstruction and hepatic function.60, 67 Additionally, Doppler is limited to 
evaluation of macroperfusion, as low-velocity flow in smaller vessels cannot be assessed.60  
 
3.3.2. Nuclear medicine 
 
Two tracers are available for measurement of effective renal plasma flow (ERPF): ortho-
iodohippuric acid (OIH) and mercaptoacetyltriglycine (MAG3).68, 69 
OIH has a similar chemical structure to para-aminohippuric acid (PAH), which is the gold standard 
for measurement of renal plasma flow. It can be labeled with 131I or 123I. 131I has the drawbacks that 
it has a long half-life, resulting in poor image quality and high patient radiation due to β-emission. 
123I has a shorter half –life and slightly better image quality, but is more expensive.69 
MAG3 has biologic similarities to OIH, however the plasma clearance is lower. Still, a very high level 
of agreement is present between both tracers for humans and dogs.69, 70 In cats significant hepatic 
clearance occurs, which may interfere with calculation of ERPF.71 MAG3 can be labeled with 99mTc, 
which is easily produced and results in superior image quality.69 Sequential images obtained 
following 99mTc-MAG3 administration are shown in Figure 5.  
The relative blood flow to the kidneys can be assessed by calculating the K/A ratio and flow index. 
The K/A ratio is the ratio of the initial rise of the kidney curve to the arterial curve. The flow index is 
calculated as the area under the aortic curve divided by the area under the kidney curve. The area 
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under the aortic curve is calculated from initial upslope to point of peak activity, the area under the 
kidney curve is calculated for the same time interval. Normal values in people and dogs are 
described, whereas no information in cats is available.69 
The use of radioactive tracers is limited by equipment availability, cost and radioprotective 
considerations. 
  
 
F igure 5 .  Dorsal  images of  a  healthy cat  fol lowing inject ion of  99mTc-MAG 3.The 
frame rate is 1 frame per second, 2 frames are summed per image staring at 5s after IV injection 
(upper left) and ending at 36s (bottom right). The following structures are sequentially visualized: 
cephalic vein (1), cranial vena cava (2), heart (3), pulmonary parenchyma (4), abdominal aorta (5), 
kidneys (6), liver (7). The arrow indicates the injection site. 
 
 
 
 
	1	 2	 3	 4	
5	 6	 7	
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3.3.3. Computed tomography  
 
The use of computed tomography (CT) dual-phase angiography has been used in cats to study 
vascular anatomy.10 In dogs, contrast-enhanced CT has been proven to be a feasible method to 
determine GFR.72 Only recently, quantitative contrast-enhanced CT has been described to determine 
the relative renal blood volume in experimental animals and people. Both studies showed a 
reduction of relative renal blood volume in patients with CKD and a correlation between relative 
renal blood volume and renal function and capillary rarefaction on histology was present.73, 74 
Contrast-enhanced CT shows great potential for its use in the diagnosis of CKD, however the risk of 
radiocontrast nephropathy, need for anesthesia, high cost and involvement of ionizing radiation 
currently limit broader use. Approaches to reduced contrast toxicity are currently under evaluation: 
iodine-free contrast agents are being developed and novel renoprotective protocols will be 
evaluated.73, 74 
 
3.3.4. Magnetic resonance imaging 
 
Renal blood volume and renal blood flow can be measured using high Tesla (≥ 3 Tesla) dynamic 
magnetic resonance imaging (MRI).75 
 
MRI has the advantages of high tissue contrast, multiplanar images capabilities and excellent 
spatial resolution. Still, small vessels may not be displayed well. Nephrogenic systemic fibrosis has 
been described in humans following administration of gadolinium-based contrast agents. It is a 
potentially life-threatening condition, mainly affecting patients with kidney dysfunction.76, 77 
Therefore, functional unenhanced techniques have recently gained more attention.76 Blood oxygen 
level dependency (BOLD) MRI provides the ability to noninvasively assess the state of intrarenal 
tissue oxygenation and is based on changing magnetic properties of blood with oxygenation level 
(hemoglobin is diamagnetic when oxygenated, paramagnetic when deoxygenated).76, 78 In 
diffusion-weighted imaging (DWI) the intrinsic motion of water molecules is used as contrast 
allowing studying capillary perfusion. Diffusion does not solely depend on capillary perfusion, but 
also on water diffusion in the extravascular space and tubular flow. A study in human medicine 
showed that DWI has promise to characterize renal disease.79 Other non-contrast based functional 
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MRI techniques are diffusion tensor imaging and arterial spin labeling.76 Research on the use of 
MRI to assess renal function is still limited and data in veterinary medicine are lacking. 
  
4 . Contrast-enhanced ultrasound 
 
4.1. General 
 
The addition of ultrasound contrast agent gives a new dimension to conventional ultrasonography. 
It allows real-time imaging of organ perfusion, up to a microvascular level.  
 
4.1.1. Ultrasound contrast agents 
 
Ultrasound contrast agent (USCA) consists of very small gas-filled microbubbles that are 
encapsulated by a shell. The microbubbles are 1-10 µm in diameter, which is in the size range of 
red blood cells. This allows the microbubbles to freely pass the lung capillaries without causing 
embolism. Furthermore, they cannot pass the vascular endothelium and thus remain strictly 
intravascular.5, 80, 81 Some USCAs (Sonazoid, Sonavist, Levovist) have a hepato/spleno-specific affinity 
in the late parenchymal phase that is probably due to pooling of the microbubbles in the hepatic 
sinusoids or due to phagocytosis by the Kupffer cells.82 The gas content of the microspheres is 
typically eliminated from the lungs by exhalation after 10 to 15 minutes, whereas shell components 
are filtered by the kidneys and eliminated by the liver.5, 83 
There is a variety of commercially available microbubble contrast agents, which differ in their shell 
and gas core makeup. The selection of the shell material determines how easily the microbubbles 
are taken up by the immune system. A more hydrophilic material tends to be taken up more easily, 
which reduces the microbubble residence time in circulation, and thus limiting the imaging time. 
Secondly, the shell material affects also the microbubble mechanical elasticity: the more elastic 
the shell, the more acoustic energy it can withstand before bursting. Currently, microbubble shells 
are composed of albumin, galactose, lipid or polymers.83 
The gas core of the microbubbles is the most important part, because this determines the 
echogenicity. Microbubbles will compress, oscillate and reflect characteristic echoes under 
influence of an ultrasonic frequency field. Gas cores can be composed of air or heavy gases, e.g., 
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perfluorocarbon or nitrogen. Inert gases (perfluor gases) with higher molecular weight provide 
advantages compared to air, because they dissolve more slowly in the blood, meaning a longer 
half-life, resulting in a longer lasting signal enhancement.5  
The most commonly used USCAs in veterinary medicine are perflutren lipid microspheres (Definity; 
Lantheus, N. Billerica, USA) and phospholipid-stabilised sulfur hexafluoride microspheres (SonoVue; 
Bracco, Milan, Italy).84 Figure 6 illustrates the composition of a typical Sonovue-microbubble. 
 
 
 
Figure 6 .  Composit ion of  a  mircobubble (Sonovue®) .  (SF6: sulfurhexafluoride;  from: 
Greis, 2009)81 
 
4.1.2. Imaging technique 
 
Gas-containing microbubbles, which are mainly administered intravenously in the systemic 
circulation, have a high degree of echogenicity, because the acoustic difference between gas in the 
microbubbles and the blood is immense.5 
 
Contrast-specific detection modes use the interaction of the microbubbles with ultrasound waves. 
This interaction depends on microbubble size, shell flexibility, transducer frequency and 
mechanical index (MI).85-87 The MI is basically conditioned by the acoustic power of the ultrasound 
beam. The acoustic power, measured in pascals (Pa), represents the energy of the sound beam 
acting on a target, e.g., a group of red cells or the contrast agent inside the blood stream. At very 
low acoustic power, oscillation of microbubbles is symmetrical and the change in size is equal in 
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both compression and expansion.83 At low values of the acoustic power (30-70 kPa), microbubbles 
start to expand more than compress, and, thus, vibrate in a particular, non-linear manner, 
producing alternating contractions and relaxations, that way generating harmonic echoes. 
However, at high acoustic power (up to the order of MPa), microbubbles are ‘broken’ and an 
irregular, non-linear signal is generated.83 
 
The goal of contrast-specific imaging techniques is to separate the signal from the microbubbles 
from the signal caused by the surrounding tissue. Earlier techniques are based on filtering the 
harmonic signals: the fundamental frequency is blocked and only the harmonics are used to 
construct the image; complete separation of the signals from tissue and microbubbles is not 
obtained by this technique. Another approach is to transmit two pulses, with the second being 
reversed in phase from the first one; this technique is called ‘pulse inversion’. Echoes from both 
pulses are summed to form the image; signals returning from tissues are opposite and cancel each 
other and are thus not displayed. Signals from non-linearly behaving microbubbles are summed.5, 83, 
88 Nowadays, ‘pulse-cancellation imaging’ or ‘Cadence Contrast Pulse Sequence’ techniques are 
used. Multiple pulses of varying phase and amplitude are produced; these pulses are then 
processed to separate the signals from tissue and microbubbles.5, 88 
 
4.1.3. Procedure 
 
Generally, 2 models or types of imaging procedures exist in perfusion imaging using CEUS. The first 
is low-MI continuous imaging, following bolus kinetics. This is the most commonly used technique 
and also the technique used in this thesis, therefore, only this type will be further discussed. The 
second technique is called destructive imaging and follows flash-replenishment kinetics. 
Microbubbles are administered as a bolus or continuous infusion, at one point, they are destroyed 
by a high MI burst, then the scanner is switched back to low MI to allow refill of microbubbles in 
the area of interest.80, 81 
 
Microbubbles are injected as a bolus into a peripheral vein using a catheter. The catheter size 
should be not smaller than 25 Gauge, as smaller sizes cause microbubble destruction. Variations in 
injection rate will have an impact on later quantification; therefore injection rate should be kept 
stable.89, 90 Moreover, microbubbles are very sensitive to overpressure, which causes microbubble 
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destruction. Overpressure is present when the USCA suspension turns clearer in the syringe upon 
injection.90 The use of a 3-way valve, allowing easy contrast injection immediately followed by 
saline flush, is recommended.90, 91 The USCA should be administered as close to the vein as possible 
to minimize destruction in the non-biological environment and adherence to the tubing.91 The 
dosage should be chosen to obtain proper uniform enhancement while avoiding 
saturation/attenuation (shadowing) in deeper regions due to too high dosage.90, 92 Dosages of 0.03 
– 0.06 mL/kg are described for dogs and cats, mainly depending on the contrast agent used.93-95  
 
Machine settings have a significant impact on the ultrasound signal. It is therefore of major 
importance to choose the settings correctly and keep them constant for all studies. As already 
discussed previously, the MI is the most important parameter. The MI should be kept low to avoid 
microbubble destruction, however too low MI will lead to a lack of penetration of the ultrasound 
beam and a weak contrast signal.92 The gain is a post-processing parameter, which has no 
influence on microbubble behavior; still, incorrect gain setting will result in poor image quality. The 
gain should be optimized to a pre-contrast level just suppressing any signal visible before contrast 
arrival.92 The time gain compensation should be kept constant in a linear matter.90 The frame rate 
should be just high enough to avoid relevant gaps between subsequent imaging planes. High 
frame rates should be avoided as they increase the possibility of destroying the USCA.92 Some 
inconsistency exists on the optimal focus position. The energy distribution and thus microbubble 
destruction is highest at the level of the focus, despite this, image quality is optimal at the level of 
the focus. It is often advised to set the focus just distal to the area of interest.92 
 
One of the major challenges of CEUS is the presence of significant variability, caused by several 
factors: factors related to the patient, the contrast agent and machine settings. Factors related to 
machine settings are discussed earlier and can be minimized using proper study design. In contrast, 
factors related to the patient and contrast agent are more difficult to standardize.  
Variations in the patient’s blood pressure will have an effect on the mean size and resonance 
frequency of the microbubbles and hence the resulting signal.89 Filtration of the microbubbles by 
the lungs has several effects on the bubbles: it will reduce the number of bubbles, mainly the 
number of larger bubbles, moreover diffusion of oxygen into the bubbles might occur. The latter is 
even more pronounced with animals under general anesthesia.90 Thus, passage of the USCA 
through the lungs will mainly reduce the microbubble concentration and size.89 Phagocytosis of 
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USCA in liver, spleen or lung might occur and thereby alter the concentration of freely flowing 
microbubbles elsewhere in the body.89 The patient’s body temperature will also influence 
microbubble concentration.89, 90  
As discussed previously, the bubble composition and type will have a large influence on imaging 
characteristics. Additionally, inconsistencies within the same agent may be present. The way the 
agent is reconstituted (manual agitation) may induce significant variation in size and 
concentration.89 
 
A linear relationship is present between the USCA concentration and resulting enhancement. 
Therefore, quantification software can be used to correlate the CEUS signal to the quantity of 
microbubbles in the tissue of interest, which is a parameter for blood volume. The timing of 
contrast enhancement is correlated with the blood flow velocity.80, 81 Typically, software is used to 
obtain a time-intensity curve from a region of interest (ROI), several parameters can be derived 
from this curves. After bolus injection, the curve has a characteristic dilution shape. There is a rapid 
increase in intensity followed by a decrease corresponding to elimination of contrast agent (wash-
out). After this first phase, a second, recirculation phase, with a slow decrease is observed.5 Several 
perfusion parameters can be derived from this curve (Figure 7). Parameters related to blood 
volume are peak enhancement (PE), wash-in area-under-the-curve (WiAUC), wash-out area-under-
the-curve (WoAUC) and total area-under-the-curve (AUC). The PE corresponds to the maximum 
contrast medium signal intensity. The WiAUC is calculated as the sum of all amplitudes inside the 
range from the beginning of the curve up to the time-to-peak (TTP). Similarly, WoAUC corresponds 
to the sum of all amplitudes inside the range from the TTP to the end of the descending curve. The 
other parameters, i.e. rise time (RT), mean transit time (mTT), TTP,  wash-in rate (WiR), wash-in 
perfusion index (WiPI), fall time (FT), wash-out rate (WoR), are related to blood velocity. The WiR 
and WoR represent the slopes of respectively the ascending and descending curves. The RT 
corresponds to the time interval between the first arrival of contrast and the time of peak 
enhancement. The FT, in contrast, is the duration of contrast wash-out. mTT is the mean duration of 
complete contrast medium perfusion.  
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F igure 7 .  Typical  t ime-intensity  curve obtained after  bolus inject ion of  USCA,  
i l lustrat ion the most important perfusion parameters (TI: point at which the maximum 
slope tangent intersects with the x-axis, TO: point at which the minimum slope intersects the x-
axis; Copyright© 2015 Bracco Suisse SA) 
 
4.1.4. Safety 
 
USCA are very safe. The rate of adverse effects in humans is close to zero (1:10000) and 
significantly lower to what is reported for iodinated contrast agents (1-10/100).92 Adverse events 
reported in humans are dizziness, warmth, itching and nausea. More serious side effects as 
dyspnea, hypotension and decreased consciousness are extremely rare.96 A large multicenter study 
including 411 dogs and 77 cats that underwent CEUS, only revealed mild and transient side effects 
in 0.9% (vomiting, syncope) of the dogs and 0% of the cats. 84 Moreover, in contrast to iodinated 
and gadolium-based contrast agents, USCAs are not nephrotoxic and can safely be used in patients 
with renal impairment.92, 97  
In experimental pigs, pseudo-anaphylaxis and secondary pulmonary hypertension in response to 
USCA administration has been reported.98 Pigs developed more severe pulmonary hypertension 
compared to other species, which was likely attributable to thromboxane A2 receptor activation 
and action of intravascular macrophages in pulmonary capillaries.99 As in humans, it is possible 
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that animals with preexisting pulmonary hypertension or impaired cardiopulmonary function 
might be at increased risk for adverse events, resulting from injection of USCA, CEUS should be 
performed with caution in those animals. 
On a cellular level, USCAs cause a variety of responses, as increased permeability for calcium ions, 
increased intracellular H2O2 levels, and decreased integrity of the cell wall. Rupture of glomerular 
capillaries, small petechiae on the surface of the kidney and transient hematuria have been noted 
in small rodents in studies using very high ultrasound frequencies, MI and exposure duration which 
do not correspond to clinical settings.100, 101 Cell viability is not affected in a clinical setting. 102, 103 
 
Beside its extreme safeness, CEUS holds other important advantages for the use in routine clinical 
practice. It is relatively inexpensive, the equipment is widely available, exams can be performed in 
intensive care unit, sedation or anesthesia is only required in selected cases, there are no 
restrictions in performing serial examinations and there is a complete absence of ionizing 
radiation.  
 
4.2.  Contrast-enhanced ultrasound of the kidney 
 
4.2.1. Normal kidney 
 
The perfusion pattern obtained after bolus injection of USCA is similar between species.94, 95, 104-108 
Typically 3 phases are observed: (1) an arterial phase, with fast enhancement of the renal artery 
and interlobar arteries, (2) a cortical phase with strong, homogeneous enhancement of the cortex, 
and (3) late phase, with gradual, less bright and more heterogeneous enhancement of the medulla 
(Figure 8). At peak medullary enhancement, there is a loss of clear delineation of cortex and 
medulla.105 However, the medulla may also remain hypoechoic compared to the cortex.  
 
The lower enhancement of the medulla is related to the vascular anatomy of the kidney. The 
medulla is significantly less vascularized compared to the cortex. Moreover, the microbubbles pass 
the cortical vasculature before reaching the medulla; therefore a portion of microbubbles is 
already destroyed by the time they reach the medulla.93, 94 
   
	33	
 
Chapter I General introduction 
 
  
 
F igure 8 .  CEUS images of  the kidney of  a  healthy cat  showing the typical  
perfusion pattern .  Early enhancement of the interlobar arteries (upper left), followed by bright 
and homogeneous enhancement of the cortex (upper right), corticomedullary phase (lower left), 
followed by a gradual wash-out (lower right). 
 
4.2.2. Experimental animals 
 
Contrast-enhanced ultrasound has been used in several studies in experimental animals. Only the 
studies with clinical relevance for small animal medicine will be briefly discussed.  
 
Multiple studies have used experimental animals as a model for frequently occurring human 
disorders. Goto-Kakizaki rats are used as an animal model for type 2 diabetes with insulin 
resistance. Contrast-enhanced ultrasound of the kidneys of these rats revealed flattened time-
intensity curves, with a longer time to peak. At 12-weeks age, slope rates of the curves further 
decreased and area under the curve increased. These changes were caused by insulin resistance-
induced renal microvascular injury. 109 
Dong et al. (2012) induced ischemic acute renal tubular necrosis in 30 rabbits. Contrast-enhanced 
ultrasound, blood exam and color Doppler flow imaging were performed 6 and 24 hours 
afterwards. At 6 hours, only CEUS was capable of detecting changes: area under the curve and time 
to peak were increased. Abnormalities were noted on blood exam after 24 hours, whereas no 
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significant changes were noted with color Doppler flow imaging.110  
Similarly, in another study, cortical blood volume was significantly decreased in pig kidneys after 
an episode of systemic hypoxia. This was noted as decreased peak enhancement. Medullary blood 
volume remained unchanged, however, a decreased blood velocity was present.111 This supports the 
hypothesis that the kidney down regulates the cortical blood flow in an attempt to protect the 
medulla from hypoxic injury.111 
 
4.2.3. Human medicine 
 
Contrast-enhanced ultrasound is well established for its use in the diagnosis of renal 
pseudolesions (e.g. hypertrophy of Bertin columns and persistence of foetal lobatures). Benign 
lesions typically show a contrast enhancement that is similar to the surrounding normal 
parenchyma.104 One of the most important applications of CEUS in nephrology, is the differentiation 
and classification of cystic lesions.104 It is also commonly used in intensive care setting to detect 
renal parenchymal injuries and active bleeding, which is revealed by microbubble extravasation. 104, 
112 Additionally, CEUS is indicated for early diagnosis of acute pyelonephritis. In this case triangular 
areas of hypoperfusion are detected.113 Renal infarcts are typically seen as wedge-shaped regions 
without contrast-enhancement, whereas renal cortical ischemia is seen as the absence of 
enhancement of the interlobular vessels in the renal cortex.104, 114  
 
The majority of research in the field of renal CEUS focuses on the study of transplanted kidneys. 
Several authors have proven that CEUS is very useful for early assessment of graft dysfunction. 
Rejection is typically diagnosed as a decreased renal enhancement, which occurs even before 
changes are present on blood work, in estimated glomerular filtration and in resistive index.115-119 A 
simple index, time difference of the rise time between cortex and medulla, is established to predict 
acute rejection with a high degree of accuracy in a recent study.120 Additionally, parametric images 
have been shown to aid in the diagnosis of acute rejection, as patients with rejection typically have 
heterogeneous contrast dynamics, in contrast to patients with normal transplant evolution with 
homogeneous contrast dynamics.121 Moreover, contrast-enhanced ultrasound is sensitive and 
specific to diagnose acute cortical necrosis.122 In this case a typical ‘peripheral rim sign’ is seen, 
representing the unenhanced renal cortex.122  
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Studies on spontaneous, diffuse renal disorders are less numerous compared to the amount of 
research performed on transplant rejection. Nevertheless, this research area is of growing interest. 
Dong et al. (2014) revealed that renal enhancement in patients with early stage CKD is delayed and 
decreased. This is reflected by increased area under the curve, an increased slope of the ascending 
curve and decreased peak enhancement.107 Similarly, in a study with 24 patients with various renal 
diseases (among them chronic glomerulonephritis, diabetic nephropathy and nephrosclerosis), the 
renal cortex of these patients was less strongly enhanced.123 Another study on 85 patients with 
chronic kidney disease revealed similar results. There was a decreased enhancement of both cortex 
and medulla, which was reflected by significant changes in the calculated perfusion parameters: 
delayed rising, reduced peak enhancement, and accelerated decay. These changes were more 
severe with progressive renal dysfunction.124 The latter observations are explained by the increased 
renal resistance noted in patients with chronic kidney disease.124 Comparable results are obtained 
in a cohort of patients with diabetic kidney damage. Both the arrival time and time to peak were 
prolonged. The intensity increment and peak enhancement were decreased in comparison to 
healthy subjects. Interestingly, the area-under-the-curve tended to increase in patients with early 
stage kidney disease, whereas a decrease was observed in the patients with more advanced 
disease.125 This can be explained by a hyperperfusion status in early stage diabetic nephropathy, 
progressing to a decreased vascularization when the disease progresses.125  
Moreover, a clear correlation was observed between CEUS parameters and other techniques to 
evaluate renal perfusion or renal function. Hosotani et al. (2002) revealed a positive correlation 
between CEUS and well-established techniques to measure renal plasma flow (PAH clearance and 
tc-99m MAG3).123 A strong positive correlation between area-under-the-curve and glomerular 
filtration rate was also determined.125  
 
CEUS has been proven to be a sensitive technique to detect changes in renal perfusion in response 
to various stimuli. These studies are extremely useful in the evaluation of the mechanism of action 
of several drugs, and in the assessment of pathophysiology of various disease processes. Imamura 
et al. (2013) found that diclofenac sodium, a non-selective non-steroidal anti-inflammatory drug, 
but not etodolac, a COX-2 selective non-steroidal anti-inflammatory drug, reduced renal blood flow 
measured with CEUS.126 Valsartan, an angiotensin receptor blocker, could evoke an increased renal 
cortical perfusion after a single oral administration. This was seen as an increased blood velocity 
on CEUS, and confirmed with increased clearance of PAH.127 In contrast, only a tendency towards 
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decreased peak enhancement was noted 1 hour after oral administration of captopril, an ACE-
inhibitor. However, significant decreased peak enhancement was observed after infusion of 
angiotensin II in the same study. Contrast-enhanced ultrasonographic parameters correlated well 
with PAH-clearance.128  
 
A new research area on the use of CEUS in the intensive care unit is currently being developed. 
CEUS would be of great value in the early diagnosis of acute kidney injury and in the assessment of 
the impact of therapeutic interventions.129 First results confirm that CEUS is a feasible and well-
tolerated technique in critically-ill patients. A decrease in renal perfusion is observed within 24 
hours after cardiac surgery.130 
 
4.2.4. Veterinary medicine 
 
Studies on the use of CEUS in canine and feline nephrology are limited.  
 
In cats, all studies have been performed on healthy subjects, describing the normal contrast-
enhancement pattern.95, 105, 106  
 
Slightly more information is available in dogs. Quantitative analysis of normal perfusion in healthy 
dogs has been performed.94, 131  
In correspondence with human medicine, CEUS appears to be a useful technique for differentiation 
between benign and malignant focal renal lesions. Malignant lesions are generally well 
vascularized. Large tortuous feeding vessels are detected in renal cell carcinomas (Figure 9). 
Smaller and less obvious arteries are seen in histiocytic sarcomas. Hemangiosarcoma metastases 
typically appear as non-enhancing nodules.132 In another study by the same author, the appearance 
of consecutive percutaneous renal biopsies was studied with CEUS. Contrast-enhanced ultrasound 
could detect more renal lesions compared to B-mode ultrasound. The lesions were hyperechoic 
immediately after biopsy, and turned hypoechoic within 30 minutes, corresponding with a 
thrombus developing after small hemorrhage. All kidneys regained normal appearance within 3 
weeks.133 
Contrast-enhanced ultrasound was used to diagnose active renal hemorrhage in a young dog with 
spontaneous renal bleeding resulting in a hemoperitoneum.134 
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F igure 9 .  Ultrasound images of  a  renal  carc inoma. B-mode US of a canine kidney with 
the presence of a hypoechoic mass (dotted line; middle image), CEUS during early phase allowing 
clear visualization of a tortuous vessel (left), and CEUS during late phase, showing early wash-out 
in the lesion compared to normal renal parenchyma. (From: Haers et al. 2010)132 
The effect of dexmedetomidine, a peripheral α-2 adrenoreceptor atagonist, on several abdominal 
organs among which the kidney, was examined with CEUS. Arrival time and time to peak were 
prolonged, whereas peak enhancement and wash-in were decreased in contrast to the control 
group. These changes could be attenuated with the addition of a peripheral α-2 adrenoreceptor 
antagonist, MK- 467.135  
Wei et al. (2001) were the first to prove the capability of CEUS to detect diffuse perfusion changes 
in canine kidneys. In a study on experimental dogs, renal perfusion was evaluated with CEUS and a 
digital flow meter, at baseline, after total renal blood flow was reduced with a renal artery 
stenosis or increased with intravenous infusion of dopamine. An excellent correlation was found 
between the CEUS parameters and the measurements obtained with the flow probe.136 CEUS could 
also detect small perfusion changes in dogs with iatrogenically induced chronic ischemic renal 
disease. An ameroid constrictor was placed on the right renal artery of 5 healthy dogs. The earliest 
significant changes on CEUS occurred 4 weeks after surgery, there was an increase in peak 
enhancement and a delayed time to peak. The first significant changes on blood exam, elevation of 
sCr and urea, occurred only after 11 weeks. First changes on color Doppler flow imaging, RI and PSV, 
occurred even not before 12 weeks (PSV) and 14 weeks (RI).107  
An increase in renal blood volume parameters (PE and AUC) was seen in beagles with iatrogenic 
hypercortisolism compared to the control group. Glucocorticoids induce a decreased renal vascular 
resistance, renal vasodilation and plasma volume expansion and thereby increased renal blood 
flow. This was reliably measured with CEUS.93  
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5 . Conclusion 
 
Renal disease is one of the most important health issues in cats. Important structural (decreased 
capillary number) and functional (vasoconstriction) loss of renal microvasculature occurs in CKD, 
resulting in decreased renal blood flow. The changes in renal vasculature are key feature in CKD 
independent of the initiating cause and play an important role in disease progression. Therefore, 
evaluation of renal perfusion using CEUS may deliver important new insights in the disease and its 
diagnosis.  
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Chronic kidney disease is a very common pathology in companion animals, especially in cats. 
Nevertheless, early diagnosis remains challenging. Vascular changes play an import role in the 
pathophysiology and occur early in the disease process.  
 
Contrast-enhanced ultrasound is a functional imaging technique that allows non-invasive 
assessment of macro- and microperfusion. It is extremely safe, allowing its use in geriatric patients 
and patients suffering from renal disease. Studies in human medicine show great potential for the 
diagnosis of diffuse renal disorders. However, data in veterinary medicine are limited. Up to date 
only few studies have described the normal perfusion pattern of the kidney in healthy cats, 
whereas data on pathological conditions are lacking. 
 
Therefore, the final goal of this thesis was to assess the potential of CEUS as a tool to evaluate 
feline renal perfusion.  
 
Specific objectives of this thesis were: 
1. To determine if significant differences in renal perfusion parameters are present between 
the first and second injection of contrast agent.  
Few studies have stated that the first injection of microbubbles may lead to more 
variable and lower enhancement of the studied organ and should thus not be 
used for evaluation, whereas others mention no significant difference between 
subsequent injections.  
 
2. To determine the variation of the perfusion parameters obtained with CEUS of the kidney 
in a population of healthy cats  
Contrast-enhanced ultrasound is inherently very sensitive to variation, which may 
complicate its diagnostic capabilities. Knowledge on the existing variation for the 
different perfusion parameters in healthy cats is therefore required. 
 
3. To determine the influence of anesthesia or sedation on renal perfusion parameters. 
Contrast-enhanced ultrasound can be performed on conscious animals, however 
sedation or anesthesia may be required in uncooperative patients. As most 
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anesthetic agents have cardiovascular effects, an influence on contrast-enhanced 
ultrasound is assumed. 
 
4. To investigate the effect of age on CEUS parameters 
Aging causes a decrease in renal plasma flow and an increase in renal vascular 
resistance in people. However, the influence of aging on feline renal perfusion has 
not been studied. 
 
5. To assess the capabilities of CEUS to detect changes in renal perfusion after infusion of AT 
II.  
To date it is unclear if CEUS is capable of detecting relatively small perfusion 
changes in cats. AT II is a potent renal vasoconstrictor that is often upregulated in 
patients with renal disease. 
 
6. To describe renal perfusion parameters of cats with CKD and compare them with those 
from healthy cats 
Few human studies have described a decreased perfusion in people with CKD, 
however the perfusion pattern and changes in perfusion parameters in cats with 
CKD remain unknown.  
 
7. To investigate renal perfusion of hyperthyroid cats, before and after radioiodine treatment  
Changes in renal hemodynamics play an important role in functional renal 
changes in cats with hyperthyroidism. CEUS allows evaluation of renal perfusion 
and may therefore deliver important insights in renal function in hyperthyroid 
cats. 
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1 . Abstract   
 
Contrast-enhanced ultrasound is a valuable and safe technique for the evaluation of organ 
perfusion. Repeated injections of ultrasound contrast agents are often administered during the 
same imaging session. However, it remains unclear if quantitative differences are present between 
the consecutive microbubble injections. Therefore, the first and second injection of contrast agent 
for the left renal cortex, renal medulla and the splenic parenchyma in healthy cats, were compared. 
A lower peak enhancement and area-under-the-curve were observed for the first injection of 
contrast agent in the feline kidney, both for the renal cortex and medulla, and spleen. Moreover, for 
the renal cortex, the time-intensity curve was steeper after the second injection. Findings from the 
current study demonstrate that a second injection of contrast agent provides stronger 
enhancement. The exact mechanism behind our findings remains unclear, however saturation of 
the lung macrophages is believed to play an important role.  
 
2 . Introduct ion  
 
Contrast-enhanced ultrasonography (CEUS) allows real-time visualization of macro- and 
microvascularization. Creating time-intensity curves and calculating several perfusion parameters 
allows quantification of tissue perfusion. The technique is extremely safe and can be performed in 
patients with renal impairment.1, 2 CEUS shows great potential for evaluation and diagnosis of 
various renal disorders in human and veterinary medicine.3, 4 
Repeated injections of contrast agent are most often required in CEUS studies for different 
reasons. The first injection is sometimes used to optimize image settings. Multiple lesions may also 
be present, urging for several injections of contrast agent to be able to study all of them. In the 
assessment of diffuse renal disorders, both kidneys must be imaged. Additionally, patient motion 
during the study may induce the need for multiple injections of contrast agent. Some authors 
already mentioned that tissue enhancement after the first injection of microbubbles is subjectively 
less bright in comparison with subsequent contrast agent injections. 3, 5, 6 A study on CEUS of liver 
and aorta in human subjects confirmed this finding quantitatively.7 In contrast, no significant 
differences were found between the first and second injection of contrast agent in mice liver and 
tumor tissue. However, a tendency towards a higher peak enhancement after consecutive 
microbubble injections was noted.8 Thus far, it remains unclear if there are significant differences 
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between the first and second injection of contrast agent. Nevertheless, it is of major importance to 
know if differences are present between both injections as this could influence study results.  
Therefore, the purpose of this study was to compare several perfusion parameters in the left 
kidney and spleen in healthy cats between the first and second contrast injection. The hypothesis is 
that the second injection of contrast agent will result in an increased enhancement of both the left 
kidney and the spleen; this will mainly be reflected by an increased peak enhancement and area-
under-the-curve.  
 
3 . Materials  and methods 
 
The experiments where approved by the Local Ethical Committee of Ghent University (EC2014/38). 
Seven healthy purpose-bred laboratory cats with a mean ± standard error age of 4.7 ± 0.9 years 
and mean ± standard error body weight of 3.1 ± 0.2 kg were used. All cats were female neutered. 
The cats were judged healthy based on physical examination, hematology, routine biochemistry, 
urinalysis and abdominal ultrasound. The kidneys had a normal size and appearance on B-mode 
ultrasound. 
A 22-Gauge catheter was placed in the cephalic vein. All cats were anesthetized with propofol 
(Propovet®, Abbott Lab, Berkshire, UK), 6 mg/kg intravenous, maintained with additional boluses of 
1 mg/kg on effect. 
A commercial contrast agent (Sonovue®, Bracco, Milan, Italy) was administered at 0.15 mL per 
bolus, immediately followed by a 1 mL saline bolus. A three-way stopcock was used to avoid delay 
between the contrast agent and the saline flush. The same person performed the injections in a 
standardized way. The cats received 2 consecutive injections, with approximately 10 minutes 
between the two injections. In-between the injections, the microbubbles were destroyed by setting 
the acoustic power at the highest value and scanning the caudal abdominal aorta, liver and spleen 
for approximately 2 minutes. 
A linear array transducer of 5-7.5 MHz on a dedicated ultrasound machine (MyLab 30 CV, Esaote, 
Genoa, Italy), equipped with CnTI-contrast tuned imaging technology, was used. Machine settings 
were kept constant between the injections. A mechanical index of 0.09 was applied. The gain 
setting was adapted to a value just suppressing signals before arrival of contrast agent (55-58%). 
An image clip of 120 s at a frame rate of 7.5 frames per second was recorded for every injection. 
Imaging was started simultaneously with the contrast agent injection. 
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The kidney was consistently imaged in a longitudinal plane. The spleen was imaged simultaneously 
with the left kidney.  
Quantitative analysis was performed using an image analysis program (Image J, US National 
Institutes of Health, Bethesda, Md). The data were not linearized before quantification. Mean pixel 
intensity was measured every second from 0s to 70s, every 2 seconds from 70s to 90s and every 4 
seconds from 90s to 120s. A circular region of interest (ROI) was drawn in the renal cortex and 
medulla at approximately the same location (ventral aspect of the renal cortex, central aspect of 
the renal medulla). The size of the ROI was kept constant (5 mm diameter). A ROI containing the 
complete visualized part of the spleen, was drawn for the splenic parenchyma. Care was taken to 
avoid large vessels. The mean pixel intensity values were used to create time-intensity curves. The 
curves were analyzed for blood flow parameters representing blood volume (baseline intensity 
(BI), peak enhancement (PE), area-under-curve (AUC)) and blood velocity (arrival time (AT), time-
to-peak (TTP), wash-in/out (Wn/Wout)). Wout was not calculated for the spleen, as only the first part of 
the wash-out occurred within the time the clip was captured (120 s). BI was defined as the 
intensity measured the first 3 seconds after contrast agent injection. AT was set at the point were 
the curve reached a value at least 5 mean pixel intensity values higher than BI. Win was calculated 
from data points between 10% higher than BI and 90% of PE; Wout from points between 90% of PE 
and T=120s (end of the study). PE and AUC were corrected for the BI.  
Statistical test selection and analysis was performed by one of the authors (LD). The statistical 
analysis was based on a mixed model with cat as random effect and sequence (first or second 
injection) as fixed effect, using F-tests at the 5% significance level (SAS Version 9.4, SAS Institute 
Inc, Cary, NC).  
 
4 . Results   
 
Subjectively, a lower enhancement was seen for the first injection compared to the second 
injection (Figure 1). 
AUC was significantly higher for the second injection compared to the first injection for both the 
renal cortex (P = 0.01) and medulla (P = 0.04). The PE was also higher for the second injection; this 
was only significant for the renal cortex (P = 0.009) while a trend was present for the renal 
medulla (P = 0.055). Additionally, for the renal cortex, the Win (P = 0.01) and Wout (P = 0.006) were 
less steep for the first injection compared to the second. No significant differences were present 
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between the first and second injection for AT (cortex: P = 0.4; medulla: P = 0.3) and TTP (cortex: P = 
0.3; medulla: P = 0.08).   
Similarly, the PE (P = 0.007) and AUC (P = 0.008) in the splenic parenchyma were significantly 
higher for the second injection compared to the first.  
The BI was consistently comparable for the first and second injection.  
Time-intensity curves, comparing the first and second injection, are represented by Figure 2.  
 
 
 
F igure 1 .  Contrast-enhanced ultrasound images of  the spleen (S)  and left  k idney 
(K)  of  a  cat ,  i l lustrat ing a lower enhancement after  the f i rst  in ject ion of  
contrast  agent ( left)  compared to the second inject ion (r ight) .  Both images are 
obtained 30 s after contrast injection. 
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F igure 2 .  Mean t ime-intensity  curves calculated from the renal  cortex ,  renal  
medulla  and spleen demonstrat ing a lower peak enhancement ,  lower area-
under-the-curve for  the f i rst  in ject ion of  microbubbles .  The time (in seconds, s) is 
displayed on the horizontal axis, the intensity (in arbitrary units, a.u.) on the vertical axis; 1st: first 
injection of microbubbles, 2nd: second injection of microbubbles within the same imaging session. 
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5. Discussion 
 
In the present study, significant differences were observed between the first and second injection 
of ultrasound contrast agent. The most reproducible differences between the two injections were a 
higher PE and AUC for the second injection, seen in the renal cortex, renal medulla and splenic 
parenchyma. For the renal cortex, the wash-in and wash-out were also steeper after the second 
injection.  
In agreement with our results, a tendency towards a higher PE after consecutive microbubble 
injections was also noted in a recent study in mice tumors.8 However, in this study, the opposite 
effect, i.e. a decreasing PE after consecutive injections, was observed in the liver.8 This might be 
due to short-term accumulation in liver Kupffer cells.  In a human study, an increased PE and AUC 
were noted in the liver after the second injection of microbubbles.7  
There were no significant differences in BI between the first and second injection, indicating that 
no residual microbubbles were remaining in tissue of interest before the second injection. In 
between the injections, the remaining microbubbles were destroyed by setting the acoustic power 
at the highest value and scanning the caudal abdominal aorta, liver and spleen for approximately 2 
minutes. We avoided applying ultrasound waves of relatively high acoustic power on the kidney, as 
this could potentially cause capillary rupture.9, 10 
Rix et al. (2014) observed an increased heart rate after the first injection of microbubbles, which 
coincides with a faster circulation. This explains the faster Win. Moreover, an elevated heart rate and 
decreased TTP might result in a concentrated microbubble bolus, resulting in a higher PE.8 In 
humans, it was found that injections of relatively low volumes of phospholipid solutions might 
result in complement activation-related pseudo-allergy, causing a transient increase in heart rate 
and pulse pressure.11 The heart rate was not measured in our study. But in another study of our 
research group, we did not observe a change in heart rate after consecutive contrast agent 
injections in healthy cats (unpublished results). Moreover, no effects on AT and TTP are present in 
the current study. It should be noted that the volume of the saline itself might cause an 
accelerated circulation in mice.8 
In mice, short-term accumulation of microbubbles in the liver sinusoids and spleen might also 
explain the higher PE in tumors.8 It is unlikely that hepatic and splenic accumulation of contrast 
agent would explain the higher PE in the current study as the majority of the microbubbles in the 
liver and spleen were destroyed by scanning these organs using high acoustic power. Moreover, it 
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can be assumed that the low volume of contrast agent does not result in liver saturation in cats. In 
humans, injection of 1.2 – 1.4 mL microbubble solution does not result in liver saturation.12 
Another explanation for the stronger enhancement after the second injection might be saturation 
of the lung macrophages by the microbubbles.7 This would allow more microbubbles to pass the 
lung and finally reach the systemic circulation. In pigs, administration of microbubbles resulted in 
an acute, transient and dose-dependent right ventricular dilatation, increased pulmonary pressure 
and increased fractional shortening.13 This could be caused by transient hypoxic pulmonary 
vasoconstriction. Pigs are known to develop severe pulmonary hypertension, which is likely to be 
caused by activation of pulmonary macrophages. Also in dogs, increased pulmonary vascular 
resistance and pulmonary artery pressure was seen after administration of high doses of Levovist.14 
No significant hemodynamic changes were observed at clinical, weight-adjusted doses in these 
dogs. The exact etiology of the effects on the pulmonary vascularization in these dogs remains 
unclear, transient pulmonary vasoconstriction might be a possible explanation.14 
The last explanation that may be raised is a local effect caused by a vascular mediator. An 
interaction could be present between the contrast agent and the endothelium, moreover, the 
influence of the ultrasound waves on microbubbles could reinforce this effect. The combination of 
both could cause local activation of vasodilative substances. Well-perfused organs as the kidneys 
and neoplastic tissues might therefore be more sensitive to this effect.  
Several factors may influence the presence and extent of differences between the first and second 
injection of contrast agent. First, the type of contrast agent may be an important factor. It is known 
that great differences are present in the extent and duration of phagocytosis by the 
reticuloendothelial system depending on the type of contrast agent.15 Generally, SonoVue shows a 
low uptake by Kupffer cells in contrast to other types of microbubbles, as Sonazoid, Optison and 
Levovist.16 Moreover, the species may play an import role. As previously mentioned, pigs are prone 
to develop extensive pulmonary hypertension after activation of lung macrophages. To our 
knowledge, no information is available on this phenomenon in cats. Finally, the organ of interest 
may influence the results, as suggested in the murine study of Rix (2014), which showed 
contrasting results in tumor tissue compared to the liver. In the latter study, PE in tumor tissue 
tended to increase after repeated microbubble injections, whereas the PE in the liver decreased 
steadily.8 
Our study has some limitations. Cardiovascular parameters were not measured regularly 
throughout the study. However, data of other studies performed by our research group in feline 
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patients, revealed no significant changes in heart rate, blood pressure, respiratory rate after the 
first injection of contrast agent. The assessment of heart rate, blood pressure and even more 
interesting, pulmonary artery pressure and the pressures in the different cardiac chambers would 
deliver important information to distinguish between the possible causes for the low enhancement 
after the first injection. Body temperature was also not measured. It is known that hypothermia 
alters the blood flow and ultimately the distribution of contrast agent.17 However, it is very unlikely 
that the cats would develop hypothermia, since the study duration was very short (15-20 minutes) 
and they were only superficially anesthetized. Moreover, only the first and second injections of 
contrast agent were studied. It would be interesting to have information about the subsequent 
injections of contrast agent. It remains unknown if differences are present between the second 
injection and following injections of contrast agent.  Last, we do not know how long this effect 
lasts. In other words, it is unclear if the same findings would be present, if a second imaging 
session would be performed in the same animal several hours later. 
In conclusion, we demonstrated clear differences in renal perfusion parameters between the first 
and second injection of contrast agent of the left kidney and spleen in cats. Less bright 
enhancement is achieved by the first injection. Unfortunately, we were not able to distinguish 
between the possible explanations for these findings. Activation/saturation of the lung 
macrophages is the most plausible explanation.  Further research is necessary to clarify the 
mechanism of our findings and investigate if similar phenomena are present in other species and 
different organs. Our findings have important implications: the first injection should not be 
compared quantitatively to the second injection; additionally it is recommended to use the second 
injection for further analysis as it provides better enhancement. 
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1 . Abstract   
 
Contrast-enhanced ultrasound (CEUS) has the ability to image and quantify tissue perfusion. It 
holds great potential for the use in the diagnosis of various diffuse renal diseases in both human 
and veterinary medicine. Nevertheless, the technique is known to have an inherent relatively high 
variability, related to various factors associated with the patient, the contrast agent and machine 
settings. Therefore, the aim of this study was to assess week-to-week intra- and inter-cat variation 
of several perfusion parameters obtained with contrast-enhanced ultrasound of both kidneys of 12 
healthy cats. Repeatability was determined by calculating the coefficient of variation (CV). The 
CEUS parameters with the lowest variation for the renal cortex were time-to-peak (CV 6.0%), rise 
time (CV 13%), fall time (CV 19%) and mean transit time (24 %). Intensity-related parameters and 
parameters related to the slope of the time-intensity curve had a CV of > 35%. Lower repeatability 
was present for perfusion parameters derived from the renal medulla compared to the renal 
cortex. Normalization to the interlobar artery did not cause a reduction in variation. In conclusion, 
time-related parameters for the cortex show a reasonable repeatability, whereas poor 
repeatability is present for intensity-related parameters and parameters related to in- and outflow 
of contrast agent. Poor repeatability is also present for all perfusion parameters for the renal 
medulla, except for time-to-peak, which has a good repeatability.  
 
2 . Introduct ion  
 
CEUS allows assessment of tissue perfusion in a wide variety of clinical conditions. It enhances the 
diagnostic accuracy of B-mode ultrasound by adding the use of an intravenously administered 
contrast agent. The contrast agent is composed of microbubbles consisting of a high molecular 
weight gas encapsulated by a stabilizing shell.1 The technique has several advantages: it is 
extremely safe, without nephro- or hepatotoxicicity, and does not use ionizing radiation.1-3 
Contrast-enhanced ultrasound shows great potential for the diagnosis of diffuse renal disorders. 
Quantitative CEUS has shown to be useful in the diagnosis of humans with renal transplant 
rejection, diabetic nephropathy and chronic renal disease.4-8 In dogs, CEUS is capable of measuring 
perfusion changes in iatrogenically induced ischemic renal disease and iatrogenic 
hypercortisolism.9, 10 Our research group demonstrated the utility of CEUS to detect renal 
vasoconstriction induced by angiotensin II infusion in cats.11 
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The major challenge in CEUS is the relatively high degree of variability, which originates from 
several factors related to the patient, the contrast agent, machine settings and the operator.12 
Machine settings and, to a lesser extent operator dependent factors, can be controlled. However, 
contrast agent composition and patient factors such as blood pressure, heart rate and respiratory 
rate cannot be controlled. It is of major importance to know the magnitude of these variations in 
and between healthy subjects to estimate to what extent quantification of the feline kidney 
perfusion with CEUS is reliable, before the technique can be used for the diagnosis of disease in 
patients. Therefore, this repeatability study is designed to determine normal inter- and intra-
individual variation in healthy cats.  
 
3 . Materials  and methods 
 
Twelve healthy European Shorthair cats, 9 female neutered and 3 male neutered cats, were 
included with the permission of the local ethical committee of Ghent University (EC 2014/148). The 
mean ± standard error age of the cats was 6.9 ± 0.8 years. Their mean ± standard error weight was 
3.3 ± 0.1 kg. The cats were healthy based on physical examination, blood pressure measurement, 
complete blood count and serum biochemical analysis, urinalysis and abdominal ultrasound. In all 
cats, both kidneys had a normal size and appearance on ultrasound. The cats were free from 
medication for at least 2 months and received the same, commercial food at least 2 months prior 
to the study and during the study period. 
 
CEUS of both feline kidneys was performed at 3 time points within a 7-day interval. At every time 
point a 22-Gauge catheter was placed in one of the cephalic veins. Anesthesia was induced with a 
bolus of propofol (Propovet 10 mg/mL; Abbott Laboratories), 4-8 mg/kg intravenously, given to 
effect, and maintained with additional boluses (1 mg/kg) as necessary. The hair was clipped over 
the ventrolateral portion of the abdomen. Alcohol and coupling gel were applied to the skin. The 
ultrasound exams were performed with the cat in dorsal recumbency.  
 
The left kidney (for the 1st and 2nd injection) and the right kidney (for the 3rd injection) were 
centered on the screen and imaged in a longitudinal plane. The transducer was manually 
positioned by the same person during each imaging procedure and was maintained at the same 
position during the CEUS examination.  
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Sulfur hexafluoride-filled microbubbles (Sonovue®, Bracco, Italy), provided in a commercially 
available kit, were reconstituted according the manufacturer’s guidelines. The contrast agent was 
used within a time interval of 6 hours. Before each injection, the suspension was rehomogenized 
by gently agitating the vial from top to bottom. A 0.05 mL/kg bolus of ultrasound contrast agent 
was manually administered intravenously over approximately 3s, followed by injection of a 1.5 mL 
saline bolus. A three-way stopcock was used to avoid any delay between the injection of contrast 
agent and saline. The same person performed the injection in all cats. Three to 4 injections of 
contrast were performed: the first one was not used for further quantification since this injection 
often results in lower enhancement.13 Between subsequent injections, to avoid artifacts, remnant 
microbubbles were destroyed by setting the acoustic power at the highest level and scanning the 
caudal abdominal aorta, external and internal iliac arteries for 2 minutes. 
All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(iU22, Philips, Bothell, WA) with contrast-specific software. Basic technical parameters were: a 
single focus placed directly under the kidney, persistency off, mechanical index 0.09, dynamic 
range C50, gain 85%, side-by-side imaging. These settings were repeated during each injection. All 
studies were digitally registered as a movie clip at a rate of 7 frames per second, and this during 
90 seconds.  
 
The movie clips were exported as DICOM and analyzed using specialized computer software 
(VueBox®, Bracco Suisse SA, Switzerland) for objective quantitative analysis. Analyses were based 
on linearized video data. Six regions-of-interest (ROIs) were manually drawn: 1 on an interlobar 
artery, 3 in the renal cortex, and 2 in the renal medulla. ROI-placement is illustrated in Figure 1. The 
ROIs for the cortex and medulla were identical in size (4 mm for the cortex, 3 mm for the medulla) 
and shape and drawn at approximately the same depth. For every ROI, the software determined 
mean pixel intensities and created a time-intensity curve. Time-intensity curves were analyzed for 
blood flow parameters representing blood volume (peak enhancement (PE), wash-in area under 
the curve (WiAUC), wash-out area under the curve (WoAUC) and total area under the curve (AUC)) 
and blood velocity (rise time (RT), mean transit time (mTT), time to peak (TTP), wash-in rate (WiR), 
wash-in perfusion index (WiPI), fall time (FT), wash-out rate (WoR)). The values for the 3 ROIs for 
the cortex and 2 ROIs for the medulla were averaged. Peak enhancement and WiAUC for the cortex 
and medulla were normalized to values from the interlobar artery (PE* and WiAUC*). 
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Statistical analyses were performed with SAS (SAS version 9.4, SAS Institute Inc.). The analysis was 
based on a random effects model using restricted maximum likelihood to estimate the variance 
components. Three variance components were estimated, v1 corresponding to the variation 
between repeated measurements on the same kidney, v2 to the extra variation when considering 
observations of the two kidneys of the same cat and v3 to the extra variation when considering 
observations of different cats. The variance components were used to determine 95% reference 
intervals for repeated observations on the same kidney and for repeated observations on kidneys 
of different cats. Furthermore, the coefficient of variation (CV), defined as the ratio of the standard 
deviation over the mean, was determined for the within cat repeated observations. 
 
 
F igure 1 .  Contrast-enhanced ultrasound image of  the left  k idney of  a  cat  
i l lustrat ing the posit ion of  the regions-of- interest  in  the renal  cortex 
(yel low___ ) ,  renal  medulla (green ---)  and interlobar artery (blue +++) .  The image 
was obtained at peak cortical enhancement (10 s after contrast injection). 
 
 
4 . Results   
 
The weight of cats remained stable and no remarkable events were reported during the study 
period. The contrast agent was well tolerated by all cats and no side effects were noticed.  
 
An overview of the variation for the different perfusion parameters is given in Tables 1-3 and 
Figure 2.  As shown in Tables 2 and 3, the CEUS parameters with the lowest CV were those related 
to the blood velocity: TTP, RT and FT. Variation was greater for the medulla (42% for FT, 26% for RT 
and 13% for TTP) compared to the renal cortex (19% for FT, 13% for RT and 6% for TTP). Mean transit 
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time (mTT), a parameter for mean duration of complete contrast medium perfusion, showed 
reasonable variation for the renal cortex (24%), whereas high CV was noted for the medulla (83%). 
Parameters related to the slope of the time-intensity curve showed moderate variation, which was 
consistently greater for the medulla. Parameters related to the signal intensity showed the highest 
variation. Coefficients of variation for PE were 41% and 46% for the renal cortex and medulla 
respectively, even increasing to 63% for the interlobar artery. Consequently, normalizing PE to the 
interlobar artery, did not reduce variance, but in contrast caused a clear increase in CV with values 
for PE* of 56% for the cortex and 67% for the medulla. Similar results were obtained for the AUC 
with CV values varying between 37% and 45% for the cortex and medulla. Similarly, normalizing 
WiAUC to the interlobar artery caused an increase in CV.  
The extra variation due to different kidneys of the same cat is small, and close to zero for the renal 
cortex. The extra variation added by considering different cats is relatively small in respect to the 
variation due to repeated measurements on the same cat.  
 
Var iable v 1 v 2 v 3 v 1 v 2 v 3 
 Renal  cortex Renal  medulla  
PE 700064.11         0.00 94321.97 17877.34         1335.34          13291.83 
PE* 67.38                   0.60 4.10 2.24                0.42              0.94    
WiAUC 3044906.72  0.00        1164708.92           1101109.68         364418.44        831708.58 
WiAUC* 80.48                   0.00             1.22 39.45                 1.95             23.43   
AUC 15666348.73                   0.00       6126522.55 10022876.60             2528158.89       3937022.34 
WoAUC 4944824.02  0.00        1947085.66           4967136.51             1058428.79        1114792.93 
mTT 45.71                   0.19             61.58 6536.44              4760.97           0.00   
RT  0.25                  0.02              0.23 20.38                5.62             4.95    
TTP 0.41                  0.10              1.64 15.58                 3.99             10.69   
FT  0.98           0.07              0.46 188.20                 59.25            40.89 
WiR 128608.35                  0.00         7729.98 314.54                 12.50            149.32   
WiPI  259793.99                 0.00         35450.72   6812.22                 529.70           5058.44 
WoR 70551.60                 0.00          2535.62   133.48                7.31            46.34    
Table 1 .  The est imated var iance components explaining the var iat ion of  
different  perfusion parameters  of  fel ine kidneys using contrast-enhanced 
ultrasound. v1 stands for the variation between repeated measurements on the same kidney, v2 
for the extra variation when considering observations of the two kidneys of the same cat and v3 for 
the extra variation when considering observations of different cats. (PE = peak enhancement; PE* = 
normalized peak enhancement; WiAUC = wash-in area-under-the curve; WIAUC* = normalized 
WiAUC; AUC = total area-under-the-curve; WoAUC = wash-out area-under-the-curve; mTT = mean 
transit time; RT = rise time; TTP = time-to-peak; FT = fall time; WiR = wash-in rate; WiPI = wash-in 
perfusion index; WoR = wash-out rate) 
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Variable Mean ± St  Err  Within cat  95% 
reference interval  
Between cat  95% 
reference interval  
CV 
PE 2042.44 ± 165.68 [369.05 – 3715.84] [259.88 – 3825.01] 41.0% 
PE* 14.65 ± 1.50 [0.00 – 32.07] [0.00 – 31.63] 56.0% 
WiAUC 4637.91 ± 426.88 [1147.98 – 8127.84] [534.44 – 8741.38] 37.6% 
WiAUC* 19.19 ± 1.53 [1.25 – 37.14] [1.12 – 37.27] 46.7% 
AUC 10718.00 ± 974.03 [2802.30 – 18634.59] [1381.88 – 20055.01] 36.9% 
WoAUC 6080.53 ± 548.25 [1633.14 – 10527.92] [830.04 – 11331.02] 36.6% 
mTT 27.94 ± 2.53 [14.41 – 41.46] [7.20 – 48.67] 24.4% 
RT 3.82 ± 0.16 [2.82 – 4.82] [2.41 – 5.23] 13.1% 
TTP 11.09 ± 0.39 [9.82 – 12.37] [8.16 – 14.03] 5.7% 
FT  5.21 ± 0.26 [3.22 – 7.19] [2.75 – 7.66] 19.0% 
WiR 733.03 ± 65.12 [15.79 – 1450.27] [0.00 – 1471.51] 48.9% 
WiPI  1248.77 ± 101.12 [229.37 – 2268.17] [162.04 – 2335.50] 40.8% 
WoR 499.95 ± 46.72 [0.00 – 1031.18] [0.00 – 1040.64] 53.1% 
Table 2 .   The mean ± standard error  (St  Err)  and the within and between cat  95% 
reference interval  and CV (coeff ic ient  of  var iat ion)  for  the within cat  repeated 
observations for  the perfusion values of  the renal  cortex of  fel ine kidneys using 
contrast-enhanced ultrasound.  (PE = peak enhancement; PE* = normalized peak 
enhancement; WiAUC = wash-in area-under-the curve; WIAUC* = normalized WiAUC; AUC = total 
area-under-the-curve; WoAUC = wash-out area-under-the-curve; mTT = mean transit time; RT = rise 
time; TTP = time-to-peak; FT = fall time; WiR = wash-in rate; WiPI = wash-in perfusion index; WoR = 
wash-out rate) 
 
Var iable Mean ± St  Err  Within cat  95% 
reference interval  
Between cat  95% 
reference interval  
CV 
PE 292.09 ±  40.92    [24.68 – 559.50] [0.00 – 652.67] 45.9%  
PE* 2.24 ±  0.40     [0.00 – 5.23] [0.00 – 6.03] 67,0% 
WiAUC 2783.10 ±  342.25     [684.42 – 4881.77] [0.00 – 5814.43] 37,7% 
WiAUC* 12.14 ± 1.53    [0.00 – 24.71] [0.00 – 28.25] 51.7% 
AUC 7679.05 ±  851.75  [1347.27 – 14010.84] [0.00 – 15800.15] 41.2% 
WoAUC 4900.04 ± 529.83     [442.63 – 9357.46] [0.00 – 10244.33] 45.5% 
mTT 96.91 ± 19.06  [0.00 – 258.60] [0.00 – 309.48] 83.4% 
RT 17.15 ±  1.11      [8.12 – 26.18] [6.02 – 28.27] 26.3% 
TTP 30.54 ±  1.23     [22.65 – 38.44] [19.54 – 41.54] 12.9% 
FT  32.83 ±  3.39    [5.39 – 60.27] [0.00 – 66.79] 41.8% 
WiR 28.7719 ± 4.67    [0.00 – 64.24] [0.00 – 72.42] 61.6% 
WiPI  182.48  ± 25.27  [17.40 – 347.55] [0.00 – 405.19] 45.2% 
WoR 15.23 ± 2.81     [0.00 – 38.33] [0.00 – 42.59] 75.9% 
Table 3 .   The mean ± standard error  (St  Err)  and the within and between cat  95% 
reference interval  and CV (coeff ic ient  of  var iat ion)  for  the within cat  repeated 
observations for  the perfusion values of  the renal  medulla of  fel ine kidneys 
using contrast-enhanced ultrasound.  (PE = peak enhancement; PE* = normalized peak 
enhancement; WiAUC = wash-in area-under-the curve; WIAUC* = normalized WiAUC; AUC = total 
area-under-the-curve; WoAUC = wash-out area-under-the-curve; mTT = mean transit time; RT = rise 
time; TTP = time-to-peak; FT = fall time; WiR = wash-in rate; WiPI = wash-in perfusion index; WoR = 
wash-out rate) 
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F igure 1 .  The 95% intervals  for  a  difference between two observations for  
different  perfusion parameters  of  fel ine kidneys using contrast-enhanced 
ultrasound for  the cortex ( left)  and medulla  (r ight) .  The thick bar corresponds to the 
95% interval of the difference between two observations from the same kidney, same cat. The 
medium bar corresponds to the additional width of the 95% reference interval when considering 
two different kidneys of the same cat, and the narrow and dotted bar to the additional width of the 
95% reference interval when considering two kidneys of different cats. (PE = peak enhancement; 
PE*=normalized peak enhancement; WiAUC = wash-in area-under-the curve; AUC = total area-
under-the-curve; WoAUC = wash-out area-under-the-curve; mTT = mean transit time; RT = rise time; 
TTP = time-to-peak; FT = fall time; WiR = wash-in rate; WoR = wash-out rate) 
 
5 . Discussion  
 
Contrast-enhanced ultrasound is associated with a relatively high degree of variability, which may 
cause diagnostic uncertainty. However, the causes of this high variability have not yet been 
completely understood, and can be related to several factors such as the operator, scanner 
settings, patient related factors and the contrast agent. Careful study design standardizing image 
acquisition and data processing may reduce variability. However, the variation caused by 
physiological patient factors and the contrast agent cannot be controlled. Therefore, the 
repeatability, referring to the variation in serial measurements performed on the same subject 
under comparable conditions14, as well as intersubject variation of several perfusion parameters 
were investigated in this study. In an effort to minimize variation, machine settings were 
standardized, the same operator performed the ultrasound, the injection and quantification were 
also performed by one person, and measurements were made within a reasonably short period of 
time. 
The highest variation in this study was related to the intensity parameters reflecting blood volume. 
The CV for PE for the renal cortex (41%) was higher compared to those previously reported in mice 
and rat kidneys, ranging from 10% - 25% for manual injections for the renal cortex.15-17 Nevertheless, 
higher values for the CV for PE were reported in a study using CEUS for assessing cerebral 
perfusion in humans (47-53%).18 The CV for AUC (36-38%) was similar to the one reported in other 
studies in rodents.15, 16 Again, lower repeatability was found in the human study on cerebral 
perfusion (CV 64-65%). The variation for time related parameters has only been reported in one 
study on mice kidneys. In our study the CV for TTP was lower, whereas the CV for WoR and mTT was 
slightly higher compared to the murine study.15 Similar values for CV were obtained for WiR.15 No 
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results have previously been published on variation of any parameter for the renal medulla or 
interlobar artery.  
There is no clear cut-off value for CV defining adequate repeatability.  CV values of 10-15% for 
successive injections of contrast agent in the same imaging session in the same animal, in rodent 
kidneys are proposed by one study.17 However, these values are set arbitrarily. Moreover, higher 
CV’s are to be expected when considering different imaging sessions and inter-subject variation. 
The CV for measurement of glomerular filtration in cats, the gold standard for evaluation of renal 
function, is reported to be up to 20%.19 
PE is the most critical parameter in terms of variation because it is influenced by many different 
factors. One of these is the concentration of microbubbles present in the contrast agent. This is 
influenced by the production process, the way the agent is reconstituted, the mode of 
administration and physical and physiological factors in the environment.12, 20, 21 Moreover, the 
acoustic window, and uncontrollable patient-related factors such as blood pressure, heart rate, 
filtration of the microbubbles by the lungs, and phagocytosis by the reticuloendothelial system will 
also induce variation.12, 17 Therefore, it has been proposed to remove part of this variation by 
normalization with neighboring ‘normal’ tissue as a reference.12, 22 However, when imaging the 
feline kidney in a standardized longitudinal plane it is impossible to consistently include other 
tissues such as the spleen for the left kidney, the liver for the right kidney or the abdominal aorta, 
as this would interfere with the standardized imaging plane of the kidneys in some cats. The 
interlobar arteries are always in the imaging plane, and were thus chosen as reference tissue. 
However, the variance in PE is higher for the interlobar artery compared to the remainder of the 
kidney. Interlobar arteries are small structures and may be inconsistently imaged, moreover they 
are highly susceptible to motion artifact from breathing. Drawing a ROI surrounding a structure of 
this size is challenging and may be susceptible to inter- and intra-observer variability. Moreover, 
under pathological conditions, as chronic kidney disease the flow within the interlobar artery could 
be affected and therefore not serve as normal reference tissue. The abdominal aorta could be used 
as reference tissue, although it should be imaged separately urging an additional administration of 
contrast. It could remove part of the variation induced by microbubble concentration and some 
patient factors. Nevertheless, the acoustic window will be different. Larger variations in blood 
pressure exist in larger arteries and may therefore induce additional variation.12 
Two main approaches are used to measure renal perfusion using CEUS: bolus kinetics and flash-
replenishment kinetics. For the bolus method, a single bolus of ultrasound contrast medium is 
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administered intravenously and a curve representing the acoustic intensity over time is obtained. 
Flash-replenishment kinetics are based on the reappearance of ultrasound contrast agent after 
complete destruction of the microbubbles by a flash of high mechanical intensity. An infusion of 
contrast agent is most often used for this technique.23 The different methods have their associated 
limitations and measure different perfusion parameters. A lower variation is suspected to result 
from flash-replenishment kinetics, however no supporting data are currently available. A manual 
bolus injection was performed in this study, as this is the most commonly used method in clinical 
imaging procedures. Increasing the injection time causes both an increase in TTP and a decrease in 
PE and WiR.24 A commercially available bolus-injection system has recently been introduced. 
Controlled injections performed by this system improved reproducibility for TTP, WiR and WoR, 
whereas PE and AUC were not significantly different between manual and controlled injections.15 
Repeatability for the TTP in this study was relatively good, whereas low repeatability was present 
for the WiR and WoR. Controlled injection might therefore aid in the improvement of the 
repeatability of these 2 parameters. 
The discrepancy between the values for cortex and medulla is likely to be related with the specific 
anatomic and physiologic characteristics of the medullary blood supply. The medulla only receives 
10% of the total renal blood flow.25, 26 The medullary blood supply directly diverges from the cortical 
supply and is derived exclusively from the juxtamedullar glomeruli. Discrepancies exist between 
the inner and outer medulla, as the outer medulla receives approximately 40% of the cortical blood 
flow, whereas the inner medulla receives 10%.26 However, outer and inner medulla cannot strictly 
be delineated on ultrasound images, therefore ROI placement is likely to be inconsistent in both 
medullary regions, hence increasing variability. Moreover, subtle changes in total and cortical renal 
blood flow, may induce larger changes in the medullary blood flow due to redistribution between 
juxtamedullar and cortical glomeruli.26 
In conclusion, this study shows that intensity-related parameters and parameters related to the 
slope of the time-intensity curve show moderate to high variation in healthy cats and may 
therefore be a complicating factor in the diagnostic capabilities of CEUS. Relatively good 
repeatability is present for time-derived parameters. It would be interesting to investigate if 
normalization to the abdominal aorta and using a bolus-injection system could reduce variation. 
Moreover, destruction-reperfusion techniques may be less susceptible to variation, although no 
data are available at the moment. 
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CHAPTER V  
INFLUENCE OF ANESTHESIA  AND SEDATION ON QUANTITATIVE 
CONTRAST-ENHANCED ULTRASONOGRAPHY OF THE HEALTHY FELINE 
KIDNEY 
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The effect of anesthesia with propofol and sedation with butorphanol on quantitative contrast-
enhanced ultrasonography of the healthy feline kidney. The Veterinary Journal 2014, 202; 637 – 
639. 
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1 . Abstract   
 
Contrast-enhanced ultrasonography of the left kidney was performed in 6 healthy adult purpose-
bred cats, using a commercial contrast agent (Sonovue, Bracco). A cross-over design was used to 
compare 3 protocols: awake, butorphanol (Dolorex, MSD AH; 0.4 mg/kg IM), and propofol (Propovet, 
Abbott Lab; 3.5-7.7 mg/kg IV boluses on effect). Time-intensity curves were created from 2 regions-
of-interest drawn in the renal cortex. The curves were analyzed for blood flow parameters 
representing blood volume (baseline intensity, peak enhancement, area-under-curve) and blood 
velocity (arrival time, time-to-peak, wash-in/out) using a mixed model with cat as random effect. 
There was no difference in the subjective enhancement pattern between the 3 protocols. No 
significant effect of butorphanol compared to awake cats was observed in any of the perfusion 
parameters. Propofol induced a significant increase in arrival time, time-to-peak and wash-in 
compared to awake and butorphanol sedated cats. 
Sedation with butorphanol has favorable cardiovascular properties without significant influence on 
renal perfusion parameters but its sedative properties are often insufficient in healthy cats. 
Propofol causes a decrease in renal blood velocity.  
 
2 . Introduct ion 
 
Contrast-enhanced ultrasonography (CEUS) is an imaging modality improving the diagnostic 
accuracy of ultrasonography (US). Ultrasound contrast agents (USCAs) are gas-filled microbubbles, 
encapsulated by a stabilizing shell which have a diameter of 1-8 µm and are administered 
intravenously (IV). As they do not cross the endothelium, they are strict blood pool agents, able to 
improve the visualization of the perfusion and vascularization of the organ of interest.1 The CEUS 
technique and the USCAs are extremely safe and well tolerated.2  
CEUS has become established as a reliable method for the differential diagnosis of focal hepatic 
and splenic lesions in small animal patients.3-7 It has been described for the characterization of 
focal renal lesions in dogs.8 Promising results have been achieved with quantitative CEUS to 
evaluate tissue perfusion. Quantitative CEUS is able to detect changes in renal blood flow in dogs 
undergoing hydrocortisone treatment.9 The perfusion of kidneys, liver, pancreas, small intestines 
and lymph nodes has been studied in healthy cats.10-13  
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Quantitative information about renal perfusion can be valuable in the diagnosis of diffuse renal 
disorders. As up to 30% of the older cats suffer from renal disease, accurate and early diagnosis is 
of major importance in veterinary medicine.14 Renal perfusion parameters in healthy cats are 
established, but these results are achieved in sedated or anesthetized cats.11, 12 However, anesthetic 
and sedative agents may affect renal blood flow and thereby altering the perfusion variables 
measured with CEUS.15  
Therefore, the objectives of this study are (1) to evaluate the renal perfusion pattern of healthy 
cats and (2) to compare the renal perfusion patterns of healthy cats that were imaged awake, 
sedated with butorphanol and anesthetized with propofol. 
 
3 . Materials  and methods  
 
Six purpose-bred laboratory cats with mean ± standard error age of 3.2 ± 0.4 years and mean ± 
standard error weight of 3.6 ± 0.3 kg, were studied. Five cats were female neutered, 1 was male 
neutered. The cats were healthy based on physical examination, Doppler blood pressure 
measurement, complete blood count and serum biochemical analysis, urinalysis (sediment, 
dipstick, specific gravity, urinary protein:creatinine ratio) and abdominal US. The kidneys had a 
normal size and appearance on US. The study protocol was approved by the Local Ethical 
Committee of Ghent University (EC2013/36). 
 
A 22-Gauge catheter was placed in the cephalic vein. The cats were scanned six times during a 
three-week period with three different protocols, with a minimum of two days wash-out period 
between each protocol. The cats were randomly assigned to a sequence of the three different 
protocols. A cross-over design with 2 periods with each 3 sequences was used. One protocol was 
assigned to each sequence within the period. In the first protocol the cats were awake and only 
manual restraint was applied. In the second protocol the cats were sedated with butorphanol 0.4 
mg/kg IM (Dolorex, MSD AH). After administration of butorphanol, a period of 15 – 20 minutes in a 
calm environment was respected. In the third protocol, anesthesia was induced with a bolus of 
propofol (Propovet, Abbott Laboratories) 3.5-7.7 mg/kg IV given to effect and maintained with 0-3 
additional boluses as necessary. The mean ± standard error total dose of propofol was 8.6 mg/kg ± 
0.9. Propofol was administered over a 30 seconds period, followed by a bolus of 2 mL sterile NaCl-
solution. 
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The hair was clipped over the ventrolateral portion of the abdomen. Alcohol and coupling gel were 
applied on the skin. The US exams were performed with the cats in dorsal recumbency. A 
conventional US examination of the abdomen was performed prior to the CEUS study. For CEUS, the 
left kidney was centered on the screen and was imaged in a dorsal plane. The transducer was 
manually positioned by the same person during each imaging procedure and was maintained at 
the same position during the CEUS examination. All cats received three bolus injections of contrast 
medium (Sonovue, Bracco), 0.15 mL for each injection, followed by a 1 mL saline bolus. A three-way 
stopcock was used to avoid any delay between the injection of USCA and saline. The first injection 
of USCA was performed and the kidney was imaged for two minutes. Thereafter, to destroy residual 
or trapped microbubbles prior to the next injection, the cranial abdomen was scanned with 
maximal acoustic pressure. This avoided enhancement artefacts and took approximately five 
minutes. The microbubble injection procedure was repeated with a second and a third injection. 
All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(iU22 xMATRIX, Philips) with contrast-specific software. A single focus, placed underneath the 
kidney was used. The mechanical index was set at 0.09. For the gain setting, we started with a 
nearly anechoic image, representing nearly full suppression of fundamental signal. The gain was 
optimized during the first injection to reach uniform brightness of the image. These settings were 
repeated during the second and third injection. All studies were digitally registered as a movie clip 
at a rate of 10 frames per second. 
 
The clips were analyzed using specialized computer software (QLab, Philips) for qualitative and 
quantitative analysis. Two ovoid regions-of-interest (ROIs) of approximately 4 mm diameter were 
manually drawn in the renal cortex, at the same location in each cat, as is shown in Figure 1. For 
every ROI, the software determined mean pixel intensities and created a time-intensity curve. 
Time-intensity curves were analyzed for blood flow parameters representing blood volume 
(baseline intensity (BI), peak enhancement (PE), area-under-curve (AUC)) and blood velocity 
(arrival time (AT), time-to-peak (TTP), wash-in/out or up/downslope (Win/Wout)). 
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F igure 1 .  Contrast-enhanced image of  the left  k idney with 2 ovoid regions-of-
interest  drawn in the renal  cortex .   
 
To compare the three protocols with respect to the different blood flow parameters, a mixed 
model with protocol and injection sequence as categorical fixed effects and cat and time period 
nested in cat as random effects was used (SAS Version 9.3). The F-test at the 5% significance level 
was performed to assess the effect of sedation/anesthesia protocol on the values of the various 
parameters of renal blood flow obtained with CEUS. The Bonferroni’s adjustment technique was 
used for multiple comparisons and adjusted P-values are reported.  
 
4 . Results   
 
The subjective enhancement pattern of the left kidney was similar in all cats, with the different 
protocols. Microbubbles were first imaged in the renal artery, followed by variable enhancement of 
the interlobar arteries. There was a uniform, rapid enhancement of the renal cortex followed by a 
slower enhancement of the renal medulla. Contrast enhancement in the medulla was more 
heterogeneous and remained hypoechoic throughout Win and Wout compared to the cortex.  
Mean ± standard error values of the renal blood flow parameters for the different protocols are 
summarized in Table 1. The time-intensity curves are represented in Figure 2. Significant effects 
were found for AT, TTP and Win. Anesthesia with propofol resulted in a significant (P<0.001) 
increase in AT and TTP, compared to sedation with butorphanol and awake cats. Win was 
significantly (P=0.0382) slower in cats that received propofol compared to cats sedated with 
butorphanol and awake cats. No significant effects between the three protocols were found for BI, 
PI, Wout and AUC. All perfusion parameters obtained during sedation with butorphanol were 
comparable with the perfusion parameters obtained for awake cats.  
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F igure 2 .  Mean t ime-intensity  curves calculated from the renal  cortex in  awake 
cats ,  cats  sedated with butorphanol  and anesthetized with propofol .  Signal 
intensity, expressed in arbitrary units (a.u.), is displayed on the y-axis and time, in seconds (s), on 
the x-axis. 
 
Perfusion 
parameter  
Awake Butorphanol  Propofol  
BI  0.77 ± 0.19 1.20 ± 0.18 0.69 ± 0.18 
PE 60.66 ± 5.08 53.73 ± 4.88 51.47 ± 4.88 
AT 3.83 ± 0.41 3.85 ± 0.40 5.14 ± 0.40a 
TTP 6.19 ± 0.40  6.18 ± 0.40 7.90 ± 0.40a 
W in 27.55 ± 2.12 23.94 ± 2.05 19.93 ± 2.05b 
W out -0.45 ± 0.04 -0.39 ± 0.04 -0.39 ± 0.04 
AUC 792.80 ± 139.74 695.55 ± 136.90  722.42 ± 136.90 
Table 1 .  Means and standard errors  of  perfusion parameters  calculated from the 
renal  cortex in  awake cats ,  cats  sedated with butorphanol  and anesthetized 
with propofol .  a value represents a significant (P<0,05) effect in respect to awake and 
butorphanol group; bvalue represents a significant (P<0,05) effect in respect to awake group (BI 
base intensity, PE peak enhancement, AT arrival time, TPP time-to-peak, Win wash-in, Wout wash-out, 
AUC area-under-curve) 
 
 
None of the cats had adverse reactions during or after contrast medium administration. In the 
awake group, it was sometimes difficult to retain the cats immobile during two minutes resulting 
in motion artifacts and rejection of clips for further quantitative assessment (2/24). Administration 
of butorphanol resulted in a low level of sedation, not improving patient cooperation. Hence, it did 
not result in a reduction of motion artifacts or rejection rate of clips (2/24). Injection of propofol 
resulted in a superficial anesthesia of variable duration. This greatly improved the ease of 
performing the contrast study and resulted in complete rejection of motion artifact (except 
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breathing artifact). Therefore, all clips in the propofol group could be used for quantitative 
analysis.  
 
5 . Discussion  
 
The kidney is a well-vascularized organ that receives 20-25% of the cardiac output. Renal 
autoregulatory mechanisms ensure a relatively constant renal blood flow over a wide range of 
perfusion pressures.16 Renal blood flow can be maintained constant for mean arterial blood 
pressures between 80 and 180 mmHg, although even within this range several extrinsic and 
intrinsic forces can cause the autoregulatory mechanism to fail which results in alterations of renal 
blood flow.15 Perfusion parameters obtained with CEUS are not only determined by renal blood flow 
but also by the systemic circulation, since the bubbles are transported by the venous and arterial 
circulation from the injection site to the kidney. 
In this study, quantitative perfusion parameters were only determined for the renal cortex. Renal 
perfusion is well reflected by its cortical perfusion as more than 90% of the blood entering the 
kidney goes to the cortex. The blood flow in the medulla is lower and more variable compared to 
the cortical blood flow.16  
The subjective enhancement pattern of the kidney obtained in this study was similar to previous 
descriptions.11, 12 In this study, no subjective enhancement differences were observed between the 
protocols. Anesthesia with butorphanol and propofol induced an increase in the heterogeneity of 
the spleen in cats, which is related to the anesthesia-induced splenic congestion.17 Congestion 
following anesthesia is not observed in the renal parenchyma. Despite the absence of effect on 
subjective enhancement pattern, there were clear differences in the quantitative perfusion 
parameters between the propofol-group and the other groups.  
Three studies have described CEUS perfusion parameters of the feline kidney. All of them used 
commercial second-generation contrast agent different from the present study (Definity, 
Lantheus).11, 12, 18 Kinns et al. (2010) only determined TTP in cats sedated with hydromorphone and 
midazolam (n=1) or  anesthetized with isoflurane (n=7).11 The TTP (13 ± 3.2 s) was markedly higher 
than the TTP in all our 3 protocols. Other studies were performed on cats premedicated with 
atropine, sedated with acepromazine and morphine and anesthetized with diazepam and 
ketamine.12, 18 The time-related parameters (AT and TTP) were comparable with our findings in 
awake cats and cats sedated with butorphanol and lower compared to the values obtained in the 
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cats anesthetized with propofol. In contrast, there were great differences between their values for 
BI, PI, Win and Wout compared to our results. A higher BI, lower PI, a slower Win and a faster Wout were 
observed. Leinonen et al. (2010, 2011a) always used the first or second contrast-injection for 
quantification.12, 18 The contrast parameters in our study resulted from the mean of the second and 
third injection. This could explain the higher PI and the effect on Win/Wout, although not the 
influence on BI. Several technical parameters influence the perfusion parameters. It is therefore 
important to standardize the imaging protocol and machine settings when performing CEUS 
studies and to be very careful with extrapolation of results.  
Butorphanol is an opiate with agonistic effects on the κ-receptor and only minor effects on the μ-
receptor, explaining its analgesic and sedative properties with minor cardiovascular effects.19 There 
were no significant differences in the perfusion parameters obtained after sedation with 
butorphanol compared with awake cats. Nevertheless, the variable and low sedation level make it 
of limited use for sedation of healthy cats. Butorphanol is still a valuable sedative agent for the 
use in cats in a poor general condition or suffering from severe cardiovascular disease.  
Propofol is an anesthetic agent acting by enhancing the GABA-receptors in the central nervous 
system. In contrast to butorphanol, propofol has well-known cardiovascular influences. The 
combined effect of a depression of the baroreceptor response and central sympathetic depression 
induces a decrease in cardiac output and systemic vascular resistance resulting in a depression of 
systolic and diastolic blood pressure.20 In dogs, induction with propofol caused decreased arterial 
blood pressure and systemic vascular resistance, although no effect on cardiac output and renal 
blood flow was noted.21 The hemodynamic effects of propofol depend on the dose and the plasma 
level.20 Systemic blood pressure and heart rate was not measured in this study due to practical 
constraints. There was a significant delay in blood velocity parameters such as AT and TTP, the 
effect on Win was less pronounced but still significant. A decrease of blood velocity is likely to be 
caused by systemic hypotension. Our findings correspond with a previous study on the feline 
spleen, in which an increase in AT was seen after anesthesia with butorphanol and propofol.17 In 
contrast, propofol anesthesia caused a reduction in TTP without a change in Win when performing 
CEUS of the liver in dogs.22 This finding was explained by an increased hepatic arterial blood flow, 
which has been described after induction of anesthesia with propofol in dogs.21 A shorter TTP from 
time of contrast reaching the kidney was also noted in dogs receiving propofol and isoflurane 
compared to awake dogs.23 This was a non-randomized, non-controlled study with only 2 dogs 
imaged awake and 6 dogs under anesthesia.  
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Other commercially available sedative agents for cats, which were not studied in this experiment, 
are dexmedetomidine and alfaxalone. Dexmedetomidine is an α-2 adrenergic agonist which can be 
administered IV and IM, and results in deep sedation with muscle relaxation. The pronounced side-
effects as bradycardia, decrease in cardiac output, increase in peripheral vascular resistance and 
respiratory depression are a major drawback for use in CEUS studies.24 Dexmedetomine caused a 
pronounced increase in AT and TTP in the canine spleen, kidney and small intestine. In the kidney, 
additionally, a decreased PI and Win were found.25 MK-467, a non-commercially available peripheral 
α-2 adrenoceptor antagonist, showed to be capable of altering these effects without reducing the 
sedative properties. The addition of MK-467 seems very promising for the use of dexmetomidine in 
CEUS examinations. Currently, studies in cats are lacking, moreover, the agent is not registered for 
use in veterinary medicine in Europe.  
Alfaxolone is a more recent anesthetic agent that can be used for sedation in cats. It can be 
administered IV, IM or even SC, but IM injection is painful.  It has similar cardiovascular effects 
compared to propofol. Moreover, the quality of recovery is poor with excitement, hyperreactivity 
and ataxia.26, 27  
In conclusion, contrast-enhanced ultrasonography can be performed in awake cats, although 
sedation or anesthesia is required for uncooperative patients. Butorphanol has no significant 
influence on CEUS parameters, but its sedative properties are often insufficient. Propofol causes a 
significant delay in AT and TTP and has an effect on Win.  
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1 . Abstract   
 
The degenerative effects of ageing on the kidneys have been extensively studied in humans. 
However, only recently interest has been addressed to renal ageing in veterinary medicine. 
Contrast-enhanced ultrasound is a relatively new technique allowing non-invasive evaluation of 
renal perfusion in conscious cats. Renal perfusion parameters were obtained in 43 healthy cats 
ageing 1 to 16 years old, and the cats were divided in 4 age categories: 1-3 years, 3-6 years, 6-10 
years and > 10 years. Routine renal parameters as serum creatinine, serum urea, urine specific 
gravity, urinary protein:creatinine ratio, and systolic blood pressure were also measured. No 
significant differences in any of the perfusion parameters were observed among the different age 
categories. A trend towards a lower peak enhancement and wash-in area-under-the-curve with 
increasing age, suggestive for a lower blood volume, was detected when comparing the cats > 10 
years with the cats between 1 and 3 years. Additionally, no significant age-effect was observed for 
the serum and urine parameters, whereas a higher blood pressure was observed in healthy cats 
between 3-6 years and > 10 years.  
 
2 . Introduct ion  
 
Renal ageing has been a hot topic in human research for several years, whereas it has only recently 
gained interest in veterinary medicine.1, 2 The population of senior and geriatric cats has been 
increasing in the past years.3-5 Consequently, effects of ageing on animal health have grown more 
interest and more attention is paid to health screening in elderly cats.6  
In people, ageing is associated with structural changes accompanied by progressive deterioration 
of renal function. A reduction in renal mass and glomerular number is present in elderly people, 
paralleled by an increased percentage of sclerotic glomeruli.1 Moreover, glomerular filtration rate 
(GFR) and renal plasma flow decrease with age, whereas renal vascular resistance increases.1, 7, 8 
The reduction in renal blood flow is believed to be primary and precede the changes in GFR and 
renal morphology.8 This decline appears to be a part of the normal physiologic process of cellular 
and organ senescence.1 Information on the influence of ageing on renal morphology and function in 
veterinary medicine is limited. An age-related decrease in GFR have been described in small breed 
dogs.9 In one study, a lower GFR was present in older cats compared to young cats as measured 
with the exogenous creatinine clearance test however, no age-effect was present when GFR was 
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measured with exo-iohexol, endo-iohexol and chromium-51 ethylenediaminetetraacetic acid.9, 10 A 
higher serum creatinine concentration (sCr) has been found in elderly cats.6, 9, 11 
Contrast-enhanced ultrasound (CEUS) is a functional imaging technique that allows evaluation of 
tissue perfusion through the use of intravenously injected contrast agent. The ultrasound contrast 
agent is composed of millions of microbubbles, which are tiny gas filled spheres, stabilized by an 
outer shell. These microbubbles have a size similar to those of red blood cells; consequently they 
do not pass the endothelium and remain strictly intravascular.12, 13 Promising results have been 
obtained with CEUS for the evaluation of diffuse renal disorders in both human and veterinary 
medicine.14-18  
The objective of this study was to determine the effect of age on several perfusion parameters 
obtained with CEUS of the kidneys in healthy cats divided in 4 age groups. The hypothesis was that 
ageing would be associated with a decline in renal blood volume and a higher vascular resistance 
seen as a decrease in slope of the time-intensity curve.  
 
3 . Materials  and methods  
 
Healthy cats of ≥ 1 year were included. The cats were divided into 4 age groups: group 1 (1-3 years), 
group 2 (3-6 years), group 3 (6-10 years) and group 4 (> 10 years). Ten to 12 cats were included in 
each group. Cats were considered healthy if no significant abnormalities were reported in the 
history, nor detected on physical examination, complete blood count, serum biochemistry profile, 
thoracic radiographs, and abdominal ultrasound. Cats with both sCr > 161.8 µmol/L 11 and urine 
specific gravity < 1.035 were excluded. Only cats free of any medication for at least 2 months were 
included.  
 
The study protocol was approved by the local ethical committee of the Faculty of Veterinary 
Medicine, Ghent University, Belgium (EC2015/68) and the Deontological Committee of the Belgian 
Federal Agency for the Safety of the Food Chain. All owners were informed about the study and 
gave their written consent.  
 
A routine physical exam, including non-invasive measurement of the systolic blood pressure (SBP) 
by Doppler ultrasonic technique, was performed in all cats. Thyroid palpation was performed in all 
cats ≥ 6 years. Five mL of blood was collected by jugular venipuncture. Blood work consisted of 
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complete blood count and serum biochemistry, including total thyroxine (T4) level in cats of ≥ 6 
years.  Five to 10 mL of urine was collected by ultrasound-guided cystocenthesis. Urinalysis 
included sediment analysis as described in Paepe et al.(2013)6, urine specific gravity (USG), urinary 
protein:creatinine ratio (UPC), dipstick, and urine culture. Thoracic radiographs (left-right lateral 
and ventrodorsal projections) and complete abdominal ultrasound were performed. 
 
For the administration of ultrasound contrast agent, a 22-Gauge indwelling catheter was placed in 
the cephalic vein. The hair was clipped over the ventrolateral aspect of the abdomen and coupling 
gel was applied to the skin. The ultrasound examinations were performed with the unsedated cat 
manually restrained in dorsal recumbency. The kidney of interest was centered on the screen and 
was imaged in a longitudinal plane using dual-screen (simultaneous display of conventional B-
mode and contrast-mode image). The transducer was manually positioned during each imaging 
procedure and was maintained at the same position during the CEUS examination.  
The contrast agent (Sonovue®, Bracco, Italy), 0.05 mL/kg, was injected IV (bolus injection over +/- 3 
s) followed by injection of 1.5 mL saline bolus. A three-way stopcock was used to avoid any delay 
between the injection of contrast agent and saline. The same person performed the injection in a 
standardized way. Three to 4 injections of contrast were performed:  two for the left kidney, one 
for the right kidney and one for the caudal abdominal aorta in 14 cats. Between subsequent 
injections, to avoid artifacts, remnant microbubbles were destroyed by setting the acoustic power 
at the highest level and scanning the caudal aspect of the abdominal aorta for approximately 2 
minutes. 
All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(iU22, Philips) equipped with contrast-specific software. Basic technical parameters were a single 
focus placed under the kidney, persistency off, mechanical index 0.09, high dynamic range setting 
(C50), timer started at the beginning of the injection, gain 85% (corresponding to a nearly 
dark/anechoic image before USCA administration). The settings were repeated during each 
injection. All studies were digitally registered as a movie clip at a rate of 9 frames per second, 
during 90 seconds.  
The clips were exported in DICOM format and analyzed using specialized computer software 
(VueBox®, Bracco Suisse SA, Geneva, Switzerland) for objective quantitative analysis. Six regions-of-
interest (ROIs) were manually drawn: 3 in the renal cortex, 2 in the renal medulla and 1 on an 
interlobar artery. The ROI’s were similar in size and drawn at the same depth for every region (4 
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mm diameter for the cortex, 3 mm diameter for the medulla and 1-1.5 mm diameter for the 
interlobar artery). For every ROI, the software determined mean pixel intensity as a function of 
time creating a time- 
intensity curve. Time-intensity curves were analyzed for peak enhancement (PE), wash-in area 
under the curve (WiAUC), rise time (RT), mean transit time (mTT), time to peak (TTP), wash-in rate 
(WiR), wash-in perfusion index (WiPI; WiAUC/RT), wash-out area under the curve (WoAUC), total 
area under the curve (AUC), fall time (FT), and wash-out rate (WoR). The values for the 3 ROIs in the 
renal cortex and 2 ROIs in the renal medulla were averaged. Peak enhancement, for the cortex and 
medulla were normalized to the values obtained for the interlobar artery (PE*) and the aorta 
(PEAO). 
 
Statistical analyses were performed with SAS (SAS version 9.4, SAS Institute Inc.). Perfusion 
parameters obtained with CEUS, sCr, serum urea, USG, UPC and, SBP were compared among the 
different age groups, using a linear fixed effects model with age as categorical fixed effect. A 
global significance level of 5% was used and adjusted P-values (Tukey’s multiple comparisons 
technique) were calculated for pairwise comparisons. 
 
4 . Results   
 
Forty-three cats were included: 41 domestic short- or longhaired cats, and 2 Ragdoll cats. The mean 
± standard error age of the total population was 6.5 ± 0.6 years, with 10 cats group 1, 11 cats in 
group 2, 12 cats in group 3 and 10 cats in group 4. The mean ± standard error body weight was 4.0 ± 
0.1 kg, with the body condition score ranging from 4/9 to 8/9. No significant abnormalities were 
seen on thoracic x-rays and routine abdominal ultrasound. The kidneys of all cats were normal in 
size (3.0 – 4.6 cm), had a smooth, regular outline and a normal internal architecture.19 
 
Systolic blood pressure, sCr, serum urea, USG and UPC are summarized in Table 1. No significant 
differences for sCr, serum urea, USG and UPC were observed among the different age groups. A 
significantly higher SBP was present in group 2 compared to group 1 (P=0.043), and in group 4 
compared to group 1 (P=0.005). Six cats in the total population had SBP > 160 mmHg, 1 cat in group 
2, 1 cat, in group 3 and 4 cats in group 4.  
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Var iables  Group 1  
(n=10)  
Group 2  
(n=11)  
Group 3  
(n=12)  
Group 4  
 (n=10)  
Reference  
values  
B lood pressure   
(mmHg)  
122.0 ± 7.6a 152.0 ± 7.6b 142.5 ± 6.1 159.4 ± 6.7ab  
sCr   
(µmolL -1)  
107.5 ± 7.1 109.5 ± 7.1 103.9 ± 6.2 117.8 ± 7.1 64.5 – 161.8  
Serum urea   
(mmolL -1)  
8.9 ± 0.5 7.7 ± 0.5 7.6 ± 0.4 8.3 ± 0.5 6.2 – 12.7 
USG 
 
1.049 ± 0.003 1.046 ± 0.003 1.050 ± 0.003 1.043 ± 0.003  
UPC 0.11 ± 0.02 0.11 ± 0.02 0.18 ± 0.02 0.16 ± 0.02 < 0.40 
Table 1 .  Basel ine character ist ics  for  the included cats  div ided into 4 age groups .  
The data are expressed as mean ± standard error. Groups with the same letter differ significantly 
from each other (group 1 = 1 to 3 years; group 2 = 3 to 6 years; group 3 = 6 to 10 years; group 4 = > 
10 years; SBP = systolic blood pressure; sCr = serum creatinine; USG = urine specific gravity; UPC = 
urinary protein:creatinine ratio) 
  
No significant differences between the age groups were present for any of the perfusion 
parameters obtained with CEUS. However, a tendency towards a lower PE (P=0.078) and WiAUC  
 (P=0.078) for the renal cortex were present when comparing group 1 and 4. 
The CEUS parameters for the renal cortex and medulla are summarized in Table 2. Figure 1 
illustrates the normal perfusion pattern of the kidney in healthy cats. 
 
 
 
F igure 1 .  Sequential  CEUS images demonstrat ing the normal  perfusion pattern 
obtained with contrast-enhanced ultrasound of  the kidney in  healthy cats . Early 
enhancement of the interlobar arteries (5 s), followed by peak cortical enhancement (7 s) and a 
late corticomedullary phase (20 s).  
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Var iable ,  by  
locat ion  
Group 1  
(n=10)  
Group 2  
(n=11)  
Group 3  
(n=12)  
Group 4  
(n=10)  
Renal  cortex      
   PE 2355.14 ± 294.54 1917.34 ± 298.90 1459.44 ± 258.33  1303.77 ± 303.47 
   PE* 30.45 ± 4.35 30.82 ± 4.35 26.74 ± 3.71 24.58 ± 4.71  
   PEAO 13.18 ± 3.50 9.84 ± 4.79 4.81 ± 5.35 2.80 ± 10.78 
   WiAUC 3780.25 ± 414.94 2765.83 ± 420.67 2471.70 ± 363.92 2297.94 ± 426.65 
   RT 2.74 ± 0.12 2.53 ± 0.12 2.85 ± 0.11 2.95 ± 0.13  
   mTT 19.00 ± 1.98 23.09 ± 2.01 21.90 ± 1.74 22.65 ± 2.05 
   TTP 7.60 ± 0.28 7.17 ± 0.28 7.87 ± 0.25  8.05 ± 0.28  
   WiR 1186.28 ± 181.47 1094.59 ± 184.29 699.69 ± 159.16  606.15 ± 187.24  
   WiPI 1440.90 ± 179.61 1174.22 ± 182.27 893.89 ± 157.53  799.12 ± 185.06 
   WoAUC 4993.57 ± 520.00 3693.11 ± 527.27 3333.16 ± 456.07  3099.85 ± 534.85 
   FT 3.81 ± 0.21 3.49 ± 0.22 3.94 ± 0.19  4.10 ± 0.22 
   WoR 793.18 ± 138.91 751.03 ± 141.38 462.15 ± 121.83 508.60 ± 143.99 
     
Renal  medul la      
   PE 209.49 ± 222.25 203.36 ± 216.32 191.75 ± 188.58  152.66 ± 228.69  
   PE* 2.88 ± 0.69 3.62 ± 0.68 2.89 ± 0.59  3.06 ± 0.73  
   PEAO 0.90 ± 0.20 1.06 ± 0.27 0.92 ± 0.32 0.65 ± 0.67 
   WiAUC 1167.18 ± 369.43 2288.19 ± 363.53 1721.03 ± 317.68  1498.01 ± 375.62  
   RT 14.96 ± 1.52 19.36 ± 1.50 16.08 ± 1.31  16.70 ± 1.55  
   mTT 103.20 ± 31.59 121.79 ± 31.09 111.21 ± 27.17  113.83 ± 32.12  
   TTP 25.98 ± 1.69 30.01 ± 1.66 27.42 ± 1.45  26.25 ± 1.72  
   WiR 25.53 ± 189.59 17.20 ± 184.53 21.66 ± 160.87  15.74 ± 195.08 
   WiPI 130.63 ± 135.99 128.58 ± 132.36 120.53 ± 115.39  96.74 ± 139.93 
   WoAUC 2904.03 ± 629.50 4799.73 ± 629.50 3158.24 ± 542.59  2698.69 ± 676.65 
   FT    29.63 ± 3.78 39.17 ± 3.78 31.11 ± 3.25  29.67 ± 4.08 
   WoR 13.19 ± 153.90 8.28 ± 153.90 11.32 ± 130.59  8.07 ± 168.59 
 
Table 2 .  Perfusion parameters  obtained with CEUS of  healthy cats  div ided into 4 
age groups .  The data are expressed as mean ± standard error. (group 1 = 1 to 3 years; group 2 = 3 
to 6 years; group 3 = 6 to 10 years; group 4 = > 10 years; PE = peak enhancement; PE* = peak 
enhancement normalized to interlobar artery; PEAO= peak enhancement normalized to the aorta; 
WiAUC = wash-in area-under-the curve; RT = rise time; mTT = mean transit time; TTP = time-to-
peak; WiR = wash-in rate; WiPI = wash-in perfusion index; WoAUC = wash-out area-under-the-
curve;; FT = fall time; WoR = wash-out rate) 
 
5. Discussion 
  
To our knowledge, this is the first study assessing the age-effect on renal perfusion in healthy cats.  
No significant changes in renal perfusion parameters were noticed in this study. However a 
tendency towards a lower PE and WiAUC was present in elderly cats, indicating a decrease in renal 
blood volume with age. This corresponds to the findings in human studies, where a reduction in 
renal blood flow is considered to be a typical functional finding with increasing age.1, 7, 8, 20 
Moreover, the renal blood flow reduction in elderly people is believed to be primary and leading to 
a reduction in GFR and morphologic renal changes.8 In humans, age-related changes involve mainly 
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the renal cortex whereas the medulla is usually unaffected corresponding to the findings in our 
study.8 Typical morphological changes in elderly people are increased glomerular sclerosis, 
reduction in glomerular volume, decrease area and hyalinization of afferent arterioles, and 
tubulointerstitial fibrosis.1, 7, 8, 21 Similarly in ageing dogs, glomerulosclerosis, interstitial fibrosis and 
lipofuscin accumulation have been described.2, 22 In contrast, no vascular morphologic changes were 
present in aged beagles.22 In dogs, structural changes in ageing kidneys may be clinically silent and 
not associated with functional deterioration as reported in humans.2 A lower GFR was detected in 
geriatric small breed dogs, whereas no decline was seen in ageing large breed dogs.9 Variable 
results are found for sCr in dogs, however no clinical significant changes were noticed as sCr 
remained within normal reference intervals in all dogs.9, 23 No age-related differences in several 
urinary markers as urinary albumin:creatinine ratio, urinary C-reactive protein:creatinine ratio, 
urinary retinol binding protein:creatinine ratio and urinary N-acetyl-beta-D-
glucosaminidase:creatinie ratio, are reported in healthy dogs.24 Research in ageing cats is even 
more limited. An age-effect on GFR was only reported in one study using an exogenous creatinine 
clearance test, whereas no age-effect was seen in other studies.9, 10 Higher sCr and serum urea is  
has been described in geriatric cats.6, 11 However, in our study, no age-effect on sCr was noted.  
Age-related effects on time-based parameters or parameters related to the slope of the time-
intensity curve were not observed in this study. Renal resistance is reported to increase in ageing 
people, commonly noted as an increase in intrarenal Doppler indices.25 Nevertheless, a significant 
age-effect on the resistive index was also not detected in a study on 24 healthy cats.26 
A significantly higher SBP was present in group 4 compared to group 1. The blood pressure in group 
2 was also higher compared to group 1. An age effect on SBP has previously been described in 
several studies in cats.6, 11, 27 Efforts were made to reduce stress-related hypertension due to the 
‘white coat effect’, however single SBP measurements as done in this study are not sufficient to 
diagnose hypertension.28 An underlying cause for hypertension was not found by the basic work-up 
included in this study. Further work-up and serial assessment of SBP was beyond the scope of our 
study.  
The main limitation of this study is the low number of cats in each group, and even more the low 
number of geriatric cats.  
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In conclusion, no significant age-related effects on renal perfusion parameters obtained with CEUS 
were detected in this study. However, a tendency towards lower PE and WiAUC, indicative for a 
lower blood volume, was present in geriatric cats. Further studies including a larger number of 
geriatric cats are needed to confirm these findings and determine the clinical relevance of these 
findings. 
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EVALUATION OF FELINE RENAL PERFUSION AFTER ANGIOTENSIN-I I  
INFUSION WITH CONTRAST-ENHANCED ULTRASONOGRAPHY AND 
SCINTIGRAPHY 
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1 . Abstract   
 
Contrast-enhanced ultrasound (CEUS) is an emerging technique to evaluate tissue perfusion. 
Promising results have been obtained in the evaluation of renal perfusion in health and disease, 
both in human and veterinary medicine. Renal scintigraphy using 99mTc-Mercaptoacetyltriglycine 
(MAG3) is another non-invasive technique that can be used to evaluate renal perfusion. However, 
no data are available on the ability of CEUS or 99mTc-MAG3 scintigraphy to detect small changes in 
renal perfusion in cats. Therefore, both techniques were applied in a normal feline population to 
evaluate detection possibilities of perfusion changes by angiotensin II (AT II).  
Contrast-enhanced ultrasound using a bolus injection of commercially available contrast agent and 
renal scintigraphy using 99mTc-MAG3 were performed in 11 healthy cats after infusion of 0.9% NaCl 
(control) and AT II.   
AT II induced changes were noticed on several CEUS parameters. Mean peak enhancement, wash-in 
perfusion index and wash-out rate for the entire kidney decreased significantly after AT II infusion. 
Moreover, a tendency towards a lower wash-in area-under-the curve was present. Renal 
scintigraphy could not detect perfusion changes induced by AT II.  
This study shows that CEUS is able to detect changes in feline renal perfusion induced by AT II 
infusion.  
 
2 . Introduct ion 
 
Chronic kidney disease is of major importance in both human and veterinary medicine with a 
prevalence of 13% in people and even up to 50% in randomly selected cats, increasing to 68.8% in 
cats with degenerative joint disease.1-3 It is a progressive disorder with often an unclear etiology. 
Early diagnosis is essential as intervention in early stage of the disease process may provide better 
life expectancy and quality of life.4 The assessment of renal perfusion is an important component 
in the evaluation of kidney disease as these renal perfusion changes occur early in the disease 
process.5  
However, performing an accurate, noninvasive measurement of renal perfusion is challenging. The 
gold standard to estimate renal plasma flow is determination of para-amino hippuric acid (PAH) 
clearance, although this is technically laborious and requires specific equipment, limiting the use in 
clinical circumstances.6  
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Renal perfusion can also be evaluated using radioactive tracers: OIH and MAG3. Both tracers have 
high first-pass extraction rate, but do not reach an extraction rate of 100%, thus the term ‘effective 
renal plasma flow’ (ERPF) is used.7 OIH has a similar chemical structure to PAH, and can be bound 
to 123I or 131I. Although the disadvantage is poor quality images compromising quantification, the 
tracer is still useful for blood clearance techniques.7 MAG3 can be labeled with 99mTc, making it a 
good tracer for imaging procedures.7 Despite its 30% lower clearance compared to OIH, high 
agreement between both tracers was found in both humans and dogs.8, 9 Significant hepatic uptake 
of MAG3 is noted in cats, requiring camera-based investigation as it allows distinction of the 
separate organs.10 Some limitations are associated with the use of radioactive tracers, including 
costs, involvement of radiation, and limited equipment availability. 
CEUS is a functional ultrasound technique that allows assessment of both macro- and 
microcirculation. Ultrasound contrast agent consists of tiny gas-filled bubbles (microbubbles) that 
have a rheology similar to red blood cells after intravenous injection.11 It is an extremely safe, cost-
effective technique, which does not involve the use of ionizing radiation.12, 13 The rate of adverse 
effects is close to zero, and, in contrast to iodinated contrast agents used in computed tomography 
or gadolinium-based contrast agent used in magnetic resonance imaging, no nephrotoxicity is 
involved, allowing safe use in geriatric and pediatric patients and patients with renal 
insufficiency.12 Several studies in human medicine have shown promising results for the use of 
CEUS in the diagnosis of diffuse renal disorders, such as early assessment of chronic kidney 
dysfunction, diabetic kidney damage, and rejection of renal transplants.14-18 In dogs, CEUS was 
proven to be useful for the early detection of iatrogenic chronic ischemic renal disease and to 
detect diffuse renal changes in beagles with iatrogenic hypercortisolism.19, 20  Nevertheless, it 
remains unclear if small changes in renal perfusion can be detected using a bolus injection of 
ultrasound contrast agent in cats.  
The objective of this study was to investigate the ability of CEUS and renal scintigraphy using 99mTc-
MAG3 to detect changes in renal perfusion of healthy cats at baseline and during infusion of AT II 
(an arterial vasoconstrictor).  
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3. Materials  and methods  
 
Animals  
The study was carried out in strict accordance with the recommendations of the European 
Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific 
Purposes. The protocol was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC2014/38). All efforts were made to minimize suffering. During the 
experiments, the cats were continuously monitored by experienced veterinarians to assess basic 
clinical parameters and signs of discomfort. Since suffering was limited and no detrimental effect 
on further life quality was present, the cats are further kept as experimental animals. 
 
Eleven healthy purpose-bred European Shorthair cats (Charles River Laboratories (30/3202), France 
and Lab of animal nutrition (LA2400378), Ghent university, Belgium) without any history of 
cardiovascular, renal or endocrine disease were included. They were judged healthy based on 
physical examination and non-invasive Doppler blood pressure measurement, hematology, 
biochemistry profile, urinalysis, and abdominal ultrasound. Both kidneys of all cats had a normal 
size and appearance on ultrasound. The mean ± standard error age of the cats 5.29 ± 0.4 years, 
with a mean ± standard error body weight of 3.53 ± 0.2 kg; body condition score 4-5/9). Eight cats 
were female, 3 were male, and all of them were neutered. The cats were housed indoor in stable 
groups of 10 cats, with free access to water, and fed a standard dry food twice a day.  
 
Study design 
The cats were premedicated with butorphanol (Dolorex, 10 mg/ml, MSD animal health) 0.2 mg/kg 
IV, 20 minutes before anesthesia induction. Anesthesia was induced with propofol (Propovet®, 10 
mg/ml, Abbott Laboratories) IV given to effect (6.30 ± 1.13 mg/kg), until endotracheal intubation 
could be performed. Anesthesia was maintained with isoflurane vaporized in 100% oxygen, using a 
non-rebreathing system, to reach an end tidal isoflurane percentage of 1.2 – 1.4%. 
 
All the subjects received a vasoconstrictor (AT II) and a control treatment (0.9% sodium chloride), in 
a randomized order, with a washout period of 14 days. Vasoconstriction was obtained with an 
infusion of AT II at a rate of 2 ng/kg/min using a syringe pump (Perfusor Space, BBraun, Germany) 
for the total duration of the CEUS study and renal scintigraphy. Cats undergoing control treatment 
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received an infusion of sterile 0.9% sodium chloride at the same rate and total volume as the AT II 
infusion. Infusion was started 5 minutes after the start of the inhalation anesthesia. On each study 
day, renal perfusion was evaluated using CEUS and MAG3 scintigraphy, started 15 minutes after 
initiation of the intravenous infusion of AT II or 0.9% sodium chloride. The imaging techniques were 
performed in a randomized order.  
 
Blood pressure (non-invasive Doppler measurement), heart rate, peripheral arterial oxygen 
saturation, end tidal isoflurane and carbon dioxide concentrations were closely monitored.  
 
Preparation AT II  
A stock solution (1000 μg/mL) was prepared by adding 1 mg of anhydrous AT II (Sigma-Aldrich, USA) 
to 1 mL of sterile 0.9% sodium chloride solution. This solution was filtered through a 0.22 μm filter 
(Steriflip Vaccuum Filtration System with millipore Express PLUS membrane, Millipore Corporation, 
Belgium), aliquoted into sterile cryovials (100 μL per vial), and stored at –80°C. On the study day, 1 
aliquot was thawed on ice and serially diluted in sterile 0.9% NaCl solution to produce solutions 
with final concentration of 0.1 μg/mL.  
 
Contrast-enhanced ultrasound  
The hair was clipped over the ventrolateral aspect of the abdomen. Alcohol and coupling gel were 
applied to the skin. The US exams were performed with the cat in dorsal recumbency.  
 
The left kidney was centered on the screen and imaged in a longitudinal plane. The transducer was 
manually positioned by the same person during each imaging procedure and was maintained at 
the same position during the CEUS examination.  
 A 0.15 mL bolus of sulfur hexafluoride-filled microbubbles (Sonovue®, Bracco, Italy) was injected 
into a 22-Gauge indwelling catheter in the cephalic vein. The same person performed the bolus 
injection in a standardized way in all cats. The ultrasound contrast agent was injected over 
approximately 3 seconds followed by injection of 1 mL saline bolus. A three-way stopcock was used 
to minimize delay between the injection of microbubbles and saline. Three injections of contrast 
were performed:  the first injection was not used for further evaluation. Between subsequent 
injections, remnant microbubbles were destroyed in the caudal abdominal aorta by setting the 
acoustic power at the highest level during 2 minutes. 
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All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(iU22, Philips, Bothell, WA) with contrast-specific software. Basic technical parameters were a high 
dynamic range setting (50 dB), single focus placed directly under the kidney, persistency off, 
mechanical index 0.09, timer started at the beginning of the injection. For the gain setting, we 
started with a nearly dark/anechoic image, representing nearly full suppression of fundamental 
signal (gain: 85 %). These settings were repeated during each injection. All studies were digitally 
registered as a movie clip at a rate of 7 frames per second, during 90 seconds.  
 
The clips were analyzed using specialized computer software (VueBox®, Bracco Suisse SA, 
Switzerland) for objective quantitative analysis. Six regions-of-interest (ROIs) were manually 
drawn: 1 on an interlobar artery, 3 in the renal cortex, 2 in the renal medulla, and a ROI containing 
the entire kidney (Figure 1). The ROIs for the cortex and medulla were identical in size for every clip 
and drawn at approximately the same depth. For every ROI, the software determined mean pixel 
intensities proportional to contrast-agent concentration and created a time-intensity curve. Time-
intensity curves were analyzed for peak enhancement (PE), wash-in area under the curve (WiAUC), 
rise time (RT), mean transit time (mTT), time to peak (TTP), wash-in rate (WiR), wash-in perfusion 
index (WiPI; WiAUC/RT), wash-out area under the curve (WoAUC), total area under the curve (AUC), 
fall time (FT), and wash-out rate (WoR). Parameters related to blood volume are PE, WiAUC, WoAUC 
and AUC. The PE corresponds to the maximum contrast medium signal intensity. The WiAUC is 
calculated as the sum of all amplitudes inside the range from the beginning of the curve up to the 
TTP. Similarly, WoAUC corresponds to the sum of all amplitudes inside the range from the TTP to 
the end of the descending curve. The other parameters, i.e. RT, mTT, TTP, WiR, WiPI, FT, WoR, are 
related to blood velocity. The WiR and WoR represent the slopes of respectively the ascending and 
descending curves. The RT corresponds to the time interval between the first arrival of contrast and 
the time of peak enhancement. The FT, in contrast, is the duration of contrast wash-out. Mean 
transit time is the mean duration of complete contrast medium perfusion.  The values for the 3 
ROIs in the renal cortex and 2 ROIs in the renal medulla were averaged. Peak enhancement, and 
WiAUC for the cortex, medulla and entire kidney were normalized to the values obtained for the 
interlobar artery. 
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F ig  1 .  Contrast-enhanced longitudinal  image of  the left  k idney of  a  cat .  Note the 
ROIs drawn around the entire kidney, in the renal cortex (upper image), renal medulla and centered 
on an interlobar artery (lower image).  
 
Scintigraphy 
The cats received 124 to 137 MBq (136.18 ± 7.44 MBq) of 99mTc-MAG3 intravenously via the cephalic 
vein catheter, followed by a 1 mL bolus of sterile saline flush, using the 3-way stopcock.  
The images were acquired using a gamma camera fitted with a low energy, high-resolution 
collimator. The cats were positioned in dorsal recumbency with the camera centered dorsal to the 
kidneys for dynamic imaging (matrix 128x128). Dynamic scanning started simultaneously with 
intravenous injection of the radiopharmaceutical. The dynamic protocol consisted of 60 frames at 1 
second per frame, followed by 120 frames at 4 seconds per frame.  
A 30 second static image of the full and empty syringe was performed. The net amount of injected 
radioactivity was determined by subtracting the amount of radioactivity in the syringe before and 
after injection measured in a dose calibrator.  
 
Image frames from the dynamic acquisition for the first 30 seconds were summed. Regions of 
interest were manually drawn around the left and the right kidney, and the aorta at the level of 
the kidneys. Equally sized background ROIs were drawn caudal to the kidneys, excluding major 
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vascular structures and the lower urinary tract (Figure 2). The regions of interest were applied to 
each frame and time-activity curves for the ROIs were generated. The kidney activity was 
background corrected. No depth correction was applied. A mathematical analysis program 
(Microsoft Excell) was used to determine the slopes of the kidney and aortic uptake curves.  
 
The K/A ratio was the ratio of the initial rise of each kidney curve to the initial rise of the arterial 
curve, using the following formula7:  
K/A ratio = slope of the kidney curve 
slope of the aortic curve
 
The flow index was calculated by using the following formula7:  
Flow index = Area under the aortic curve 
Area under the kidney curve
 
The area under the aortic curve was calculated from initial upslope to the point of peak activity. 
The area under the kidney curve was calculated for the same time interval.  
 
Statistical analysis  
A mixed model with period and treatment as categorical fixed effects and cat as random effect 
was used (SAS Version 9.3). Analysis for the CEUS parameters was performed per location. The F-
test at the 5% significance level was used to assess the effect of AT II infusion on the values of the 
various parameters of renal blood flow obtained with CEUS and MAG3. Correlations between 
perfusion parameters obtained with CEUS and renal scintigraphy were calculated using Pearson 
correlation coefficients. 
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F ig  2 .  Summed dynamic dorsal  images from a cat  in jected with 99mTc-MAG 3.  Note 
the ROIs drawn on both kidneys with the rectangular background placed caudal to the kidneys and 
a rectangular ROI drawn on the aorta at the level of the kidneys. 
 
4 . Results  
 
General 
AT II infusion, administration of SonoVue® and 99mTc -MAG3 were well tolerated and no adverse 
effects were noticed. Good quality images were obtained  
with both imaging techniques in all study subjects. 
The mean systolic blood pressure during the procedure was 88 ± 22 mmHg (ranging from 63 to 
132 mmHg) for the AT II treatment and 72 ± 8 mmHg (ranging from 60 – 82 mmHg) for the 
placebo treatment. There was a statistically significant increase (P=0.03) in systolic blood pressure 
with infusion of AT II whereas no influence of AT II infusion was noted on the heart rate.  
 
Contrast-enhanced ultrasound 
A mean decrease of 26.1% (P=0.04) in PE for the entire kidney and a 19.7 % (P=0.12) decrease for 
the renal cortex was noticed with infusion of AT II compared to control treatment. However, only 
the results for the entire kidney reached statistical significance.  
Although not significant, a tendency for a lower AUC was observed after AT II infusion for the entire 
kidney and renal cortex, with the effect being most prominent for WiAUC.  A 23.2% (P=0.08) 
reduction in WiAUC was noted for the entire kidney, while a 21.3% (P=0.15) reduction was present 
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for the renal cortex. Similarly, a reduction of 18.8% (P=0.20) for the entire kidney and 21.9% 
(P=0.18) for the renal cortex for the WoAUC and a reduction of 20.7% (P=0.14; entire kidney) and 
21.8% (P=0.14; renal cortex) in total AUC were present. None of the results reached statistical 
significance.  
Furthermore, AT II infusion induced a significant reduction in WiPI (P=0.04) and WoR (P=0.02) for 
the entire kidney.  
 
The results of PE and WiAUC normalized to the interlobar artery (PE* and WiAUC*) were in 
accordance with PE and WiAUC, i.e. a decrease of these parameters was observed with AT II 
infusion. However, none of these results reached statistical significance (P-values ranging between 
0.34 and 0.22). 
 
No changes were observed in any of the perfusion parameters for the renal medulla and the time-
related parameters for the renal cortex.  
 
Graphs demonstrating the influence of AT II on the most important perfusion parameters can be 
consulted in Figure 3. 
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F ig  3 .  Changes in  CEUS parameters  induced by angiotensin I I  (AT I I )  presented as 
means +/-  standard error .  * p value < 0.05. From left to right, top to bottom: peak 
enhancement (PE), ratio of peak enhancement with interlobar artery (PE*), wash-in area-under-
the-curve (WiAUC), total area-under-the-curve (total AUC), wash-out area-under-the-curve 
(WoAUC), wash-in perfusion index (WiPI) and wash-out-rate (WoR). All parameters are expressed in 
arbitrary units.  
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Renal scintigraphy 
A negligible effect of AT II was noticed on the flow index for the left kidney (4% decrease, P=0.52), 
while a 26% (P=0.19) decrease was noted for the right kidney. K/A ratio decreased by 16% (P=0.22) 
for the left kidney and 11% (P=0.50) for the right kidney (Figure 4). However, none of the 
parameters reached statistical significance when comparing AT II infusion with control treatment. 
 
 
F ig  4 .  Changes in  sc int igraphic  perfusion parameters  induced by angiotensin I I  
(ATI I )  presented as means +/-  standard error .   LK: left kidney, RK: right kidney.  
 
No association was observed between the perfusion variables obtained with CEUS and those 
obtained with renal scintigraphy.  
 
5 . Discussion  
 
In this study, we have shown that CEUS is capable of detecting perfusion changes induced by AT II 
infusion in healthy cats. We found a significant decrease in PE and a tendency towards a lower 
WiAUC compared to control measurements. Moreover a significant reduction in WiPI and WoR was 
noticed with AT II infusion.  
The physiologic effects of AT II can easily explain the AT II-induced decrease in renal blood volume, 
noticed as a decrease in PE and AUC. AT II is a potent vasoconstrictor, causing an increased systemic 
blood pressure and even more important, an increased renal perfusion pressure. The latter is 
achieved by vasoconstriction of both the afferent and efferent glomerular arterioles.21, 22 
Consequently, AT II causes dose-dependent decreases in total and cortical renal blood flow.22, 23 The 
efferent arteriole is more sensitive to the vasoconstrictive effects of AT II compared to the afferent 
arteriole.24 Additionally, a decreased WiPI and WoR were noted after AT II infusion. WiPI is 
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calculated as a ratio of WiAUC and RT.  The reduction in WoR corresponds to slower outflow of 
contrast medium.  
In our study, infusion of AT II did not alter any of the perfusion parameters for the renal medulla. 
Studies performed on rats using invasive laser Doppler perfusion monitoring, report an 
inconsistent effect of angiotensin on the medullary blood flow varying from no influence to an 
increase in medullary blood flow.23, 25, 26 The exact etiology remains unclear: a higher concentration 
of vasodilatory substances as prostaglandins, kinins and nitrogen oxide in the renal medulla, may 
likely cause this phenomenon.23, 26  
Our results are in accordance with a study in humans where a dose-dependent decrease in 
perfusion index of the renal cortex was observed with CEUS after infusion of AT II. The changes in 
perfusion index paralleled those in estimated renal plasma flow measured with PAH-clearance 
techniques.27 In a recent study in sheep, a very heterogeneous and inconsistent response on CEUS 
parameters was noticed after infusion of AT II. The only significant finding was an increase in mean 
transit time, corresponding with a delayed replenishment, caused by a high dose AT II infusion.28 In 
both the human and sheep study, CEUS was performed using continuous infusion of contrast agent 
followed by several destruction-refilling sequences, whereas in our study a bolus injection was 
performed. Therefore, different perfusion parameters are obtained in our study compared to the 
human and sheep study, and thus exact comparison of the results is not possible.  
The discrepancy between the flow index for the left and right kidney is most likely related to 
inclusion of liver activity in the ROI for the right kidney. Variable hepatic uptake of 99mTc-MAG3 has 
been described in cats.10 The anatomic location of the right kidney close to the caudate lobe of the 
liver complicates complete exclusion of liver activity within the renal ROI.  
We did not observe an association between any of the CEUS parameters and values obtained with 
99mTc-MAG3 scintigraphy. Perfusion changes induced by AT II did not reach statistical significance 
with renal scintigraphy. In a study with human patients with various renal diseases, a significant 
correlation was present between ERPF determined by PAH-clearance, ERPF determined by 99mTc-
MAG3 scintigraphy and decline ratio obtained with CEUS. However, no association was seen 
between the peak enhancement obtained with CEUS, scintigraphy and PAH-clearance. Contrast-
enhanced ultrasound in the latter study was performed using a combination of harmonic power 
Doppler and intermittent imaging during a continuous infusion of contrast agent.29 A strict 
comparison between CEUS and renal scintigraphy is impossible because with CEUS regional blood 
flow is determined on a microvascular level while total renal blood flow on a macrovascular level 
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is assessed using renal scintigraphy. Moreover, both techniques only deliver relative perfusion 
parameters, as no formulas exist to calculate effective or estimated renal plasma flow derived 
from these techniques in cats. Different perfusion parameters are calculated from both techniques, 
further complicating a comparison. Furthermore, there is a high heterogeneity in the parameters 
that are determined by CEUS. The assessed parameters depend on the injection procedure: 
different parameters are calculated using continuous infusing of contrast-agent compared by 
bolus injection.  
This study has some limitations. Although there is a gold standard for global renal plasma flow 
evaluation (PAH), there is not one for microperfusion. Laser Doppler probes have been used in rats 
for evaluation of global renal perfusion as well as cortical and medullary perfusion.23, 25, 26 However, 
the technique has not been described in cats and is due to its invasiveness unethical to use. Renal 
scintigraphy using 99mTc-MAG3 is the only non-invasive technique available for evaluation of 
perfusion in cats. Data on the use of renal scintigraphy in cats is limited and no formula is 
established to determine ERPF as available in dogs and human.7  
Second, anesthesia might suppress the effect of AT II. Therefore, the response of the anesthetized 
cats in this study might differ from the response that would be seen in conscious cats. We choose 
to anesthetize the cats to eliminate the variable and unpredictable variations in blood pressure 
caused by stress. In a murine study, barbiturate anesthesia was found to decrease baseline arterial 
pressure, however it did not alter the response to AT II.30 In sheep, isoflurane anesthesia reduced 
the hypertensive response to AT II both in magnitude and duration, however the reduction in renal 
blood flow was similar to conscious animals.31 
In conclusion, this study demonstrates that CEUS is a potentially valuable technique to detect 
changes in feline renal perfusion after infusion of AT II. These perfusion changes were not depicted 
by renal scintigraphy. Further research is warranted to determine the value of CEUS for diagnosis 
of naturally occurring diffuse renal pathology.  
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EVALUATION OF RENAL PERFUSION IN HYPERTHYROID CATS BEFORE 
AND AFTER RADIOIODINE TREATMENT 
 
 
 
 
 
 
 
 
 
Adapted from:   
Stock E., Daminet S., Paepe D., Buresova E., Vandermeulen E., Smets P., Duchateau L., Saunders J.H.*, 
Vanderperren K.*(*shared senior authorship). Evaluation of renal perfusion in hyperthyroid cats 
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1 . Abstract  
 
Hyperthyroidism and renal disease are among the most important health issues in geriatric cats. 
Both diseases often occur concurrently and mutually influence each other, with hyperthyroidism 
possibly masking underlying renal disease. As changes in renal perfusion play an important role in 
functional renal changes in hyperthyroid cats, investigation of renal perfusion may deliver novel 
insights. Contrast-enhanced ultrasound (CEUS) is a safe and non-invasive technique that allows 
evaluation of tissue perfusion. In this study, renal perfusion is assessed with CEUS in 42 
hyperthyroid cats, before and after radioiodine treatment.  
An increase in several time-related perfusion parameters was observed after radioiodine 
treatment, indicating a decreased blood velocity upon resolution of the hyperthyroid state. Further, 
a small post-treatment decrease in peak enhancement was present in the renal medulla, 
suggesting a lower medullar blood volume.  
In conclusion, CEUS shows a higher cortical and medullary blood velocity and higher medullary 
blood volume in hyperthyroid cats before radioactive treatment in comparison with 1-month 
control.  
 
2 . Introduct ion  
 
Both hyperthyroidism and renal disease are common pathologies in elderly cats, and 
unsurprisingly these pathologies often occur concurrently. The prevalence of cats suffering from 
both diseases has been reported to be approximately 14%.1 The incidence of azotemia occurring 
shortly after treatment of hyperthyroidism even reaches 40% suggesting unmasking of pre-
existing impaired renal function. 1-3  
A complex relationship exists between the thyroid glands and the kidneys. In cats with 
hyperthyroidism, increased thyroxin levels induce decreased vascular resistance as well as 
increased cardiac output, leading to increased renal blood flow, and subsequently increased 
glomerular filtration rate (GFR).4 Treatment of hyperthyroidism inversely results in a decrease in 
GFR 1 month after treatment, whereas GFR is found to be stable between 1 and 6 months post 
treatment.2, 5 Importantly, predicting changes in renal function before treatment of 
hyperthyroidism is complicated. Routine renal variables as serum creatinine (sCr), serum urea, 
urine specific gravity (USG) and proteinuria are insensitive since they are strongly influenced by 
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the hyperthyroid state of the cat.4 Pre-treatment measurement of GFR shows promise in predicting 
post-treatment azotemia, however great overlap exists with cats that remain non-azotemic.2, 4 
Therefore, an ideal test to predict post-treatment azotemia is not available at this moment. 
Renal blood flow plays a fundamental role in the functional renal changes present in hyperthyroid 
cats, hence evaluation of renal perfusion could deliver important new insights in renal function in 
hyperthyroid cats.4 CEUS is a functional imaging modality that allows assessment of macro- and 
microperfusion through the use of an intravenously administered contrast agent.  The contrast 
agent consists of gas-filled microbubbles stabilized by an outer phospholipid shell and have 
approximately the size of red blood cells. Consequently, they do not cross the endothelium after 
intravenous administration and act as blood pool agents. Major advantages associated with CEUS 
are its excellent safety profile allowing the use in geriatric patients and patients suffering from 
renal disease, the non-invasiveness, the absence of ionizing radiation and relatively short imaging 
times.6 
The objective of this study was to evaluate renal perfusion using CEUS in hyperthyroid cats, before 
and after radioiodine treatment. The hypothesis was that a higher renal perfusion, both a higher 
blood velocity and higher blood volume, would be present before radioiodine treatment compared 
to the 1-month control.  
 
3 . Materials  and methods 
 
Fifty-one client-owned hyperthyroid cats presented for radioiodine treatment at the Faculty of 
Veterinary Medicine of Ghent University (Belgium) were included in the study with the permission 
of the local ethical committee of Ghent University (EC 2015/67). Owners signed an informed 
consent prior to inclusion. 
 
Inclusion criteria were a diagnosis of hyperthyroidism based on clinical signs, increased serum 
total thyroxine (T4) concentration and increased pertechnetate uptake in one or both thyroid 
glands on scintigraphic scan. Cats with concurrent systemic disease, including pre-existing overt 
renal disease or with hemodynamic significant cardiac disease, defined as severe left atrial 
dilation, signs of congestive heart failure or significant arrhythmias, were excluded. Anti-thyroid 
treatment, either medication (methimazole, carbimazole) or diet (Hill’s prescription Y/D), was 
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ceased at least 10 days prior to radioiodine treatment. Cats maintained their original, commercial 
diet throughout the study period.  
 
The cats were evaluated on the day of radioiodine treatment and 1 month after treatment. Pre-
treatment evaluation included a thorough physical exam, standard two-view thoracic x-rays 
(lateral and ventrodorsal projections), abdominal ultrasound, CEUS of the kidneys and cardiac 
ultrasound.  Post-treatment evaluation included physical examination, CEUS of the kidneys and 
cardiac ultrasound. A complete blood count, serum biochemistry profile including serum total T4, 
and complete urinalysis (USG, urinary pH, urinary protein:creatinine ratio (UPC), sediment 
examination7 and bacterial culture) were performed at both occasions. At both occasions systolic 
blood pressure was measured by Doppler ultrasonic technique, following the consensus statement 
of the American College of Veterinary Internal Medicine.8  
 
In 10 cats, GFR was measured with a plasma exogenous creatinine clearance test. This was 
performed one day prior to radioiodine treatment and repeated 1 day prior to the post-treatment 
exam. A limited sampling strategy, minimally impacting the reliability of the GFR estimate, was 
used, as previously described.9 Briefly, 40.0 mg/kg creatinine was administered intravenously and 
blood samples were taken in EDTA tubes before and 5, 30, 60, 120, 180, 360 and 600 minutes after 
injection. The borderline GFR cut-off value was defined as 1.7 mL/min/kg, the lower GFR cut-off 
value as 1.2 mL/min/kg.9 
 
CEUS procedure  
A 22-Gauge indwelling catheter was placed in the cephalic vein. Anesthesia was induced with a 
bolus of propofol (Propovet®, Abbott Laboratories) 3.5-7.7 mg/kg IV given to effect and maintained 
with 0-3 additional boluses as necessary. 
 
The hair was clipped over the ventrolateral aspect of the abdomen and coupling gel was applied to 
the skin. The ultrasound examinations were performed with the cat in dorsal recumbency. The 
kidney of interest was centered on the screen and was imaged in a longitudinal plane using dual-
screen (simultaneous display of conventional B-mode and contrast-mode image). The transducer 
was manually positioned during each imaging procedure and was maintained at the same position 
during the CEUS examination.  
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The contrast agent (Sonovue®, Bracco, Italy), 0.05 mL/kg, was injected IV (bolus injection over +/- 3 
s) followed by injection of 1.5 mL saline bolus. A three-way stopcock was used to avoid any delay 
between the injection of contrast agent and saline. The same person performed the injection in a 
standardized way. Three to four injections of contrast were performed:  two for the left kidney, one 
for the right kidney and one for the abdominal aorta in 13 cats. Between subsequent injections, to 
avoid artifacts, remnant microbubbles were completely destroyed by setting the acoustic power at 
the highest level and scanning the caudal aspect of the abdominal aorta for approximately 2 
minutes. 
 
All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(iU22, Philips) with contrast-specific software. Basic technical parameters were a single focus 
placed under the kidney, persistency off, mechanical index 0.09, high dynamic range setting (C50), 
timer started at the beginning of the injection, gain 85% (corresponding to a nearly dark/anechoic 
image before contrast administration). The settings were repeated during each injection. All 
studies were digitally registered as a movie clip at a rate of 9 frames per second, during 90 
seconds.  
 
The clips were exported in DICOM format and analyzed using specialized computer software 
(VueBox®, Bracco Suisse SA, Geneva, Switzerland) for objective quantitative analysis. Six regions-of-
interest (ROIs) were manually drawn: 3 in the renal cortex, 2 in the renal medulla and 1 on an 
interlobar artery. If the abdominal aorta was included, 3 ROIs were drawn in the middle of the 
aortic lumen. The ROIs were similar in size and drawn at the same depth for every region. Care was 
taken to avoid including cystic lesions and focal parenchymal lesions within the ROI. For every ROI, 
the software determined mean pixel intensity as a function of time and created a time-intensity 
curve. Time-intensity curves were analyzed for peak enhancement (PE), wash-in area under the 
curve (WiAUC), rise time (RT), mean transit time (mTT), time to peak (TTP), wash-in rate (WiR), 
wash-in perfusion index (WiPI; WiAUC/RT), wash-out area under the curve (WoAUC), total area 
under the curve (AUC), fall time (FT), and wash-out rate (WoR). The PE corresponds to the maximum 
contrast medium signal intensity. The WiAUC is calculated as the sum of all amplitudes inside the 
range from the beginning of the curve up to the TTP. Similarly, WoAUC corresponds to the sum of all 
amplitudes inside the range from the TTP to the end of the descending curve. The other 
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parameters, i.e. RT, mTT, TTP, WiR, WiPI, FT, WoR, are related to blood velocity. The WiR and WoR 
represent the maximum and minimum slopes of the time-intensity curves. The RT corresponds to 
the time interval between the first arrival of contrast and the time of peak enhancement. The FT, in 
contrast, is the duration of contrast wash-out. Mean transit time is the mean duration of complete 
contrast medium perfusion. The values for the 3 ROIs in the renal cortex, 2 ROIs in the renal 
medulla, and the 2 ROIs in aorta were averaged. Peak enhancement for the cortex and medulla was 
normalized to the values obtained for the interlobar artery (PE*) and abdominal aorta (PEAO).  
 
Statistical analysis 
Analyses were based on a linear mixed model with cat and kidney nested in cat as random effects 
and treatment (pre/post radioiodine treatment) as a categorical fixed effect (SAS version 9.4). 
Analyses were done separately for the renal cortex and medulla. Correlations between perfusion 
parameters and heart rate, blood pressure, total T4, serum sCr, and GFR were calculated for the 
renal cortex and medulla using Spearman correlation coefficients (ρ). A difference was considered 
statistically significant if P < 0.05. 
 
4 . Results  
 
In total 9 cats were excluded from the study: 4 cats because of an additional pathology (suspected 
pulmonary neoplasia n=1, intestinal lymphoma n=1, severe cardiomegaly and left atrial dilation n=1, 
second-degree atrioventricular block n=1), 4 cats due to aggressive behavior and 1 cat was lost for 
follow-up. For the 42 remaining cats, no significant abnormalities were noted on thoracic 
radiographs or abdominal ultrasound. Alterations seen on echocardiography were compatible with 
hyperthyroidism and improved or remained stable after treatment.  
 
The median age at time of inclusion was 12 years 9 months (range 7y5m to 16y7m).  
 
Of the 42 cats included, 27 (64%) had a post-treatment total T4 value within the normal reference 
interval, and 15 (36%) showed a total T4 value below. None showed a total T4 value above the 
normal reference interval at 1 month after radioiodine therapy. Two cats (4.8 %) developed post-
treatment azotemia, one of them had total T4 level below the reference range 1 month post-
treatment. Additionally, 1 cat with normal sCr levels had decreased post-treatment GFR and one cat 
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with normal sCr had borderline GFR. An overview of the baseline characteristics of the cats, before 
and after radioiodine treatment is provided in Table 1. 
 
Var iables  Pre-treatment  Post-treatment  P-value  
Body  weight  (kg)  3.8 ± 0.1 4.1 ± 0.1 < 0.001 
Heart  rate  (bpm) 209.4 ± 4.2 169.7 ± 4.4 < 0.001 
B lood pressure  (mmHg)  161.2 ± 4.6 162.7 ± 4.9 0.793 
Total  T4  114.6 ± 4.3 13.0 ± 4.3 < 0.001 
sCr  (µmolL -1)  65.3 ± 4.1 109.6 ± 4.1 < 0.001 
Serum urea  (mmolL -1)  8.7 ± 0.5 10.4 ± 0.5 < 0.001 
USG 1.044 ± 0.001 1.037 ± 0.001 < 0.001 
UPC 0.71 ± 0.05 0.23 ± 0.05 < 0.001 
GFR (mL/kg/min)  3.9 ± 0.3 2.5 ± 0.3 0.003 
 
Table 1 .  C l in ical  parameters  before and after  radioiodine treatment provided as 
mean ± standard error  (bpm beats per minute; T4 thyroxine; sCr serum creatinine; USG urine 
specific gravity; UPC urinary protein:creatinine ratio; GFR glomerular filtration rate) 
 
Both kidneys had a normal appearance on B-mode ultrasonography in 27 cats, including 1 of the 2 
cats developing post-treatment azotemia. Two cats had a unilateral small kidney (< 3 cm), with a 
subjectively decreased corticomedullary definition, 1 of these developed post-treatment azotemia, 
whereas the other did not. Three other cats showed a mildly decreased corticomedullary definition 
in normal-sized kidneys. Three cats had a mildly irregular renal outline, 5 had segmental cortical 
lesions and 4 had small cystic lesions, none of these cats developed post-treatment azotemia. One 
cat, without post-treatment azotemia, had mild bilateral pyelectasia without signs of obstruction, 
this improved post-treatment. Eight cats had bilateral hyperechoic renal cortices, all of them were 
male castrated, suggesting fat infiltration.10 
 
No significant side effects of the sonographic contrast material were noted. However, 1 cat showed 
mild and transient tachypnea after the first injection of contrast agent during the pre-treatment 
evaluation, which resolved spontaneously within 10 minutes. 
 
Several perfusion parameters showed significant changes between pre- and post-treatment 
values. A comparison between the perfusion parameters before and after radioiodine treatment is 
provided in Table 2. Moreover, representative time-intensity curves are provided in Figure 1.  
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Var iable ,  by  
locat ion  
Pre-treatment  Post-treatment  P-value  
Renal  cortex     
   PE 2193.27 ± 147.85 2146.47 ± 147.85 0.771 
   PE* 20.09 ± 1.48 19.06 ± 1.49 0.557 
   PEAO 9.89 ± 1.23 8.54 ± 1.11 0.31 
   WiAUC 3566.26 ± 270.32 4864.32 ± 270.32 < 0.001 
   RT 2.79 ± 0.10 3.79 ± 0.10 < 0.001 
   mTT 24.36 ± 1.60 28.73 ± 1.60 0.011 
   TTP 7.83 ± 0.22 9.91 ± 0.22 < 0.001 
   WiR 1119.38 ± 85.46 793.75 ± 85.46 0.008 
   WiPI 1342.53 ± 90.26 1317.72 ± 90.26 0.801 
   WoAUC 4830.39 ± 368.63 6767.46 ± 368.63 < 0.001 
   AUC 8396.54 ± 636.37 11632.00 ± 636.37 < 0.001 
   FT 3.87 ± 0.17 5.46 ± 0.17 < 0.001 
   WoR 755.90 ± 62.89 501.47 ± 62.89 0.004 
    
Renal  medul la     
   PE 308.93 ± 25.14 270.59 ± 25.52 0.093 
   PE* 3.01 ± 0.26 2.37 ± 0.26 0.044 
   PEAO 1.40 ± 0.23 1.10 ± 0.21 0.30 
   WiAUC 2530.39 ± 202.54 2512.68 ± 205.86 0.935 
   RT 14.01 ± 0.66 16.25 ± 0.68 0.001 
   mTT 68.36 ± 10.93 87.84 ± 11.19 0.196 
   TTP 24.58 ± 0.76 30.99 ± 0.77 < 0.001 
   WiR 36.90 ± 3.83 27.40 ± 3.88 0.004 
   WiPI 194.04 ± 15.64 168.53 ± 15.87 0.075 
   WoAUC 4403.78 ± 363.00 3974.35 ± 370.89 0.259 
   AUC 6949.01 ± 560.01 6442.36 ± 572.20 0.387 
   FT    25.54 ± 1.32 26.80 ± 1.35 0.386 
   WoR 18.98 ± 2.26 15.28 ± 2.30 0.072 
 
Table 2 .  Mean ± standard error  values of  renal  perfusion parameters  in  
hyperthyroid cats  before and 1  month after  radioiodine treatment .  (PE peak 
enhancement, PE* peak enhancement normalized to interlobar artery, PEAO peak enhancement 
normalized to abdominal aorta, WiAUC wash-in area-under-the-curve, RT rise time, mTT mean 
transit time, TTP time-to-peak, WiR wash-in rate, WiPI wash-in perfusion index, WoAUC wash-out 
area-under-the-curve, AUC total area-under-the-curve, FT fall time, WoR wash-out rate) 
 
 
The RT (P<0.001), mTT (P=0.011), TTP (P<0.001) and FT (P<0.001) for the renal cortex increased 
significantly post-treatment. In parallel with this, the WiR (P=0.008) and WoR (P=0.004) 
decreased. A post-treatment increase was also seen for the WiAUC (P<0.001), WoAUC (P<0.001) and 
total AUC (P<0.001) for the renal cortex. Similarly, for the renal medulla, RT (P=0.001) and TTP 
(P<0.001) increased post-treatment, whereas WiR (P=0.004) decreased. Moreover, a significant 
post-treatment decrease in normalized PE (PE*; P=0.044) was noticed for the medulla.  
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F igure 1 .   Representat ive t ime-intensity  curves for  the renal  cortex of  a  
hyperthyroid cat  before (pre)  and 1  month after  (post)  radioiodine treatment .  
 
Significant negative correlations were present between the heart frequency and RT in the cortex 
(ρ=-0.46; P<0.001) and TTP for both cortex (ρ=-0.42; P=0.001) and medulla (ρ=-0.39; P=0.003), 
meaning that shorter TTP and RT, and thus higher renal blood velocity, are present as heart 
frequency increases. Similarly, significant negative correlations were present between the total T4 
and cortical RT (ρ=-0.60; P<0.001), TTP (ρ=-0.59; P<0.001) and FT (ρ=-0.57; P<0.001), and 
medullary TTP (ρ=-0.48; P<0.001). Moreover, a positive correlation was present between sCr and 
cortical (ρ=0.68; P<0.001) and medullary (ρ=0.41; P=0.001) TTP, and cortical FT (ρ=0.52; P<0.001). 
Negative correlations were found between GFR and cortical TTP (ρ=-0.51; P=0.021), cortical RT (ρ=-
0.53; P=0.002), cortical FT (ρ=-0.50; P=0.024) and medullary RT (ρ=-0.62; P=0.004) and FT (ρ=-
0.68; P=0.001).  
However, significant correlations were also present between heart frequency and sCr (ρ=-0.48; 
P<0.001), heart frequency and GFR (ρ=0.47; P=0.042), heart frequency and total T4 (ρ=0.59; 
P<0.001), total T4 and sCr (ρ=-0.71; P<0.001), total T4 and GFR (ρ=0.61; P=0.004), complicating the 
interpretation. 
 
5 . Discussion  
 
Multiple studies have been investigating routine urine and serum renal markers and GFR in 
hyperthyroid cats before and after treatment.2, 3, 5, 11-14 This is the first study focusing on renal 
perfusion where we showed that CEUS was capable to detect significant changes in renal blood 
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flow before and after radioiodine treatment. A faster inflow of contrast agent, reflected by lower 
RT and TTP, was present during the hyperthyroid state pre-treatment. Similarly, a faster outflow 
(FT) was present. Consequently, the mTT, time of duration of contrast enhancement, was shorter. 
WiR and WoR, representing the slope of respectively the inflow and outflow phase of the time-
intensity curve, were higher in the pre-treatment phase. The combination of these findings 
indicates a higher velocity of renal blood flow in hyperthyroid cats, which decreases significantly 1 
month after 131-I treatment. Similar changes were present for the renal medulla. The changes in 
CEUS parameters can in part be attributed to the decreased systemic vascular resistance that is 
present in hyperthyroidism. Thyroid hormones induce increased nitric oxide levels in the renal 
cortex and medulla, resulting in vasodilation. Additionally, an increased number of beta-adrenergic 
receptors is present in the renal cortex during the hyperthyroid state.4 Secondly, it should be 
mentioned that the ultrasound contrast agent is injected intravenously and hence ‘travels’ in the 
systemic circulation before reaching the kidney. Therefore, the higher heart rate and cardiac output 
in hyperthyroid cats will have reinforced the effects on renal blood velocity. This is also reflected 
by the moderate negative correlations between heart rate and several time-based perfusion 
parameters. 
The AUC of the renal cortex significantly increased after radioiodine treatment. The AUC is 
influenced by both the height of the time-intensity curve (intensity, represented by the PE) and the 
width of the curve (time, represented by several time-based parameters, most importantly mTT). 
No significant changes were observed in PE after radioiodine treatment; therefore, the change in 
AUC can be attributed to the longer duration of contrast enhancement after radioiodine treatment. 
While most of the previously mentioned data were obtained in the renal cortex, little is known 
about the microvascular alterations accompanying hyperthyroidism in the renal medulla. This 
study showed a small, but significant decrease in normalized PE (PE*) for the renal medulla after 
radioiodine treatment indicating a larger blood volume in the renal medulla during the 
hyperthyroid state. It is known that the hyperthyroid state induces an increased renal blood flow, 
resulting from a combination of increased cardiac output, decreased vascular resistance, overall 
increased blood volume, and upregulation of beta-adrenergic receptors in the renal cortex.4, 15 A 
higher estimated renal blood flow in hyperthyroid cats has been described by Adams et al. (1997). 
In the latter study, total renal blood flow was measured using a radionuclide based technique (131-
I ortho-iodo-hippurate).16 Nevertheless, no significant changes were observed in PE for the renal 
cortex in our study, although they were expected. This is most likely caused by the high variability 
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and consequently broad 95% confidence intervals for this parameter.17, 18 The intensity measured on 
CEUS images, and thus the PE, is strongly influenced by several factors. Uncontrollable patient-
related factors as filtration by the lungs and phagocytosis by the reticuloendothelial system will 
influence the final microbubble concentration in the renal parenchyma.19, 20 
Only 4.8% of the cats in this study developed post-treatment azotemia, which is considerably lower 
than the 17% - 39% reported in literature.1, 2, 12, 13 The percentage of cats having low total T4 one 
month after radioiodine treatment (36%) was similar to the values reported in literature (24%-
51%).11, 21, 22 Iatrogenic hypothyroidism is well-known to contribute to the development of renal 
dysfunction.22 On the other hand, CKD can induce euthyroid sick syndrome with suppression of the 
serum total T4 levels. Measurement of thyroid-stimulating hormone (TSH) allows differentiation 
between iatrogenic hypothyroidism and euthyroid sick syndrome. The combination of low total T4 
and elevated TSH is consistent with iatrogenic hypothyroidism.4, 15  However, TSH concentration is 
also influenced by the radioiodine treatment, TSH concentration is reported to be within normal 
reference interval 3 months after radioiodine treatment.22 Therefore, TSH was not measured in this 
study. 
Due to the low number of cats developing CKD after radioiodine treatment in this study it was not 
possible to assess the predictive value of CEUS for the development of post-treatment azotemia. 
Longer follow-up might have allowed identification of slightly more cats developing CKD, however 
significant changes in renal function are reported to occur within 4 weeks after treatment and not 
thereafter.2, 5 
In conclusion, CEUS allowed assessment of renal perfusion in hyperthyroid cats before and after 
radioiodine treatment. A significant reduction in both cortical and medullary blood velocity was 
noted 1 month after radioiodine treatment. However, no significant decrease in cortical blood 
volume could be detected. Further research is warranted to investigate the diagnostic capabilities 
of CEUS in the assessment of renal perfusion in hyperthyroid cats and investigate its predictive 
value for the development of post-treatment azotemia. 
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1 . Abstract   
 
Contrast-enhanced ultrasound (CEUS) is an emerging, functional imaging technique allowing non-
invasive assessment of tissue perfusion. Human studies show that the technique holds great 
potential to be used in the diagnosis of chronic kidney disease (CKD). However, data in veterinary 
medicine are currently lacking. This study evaluates the diagnostic capabilities of CEUS in client-
owned cats with CKD (n=14) in comparison with healthy control cats (n=43).  
In cats with CKD, longer time-to-peak and shorter mean transit times were observed for the renal 
cortex. In contrast, a shorter time-to-peak and rise time were seen for the renal medulla. The 
findings for the renal cortex indicate a decreased blood velocity and shorter total duration of 
enhancement, likely caused by increased vascular resistance in CKD. An increased blood velocity in 
the renal medulla has not been described before, and may be due to a different response to 
regulatory factors in cortex and medulla.  
In conclusion, CEUS was capable of detecting perfusion changes in cats with CKD. Further research 
is warranted to assess the diagnostic capabilities of CEUS in early stage of the disease process. 
 
2 . Introduct ion  
 
CKD is one of the most commonly diagnosed diseases in elderly cats. The prevalence has been 
reported to be approximately 1-3% in the general feline population, even increasing to 30% in 
geriatric cats.1-3 Renal disease is reported to be the cause of death in 14-17% of senior and geriatric 
cats.4 A primary, often unidentified trigger, initiates renal damage and nephron loss, which finally 
results in self-perpetuating renal injury and progressive renal disease.5 The most common 
histologic findings in cats with CKD are tubulointersitial lesions as tubular atrophy, interstitial 
inflammation and fibrosis.6 Diagnosis in early stage of the disease progress allows timely initiation 
of supportive therapy and slows the disease progress.7 Prompt diagnosis remains challenging. The 
diagnosis is most often based on elevations of serum urea and creatinine concentrations combined 
with a low urine specific gravity.  These changes are unfortunately only present when already a 
substantial portion of renal function is lost. Measurement of glomerular filtration rate (GFR) 
provides more accurate assessment of renal function, but requires multiple blood samples, limiting 
its use in routine clinical practice.8, 9 Therefore, the search for improved noninvasive diagnostic 
methods for early renal disease is still ongoing.  
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Renal function is closely related to renal perfusion; hence evaluation of renal perfusion could yield 
new information about kidney function and improve diagnosis. Performing an accurate and non-
invasive measurement of renal perfusion is challenging. Dynamic high-field magnetic resonance 
imaging, contrast-enhanced computed tomography or renal scintigraphy can be used to assess 
renal perfusion. In practice, clinical application of those techniques is limited by relatively high 
costs, limited availability, long examination times and exposure to ionizing radiation.10, 11 Doppler 
ultrasound allows calculation of perfusion indices providing information about vascular resistance. 
These indices are elevated in animals with renal disease, but are relatively unspecific as they are 
influenced by multiple non-renal factors.12-14 Moreover, Doppler ultrasound is limited to evaluation 
of macroperfusion since low-velocity flow in smaller vessels cannot be assessed.12 
Contrast-enhanced ultrasound (CEUS) is an emerging technique using microbubbles to enhance 
detection of tissue perfusion up to a microvascular level. These bubbles are gas-filled spheres 
stabilized by an outer shell. They have a size similar to those of red blood cells and thus remain 
strictly in the blood pool after intravenous injection. CEUS has been shown to be a promising 
technique for the early diagnosis of renal disease in humans, however data in veterinary medicine 
are lacking.15, 16 
The aim of this study was to evaluate the efficacy of CEUS in the diagnosis of CKD in cats. The 
hypothesis is that CEUS would be a practical, non-invasive technique to detect perfusion changes in 
cats with CKD. 
 
3 . Materials  and methods 
 
The study was performed with approval of the local ethical committee of the Faculty of Veterinary 
Medicine, Ghent University, Belgium and the deontological committee of the Belgian Federal 
Agency for the Safety of the Food Chain (EC2015-68). All owners gave their full informed consent to 
participate in the study.  
 
Subjects 
Fourteen cats with CKD and 43 healthy control cats were included. The diagnosis of CKD was made 
prior to inclusion and was based on the presence of compatible clinical signs and laboratory 
findings i.e. increased serum creatinine (> 161.8 µmol/L)17 and decreased urine specific gravity (< 
1.035). Cats with significant concurrent systemic disease, hyperthyroidism, and urinary tract 
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obstructions leading to postrenal azotemia were excluded. The CKD cats were subdivided into 4 
stages according to the classification of the International Renal Interest Society (IRIS) 
classification.18 Cats with lack of significant abnormalities in history, on physical examination, 
thoracic radiographs, abdominal ultrasound, complete blood count, biochemistry, and urinalysis 
were defined as ‘healthy’. All medication or nutritional supplements, except for phosphorus binders 
in the CKD group, were withdrawn at least 14 days prior to inclusion.  
 
Study design 
A routine physical exam, including non-invasive measurement of the blood pressure by Doppler 
ultrasonic technique, assessment of body weight, body condition score on a 9-point scale and 
muscle condition score19, cervical palpation for scoring the thyroid gland size (in cats > 6 years) 20, 
cardiac and lung auscultation, abdominal palpation, peripheral lymph node palpation, evaluation of 
the color and refill of the mucous membranes, was performed in all cats. Blood work consisted of 
complete blood count and serum biochemistry, including total thyroxine (T4) level in cats of 6 
years and older. Urinalysis included urine specific gravity (USG), sediment analysis (as described in 
Paepe et al. (2013))21, urinary protein: creatinine ratio (UPC), dipstick, and bacterial urine culture. 
Thoracic radiographs (left-right lateral and ventrodorsal projections) and complete abdominal 
ultrasound were performed. 
 
CEUS procedure 
A 22-Gauge indwelling catheter was placed in the cephalic vein.  
The hair was clipped over the ventrolateral portion of the abdomen and coupling gel was applied 
to the skin. The ultrasound exams were performed with the cat in dorsal recumbency. The kidney of 
interest was centered on the screen and was imaged in a longitudinal plane using dual-screen 
(simultaneous display of conventional B-mode and contrast-mode image). The transducer was 
manually positioned during each imaging procedure and was maintained at the same position 
during the CEUS examination.  
 
The contrast agent (Sonovue®, Bracco, Italy), 0.05 mL/kg, was injected IV (bolus injection over +/- 3 
s) followed by injection of 1.5 mL saline bolus. A three-way stopcock was used to avoid any delay 
between the injection of contrast agent and saline. The same person performed the injection in a 
standardized way in all cats. Three injections of contrast were performed:  two for the left kidney 
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and one for the right kidney. The first injection was not used for further analysis.22 Between 
subsequent injections, to avoid artifacts, remnant microbubbles were completely destroyed by 
setting the acoustic power at the highest level and scanning the caudal aspect of the abdominal 
aorta for approximately 2 minutes. 
All examinations were performed using a linear transducer of 12-5 MHz on a dedicated machine 
(IU22, Philips) with contrast-specific software. Basic technical parameters were a single focus 
placed under the kidney, persistency off, mechanical index 0.09, high dynamic range setting (C50), 
timer started at the beginning of the injection, gain (85%, corresponding to a nearly dark/anechoic 
image before USCA administration). The settings were repeated during each injection. All studies 
were digitally registered as a movie clip at a rate of 9 frames per second, during 90 seconds.  
The clips were analyzed using specialized computer software (VueBox®, Bracco Research, 
Switzerland) for objective quantitative analysis. Six regions-of-interest (ROIs) were manually 
drawn: 3 in the renal cortex, 2 in the renal medulla and 1 on an interlobar artery. The ROIs were 
similar in size and drawn at the same depth for every region. Cystic lesions and focal parenchymal 
lesions were not included in the ROIs. For every ROI, the software determined mean pixel intensity 
and created a time-intensity curve. Time-intensity curves were analyzed for peak enhancement 
(PE), wash-in area under the curve (WiAUC), rise time (RT), mean transit time (mTT), time to peak 
(TTP), wash-in rate (WiR), wash-in perfusion index (WiPI; WiAUC/RT), wash-out area under the curve 
(WoAUC), total area under the curve (AUC), fall time (FT), and wash-out rate (WoR). Parameters 
related to blood volume are PE, WiAUC, WoAUC and AUC. The PE corresponds to the maximum 
contrast medium signal intensity. The WiAUC is calculated as the sum of all amplitudes inside the 
range from the beginning of the curve up to the TTP. Similarly, WoAUC corresponds to the sum of all 
amplitudes inside the range from the TTP to the end of the descending curve. The other 
parameters, i.e. RT, mTT, TTP, WiR, WiPI, FT, WoR, are related to blood velocity. The WiR and WoR 
represent the maximum and minimum slopes of time-intensity curve. The RT corresponds to the 
time interval between the first arrival of contrast and the time of peak enhancement. The FT, in 
contrast, is the duration of contrast wash-out. Mean transit time is the mean duration of complete 
contrast medium perfusion.  The values for the 3 ROIs in the renal cortex and 2 ROIs in the renal 
medulla were averaged. Peak enhancement for the cortex, and medulla was normalized to the 
values obtained for the interlobar artery (PE*). 
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Statistical analysis 
Statistical analyses were performed using statistical software (SAS version 9.4). A linear mixed 
model with cat as random effect and health status (CKD/healthy) as categorical fixed effect was 
used. Age-group was also incorporated in the model as a categorical fixed effect to adjust in age 
between CKD and healthy cats. Age-groups were defined as: group 1 (1-3 years), group 2 (3-6 
years), group 3 (6-10 years) and group 4 (> 10 years). Correlations between perfusion parameters 
and renal size, IRIS stage, serum creatinine (sCr), USG and UPC were calculated for the renal cortex 
and medulla using Spearman correlation coefficients (ρ). A difference was considered statistically 
significant if P < 0.05. 
 
4 . Results   
 
Breed distribution consisted of 9 domestic short- or longhaired cats and 5 purebred cats (2 Ragdoll 
cats, 2 Bengals, and 1 British Shorthair) for the group of CKD cats and 41 domestic short- or 
longhaired cats and 2 purebred cats (2 ragdolls) for the healthy cats. The mean ± standard error 
age for the CKD group was 9.3 ± 1.4 years, and 6.5 ± 0.6 years for the healthy group. The mean ± 
standard error body weight for the CKD group was 4.2 ± 0.3 kg, and for the healthy group 4.0 ± 0.1 
kg.  Six cats had CKD IRIS stage 2, one of them was proteinuric (UPC > 0.4). Eight cats had CKD IRIS 
stage 3, of which 2 cats with proteinuria. 
Systolic blood pressure, sCr, serum urea, USG and UPC are summarized in Table 1.  
 
Var iables  Contro l  group (n=43)  CKD group (n=14)  P-value  
Blood pressure  (mmHg)  144.3 ± 3.6 141.0 ± 5.9 0.632 
sCr  (µmolL -1)  110.4 ± 5.2* 278.1 ± 9.3* < 0.001 
Serum urea  (mmolL -1)  8.2 ± 0.4* 18.8 ± 0.7* < 0.001 
USG 1.048 ± 0.001* 1.021 ± 0.002* < 0.001 
UPC 0.13± 0.03* 0.34 ± 0.05* 0.004 
 
Table 1 .  Basel ine character ist ics  for  CKD and healthy cats  presented as mean ± 
standard errors . (sCr serum creatinine concentrations, USG urine specific gravity, UPC urinary 
protein: creatinine ratio) 
 
All healthy cats had a normal size and appearance of their kidneys on B-mode ultrasonography. For 
the CKD group, renal size was < 3.0 cm for one or both kidneys in 6 cats, 7 cats had segmental 
cortical lesions in one or both kidneys, an irregular outline for one of both kidneys was observed in 
10 cats, and corticomedullary definition was decreased in all cats. One cat showed mild unilateral 
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pyelectasia, and another cat mild bilateral pyelectasia, without signs of ureteral obstruction. A 
single large cyst deforming the renal cortex was present in one cat, whereas few small cortical 
cystic lesions were detected in both kidneys in another, domestic shorthaired cat. None of the cats 
was diagnosed with polycystic kidney disease.  
 
The contrast agent and the imaging procedure were well tolerated by all cats and no side effects 
were noticed.  
 
Qualitative analysis of the CEUS images showed heterogeneous cortical enhancement in all cats 
with segmental cortical lesions.  
Quantitative CEUS demonstrated significant differences between CKD and healthy cats in several 
perfusion parameters for the renal cortex and medulla (Table 2 and Figures 1-3). The mTT for the 
renal cortex, a parameter for mean duration of complete contrast medium perfusion, was 
approximately 4 s shorter in cats with CKD compared to healthy cats (P=0.028). The TTP for the 
cortex was longer in the CKD group (P=0.003). In contrast, for the medulla, the TTP decreased for 
the CKD patients (P=0.003), associated with a shorter RT (P=0.001) and FT (P=0.04) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IX Cats with chronic kidney disease 
144	
Var iable ,  by  
locat ion  
CKD Healthy   P-value  
Renal  cortex     
   PE 1635.12 ± 269.59  1779.16 ± 151.24  0.643 
   PE* 19.24 ± 3.96  27.72 ± 2.01  0.065 
   WiAUC 2751.49 ± 385.53  2869.57 ± 216.27  0.791 
   RT 3.01 ± 0.12  2.77 ± 0.06 0.068 
   mTT 17.63 ± 1.62 21.84 ± 0.91  0.028 
   TTP 8.75 ± 0.29 7.71 ± 0.16  0.003 
   WiR 800.61 ± 161.92  904.15 ± 90.84  0.580 
   WiPI 1000.53 ± 164.59  1089.36 ± 92.33  0.640 
   WoAUC 3606.29 ± 487.55  3830.47 ± 273.50  0.690 
   AUC 6357.95 ± 871.83 6700.00 ± 489.07  0.733 
   FT 4.12 ± 0.20 3.83 ± 0.11  0.199 
   WoR 523.94 ± 118.77  638.30 ± 66.65  0.405 
    
Renal  medul la     
   PE 208.71 ± 203.82  276.83 ± 99.06  0.766 
   PE*  3.65 ± 0.70  3.02 ± 0.36  0.433 
   WiAUC 1653.36 ± 349.31  1892.97 ± 172.91  0.542 
   RT 11.23 ± 1.45  16.69 ± 0.71  0.001 
   mTT 50.48 ± 28.14  111.03 ± 13.89  0.060 
   TTP 20.16 ± 1.66  27.37 ± 0.82  0.003 
   WiR 4.69 ± 173.44 93.23 ± 84.29 0.649 
   WiPI 130.85 ± 124.72  172.68 ± 60.62  0.765 
   WoAUC 2934.74 ± 592.16 3519.01 ± 300.48  0.387 
   AUC 4570.11 ± 921.83 5446.80 ± 467.50  0.404 
   FT    23.25 ± 3.76  32.05 ± 1.90  0.043 
   WoR 0.00 ± 141.21 70.26 ± 70.48  0.631 
 
Table 2 .  Table 2 .  Mean ± standard error  values of  renal  perfusion parameters  
obtained by contrast-enhanced ultrasound for  cats  suffer ing from CKD and 
healthy cats .  (PE peak enhancement, PE* normalized PE, WiAUC wash-in area-under-the-curve, 
RT rise time, mTT mean transit time, TTP time-to-peak, WiR wash-in rate, WiPI wash-in perfusion 
index, WoAUC wash-out area-under-the-curve, AUC total area-under-the-curve, FT fall time, WoR 
wash-out rate) 
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F igure 1 .  Representat ive ser ial  contrast  ultrasound images of  a  cat  suffer ing 
from chronic  k idney disease ( left)  and a healthy cat  (r ight) .  The enhancement starts 
later in the CKD cat compared to the healthy cat and is of shorter duration.  
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F igure 2 .  Differences in  PE ,  PE* ,  AUC,  RT ,  TTP ,  mTT from the renal  cortex between 
cats  with CKD and healthy cats ,  presented as mean ± standard error .  * P-value < 
0.05. (PE peak enhancement, PE* normalized peak enhancement, AUC total area-under-the-curve, 
RT rise time, mTT mean transit time, TTP time-to-peak) 
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F igure 3 .  Differences in  in  PE ,  PE* ,  AUC,  RT ,  TTP ,  mTT from the renal  medulla  
between cats  with CKD and healthy cats ,  presented as mean ± standard error .  * 
P-value < 0.05. (PE peak enhancement, PE* normalized peak enhancement, AUC total area-under-
the-curve, RT rise time, mTT mean transit time, TTP time-to-peak) 
 
For the renal cortex and medulla, significant correlations were present between the mTT and TTP 
and IRIS stage, and renal size. Additionally, significant correlations were present between the RT 
for the renal medulla and sCr, IRIS stage, USG and renal size. For the renal medulla, mTT and TPP 
were also significantly correlated to sCr, USG and renal size. Urine specific gravity was significantly 
correlated to medullary RT, mTT and TTP and to cortical PE*. Additionally, a significant correlation 
was present for the cortical PE* and IRIS stage. Spearman correlation coefficients and P-values are 
summarized in Table 3 and 4. 
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Var iable  pa ir  ρ   (P)  
 
IR IS  stage  –  mTT   -0.29 (0.03) 
IR IS  stage  –  TTP  0.32 (0.02) 
IR IS  stage  –  PE*  -0.37 (0.005) 
Renal  s ize  –  mTT  0.30 (0.02) 
Renal  s ize  –TTP -0.30 (0.02) 
USG –  PE*   0.10 (0.02) 
 
Table 3 .  Correlat ions between IRIS  stage,  renal  s ize ,  USG,  and renal  perfusion 
parameters  for  the renal  cortex . (mTT mean transit time, TTP time-to-peak, PE* normalized 
peak enhancement) 
 
Corre lat ion  ρ   (P)  
 
sCr  –  mTT  -0.38 (0.004) 
sCr  –  TTP  -0.43 (0.001) 
sCr  -  RT  - 0.46 (0.003) 
IR IS  stage  –  mTT   -0.38 (0.005) 
IR IS  stage  –  TTP  -0.47 (0.003) 
IR IS  stage  –  RT  -0.41 (0.002) 
Renal  s ize  –  mTT  0.43 (0.001) 
Renal  s ize  –TTP 0.33 (0.01) 
Renal  s ize  -  RT  0.41 (0.001) 
USG –mTT 0.45 (0.005) 
USG –  TTP    0.37 (0.006) 
USG –  RT   0.31 (0.02) 
 
Table 4 .  Correlat ions between IRIS  stage,  renal  s ize ,  USG,  and renal  perfusion 
parameters  for  the renal  medulla . (sCr serum creatinine, IRIS international renal interest 
society, USG urine specific gravity, mTT mean transit time, TTP time-to-peak, RT riste time) 
 
5 . Discussion  
 
This is the first study describing quantitative perfusion parameters of kidneys in cats with CKD, 
using CEUS.  
Chronic kidney disease is one of the most important health issues in elderly cats.2 Tubular atrophy, 
tubulointerstitial inflammation and fibrosis are the most common histologic abnormalities in cats 
with CKD.6 Histologic studies in human and rodent kidneys have shown that tubulointerstitial 
lesions are associated with damage to the renal arterioles and arteries, and distortion and loss of 
peritubular capillaries.23 Tubulointerstitial fibrosis impairs renal blood flow and increases renal 
vascular resistance.23, 24  Renal capillary rarefaction is considered a central mechanism in initiation 
and progression of CKD in people and rodents.25, 26 Moreover, the renin-angiotensin system is 
activated in CKD leading to higher renal tissue concentrations of angiotensin II compared to 
plasma concentrations. As angiotensin II is a potent vasoconstrictor, the combination of these 
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changes is likely to decrease renal blood flow in patients with CKD, resulting in decreased blood 
volume and decreased blood velocity. A recent study using CT angiography to evaluate renal blood 
volume and vascular anatomy in people showed a 41% reduction in cortical renal blood volume in 
patients with CKD compared to healthy subjects. CKD patients also showed reduction in luminal 
diameters of segmental arteries. Moreover, cortical renal blood volume decreased during 
progression of CKD and was correlated with a decline in GFR.26 Medullary blood volume values were 
more variable and did not correlate with GFR.26 
The most striking findings of our study were a shorter mTT time, indicating shorter enhancement, 
and an increased TTP for the renal cortex. The longer TTP suggests a decreased blood velocity. 
These findings correspond to previous studies in human medicine, in which a decreased TTP was 
also described in patients with CKD of various origin and patients with diabetic nephropathy.27, 28 A 
decreased TTP was also an early finding in dogs in which ischemic renal disease was induced by 
placing an ameroid constrictor around the renal artery.29  
The PE, a parameter for the intensity of enhancement, reflects the blood volume entering the 
kidney and is hence expected to be decreased in patients with CKD. Previous studies on CEUS in 
humans with CKD reported a decrease in PE 15, 16, 27, 28, however a significant decrease in PE was not 
present in this study. Close inspection of the results in the human studies shows that a great 
degree of overlap in PE for patients with CKD and healthy subjects.15, 16, 27, 28 A relatively low number 
of feline patients with CKD were included in our study; significance might have been achieved by 
including a higher number of patients. Moreover, PE is known to suffer from an inherently high 
variability, as it is susceptible to many influencing factors.30, 31 Variation may be attributed to the 
contrast agent itself (amount and physical properties of the microbubbles), uncontrollable patient-
factors as blood pressure, heart rate, filtration of the bubbles by the lungs and phagocytosis by the 
reticuloendothelial system and the manual injection procedure.  
Changes in AUC have also been described in humans with CKD, whereas no significance was 
obtained in our study. Both an increase as a decrease in AUC has been described in people with 
CKD. Ma et al. (2012) observed an increase in AUC in early stage diabetic nephropathy, whereas a 
decrease was noticed in advanced stages.28 An increase in AUC was reported in 41 humans with 
CKD, whereas a decrease was reported in the canine study with iatrogenic ischemic renal disease.15, 
29 The variable effects on AUC may be explained by the fact that AUC is influenced by the PE, as well 
as the slope of the time-intensity curve. The AUC is composed of 2 parts: an initial part relating to 
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inflow of contrast and a descending part related to the outflow of contrast medium. Moreover, AUC 
may be influenced by the stage and progression of CKD. 
The decreased TTP and RT for the renal medulla in CKD patients in this study were not completely 
expected. Only one study has described CEUS of the medulla in people with CKD. In the human 
study, findings for the medulla paralleled those from the cortex, thus showing delayed time to 
peak.27 Still, it has been described that the vascular anatomy and physiology of the renal medulla 
differs importantly from those of the cortex. The renal medulla makes up less than 30% of the total 
renal volume but only receives 10% of the total renal blood flow. Additionally, local differences are 
described for the outer and inner medulla, with the latter being less perfused. Vasoactive 
regulatory factors have different effects on cortical and medullary blood flow. The medulla is 
relative insensitive to vasoconstriction.32 Therefore, local increased blood velocity could be present 
in the medulla in cats with CKD. However, further studies are needed to confirm this finding and 
further investigate the underlying pathophysiology.  
Significant correlations were found between time-based perfusion parameters and sCr, IRIS stage, 
USG, UPC and renal size in this study. However, correlation coefficients were low and did even not 
exceed 0.50 in most cases. The highest correlated coefficient was observed for the UPC and TTP for 
the renal medulla. Similarly low, but significant correlation coefficients are described in 2 human 
studies. Tsuruoka et al. (2010), observed a correlation between the slope of the ascending and 
descending parts of the time-intensity curve and sCr-based estimated GFR (correlation coefficients 
ranging from 0.26 – 0.40). Additionally, a significant correlation was present between PE and 
estimated GFR (r = 0.27).27 Similarly, a correlation (r = 0.47) between AUC and GFR measured by 
radionuclide clearance techniques has been described in people with diabetic nephropathy.28 
Moreover, the correlations calculated in our feline study are only based on a small number of 
subjects and should therefore be interpreted with caution. 
In conclusion, our findings in a small cohort of cats with CKD are encouraging to use CEUS to 
evaluate renal perfusion in cats. A decrease in blood velocity was detected for the renal cortex 
whereas an increased blood velocity was present for the renal medulla. The enhancement of the 
renal cortex was found to be of shorter duration in cats with CKD (decreased mTT). However, no 
significant changes could be detected in parameters representing the blood volume. Further 
studies are necessary to evaluate the added value of CEUS to diagnose early, non-azotemic CKD.  
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1 . Introduct ion  
 
One of the most important health issues in cats, and more importantly in older cats, is chronic 
kidney disease (CKD).1, 2 The diagnosis is based on a combination of clinical signs, a blood test 
showing an increased serum creatinine and urinalysis demonstrating a decreased urine specific 
gravity. Unfortunately, this only allows diagnosis in a relatively late stage of the disease process, 
as approximately two-thirds to three-quarters of functional renal mass must be lost before these 
abnormalities will develop.3, 4 Therefore, the search for non-invasive, safe and clinical applicable 
methods allowing early diagnosis of chronic renal disease in cats, is still of great interest.  
The underlying cause of feline renal disease is poorly understood and is likely to be influenced by 
several genetic, individual and environmental factors.5 The diagnosis of feline CKD is hence not 
based on identifying the primary cause, but rather on detecting early changes indicative for 
progressive renal damage. Renal function is closely related to renal perfusion, moreover changes in 
renal perfusion are believed to play a key role in the pathophysiology of renal disease.6, 7 
Consequently, assessment of renal perfusion could deliver important new insights in feline CKD 
and its diagnosis.  
 
Contrast-enhanced ultrasound (CEUS) is an emerging technique in veterinary medicine. The unique 
nature of the contrast agents used in CEUS provides real-time and quantitative imaging of the 
vasculature. CEUS has many favorable characteristics for its use in clinical practice: it is very safe, 
non-invasive, relatively fast and cost-effective, and does not involve the use of ionizing radiation.8, 9 
Studies in human medicine and preliminary studies in dogs have shown great promise for the use 
of CEUS in the diagnosis of diffuse renal diseases.10-14 However, studies in cats are currently limited 
to description of the normal perfusion pattern in healthy cats.15-17 An overview of the current 
knowledge on CEUS in human and veterinary medicine is provided in Chapter  I . 
 
The main objective of this thesis was to establish the potential value of CEUS in the evaluation of 
feline renal perfusion.  
Contrast-enhanced ultrasound is a relatively new technique, hence no uniform, standardized 
protocols are currently available. Nevertheless, the reliability and reproducibility of the technique 
strongly relies on a well-designed and punctually executed protocol.18 Contrast-enhanced 
ultrasound is a fast-growing imaging modality, 
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are being developed continuously. Therefore, the protocols used in this thesis were adapted as 
knowledge increased and as new software programs became available. The main study design 
(bolus-kinetics) and technical parameters (low mechanical index, gain setting, focus setting), as 
explained in Chapter  I , remained constant during this thesis.  
The first study (Chapter  I I I ) was performed using a MyLab 30CV ultrasound machine (Esaote), 
equipped with a linear probe. Subsequent quantitative analysis was performed with ImageJ. 
Analysis was labor intensive; moreover only log-compressed data could be analyzed. However, it 
was revealed that log compression leads to loss of linearity between local contrast agent 
concentrations and the resulting signal intensity.18-20 Therefore, the study in Chapter  V  was 
performed on an iU22xMATRIX system (Philips), allowing us to export native radio-frequency data, 
which overcomes the problem of log compression. These data were analyzed using a more user-
friendly software program (QLab®, Philips). After this study (Chapters IV ,  VI ,  VI I ,  VI I I  and IX), 
we were able to use the recently developed quantification software VueBox® (Bracco Suisse SA).  
This system- and user-independent application allows standardized perfusion quantification across 
different users and systems, thereby improving reproducibility of results across several research 
centers. The software allows linearization of all video data, a reliable tool to overcome the 
problems encountered with log compression, moreover, a motion compensation tool allows 
reduction of breathing artifact. Automatic curve fitting is applied to the time-intensity curve 
allowing to extract multiple perfusion parameters.  
For the first studies (Chapters  I I I  and V) a typical clinical dynamic range setting of 38 dB was 
used, whereas a high dynamic range (50 dB) was used for the later studies (Chapters IV ,  VI ,  VI I ,  
V I I I  and IX). Signal saturation may occur with lower dynamic range setting, which can prevent 
proper linearization of log-compressed data.20 
The contrast agent dose has also evolved: a fixed dose of contrast agent (0.15 mL per cat) was used 
in most studies on experimental animals (Chapters  I I I ,  V ,  VI I ), whereas a dose per kg of 
bodyweight (0.05 mL/kg) was used in studies on clinical patients (Chapters  VI ,  V I I I ,  and IX). 
The experimental cats were within the same weight category and the dose corresponded 
approximately to the dose per kg used in patients. In contrary, the clinical patients showed more 
variability in weight, and therefore we decided to adapt the dose to their body weight, as this 
would be more correct. Moreover, in Chapter  VI I I , an increase in body weight was noticed for the 
cats after 131-I treatment. In general, the dosage of contrast agent used in our studies was judged 
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to be appropriate, since a good signal-to-noise ratio was obtained with uniform enhancement in 
most cats, eliminating attenuation artifacts.  
The major consequence of the slight modifications of the study protocol is that the absolute values 
of the perfusion parameters cannot be compared between studies with a different protocol. 
However, this has no influence on the results of the separate studies neither on the final 
conclusions of this thesis. 
In Chapters I I I ,  V  and VI I  only the left kidney was studied. This is justified since the response of 
renal perfusion in healthy individuals is similar in both kidneys.6 However in disease states, the left 
and right kidneys can be affected in a different degree and therefore CEUS of both kidneys was 
performed (Chapters VI ,  VI I I ,  and IX). The left kidney is located more caudal compared to the 
right kidney21, resulting in an easier accessibility, even more since linear transducers were used. 
Linear transducers were chosen given their superior image resolution compared to curvilinear 
transducers. However, the larger footprint of linear transducers complicates visualization of organs 
(partially) located under the rib cage, as the right kidney. In Chapter  IV , we found that the extra 
variation added by studying a different kidney in the same cats, was minimal. Nevertheless, few 
clips of the right kidney of clinical patients in Chapters  VI ,  V I I I  and IX could not be analyzed 
due to difficult visualizing of this kidney which was never noticed for the left kidney. 
 
2 . Quantitat ive differences between sequential  in ject ions 
 
In this thesis, manual bolus injections of ultrasound contrast agent (USCA) were used. Manual bolus 
injections are the most common way of contrast administration in veterinary CEUS, mainly because 
no special equipment is needed to perform the injection. In theory, a single injection per studied 
organ should be sufficient. However, some authors have previously described unsatisfactory 
enhancement after the first injection of USCA 22-25, whereas this is not mentioned in multiple other 
publications. Subjectively we had the impression that the first injection often leads to poor 
enhancement. Performing an additional injection increases the imaging time and total 
administered dose of USCA, and could thereby increase the costs. However, image quality and 
reliability of quantification are always of superior importance. Therefore, in Chapter  I I I , we 
assessed if quantitative differences were present between the first and second injection of USCA. 
Perfusion parameters for the left kidney and spleen, imaged simultaneously, for the first and 
second injection of USCA, of 7 healthy cats were compared.  
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In our study, higher peak enhancement (PE) and area-under-the-curve (AUC) were present for the 
second injection compared to the first injection. This was significant for the renal cortex and 
spleen, whereas a tendency was noted for the PE for the renal medulla. Additionally, for the renal 
cortex, the time-intensity curve was flatter for the first injection. This was reflected by lower wash-
in (Win) and wash-out (Wout) values. Moreover, additional quantifications on data of other studies in 
this thesis learned that no significant differences were present between the second and third 
injection, nor between the right and left kidney (unpublished results). 
The underlying mechanism remains still unclear and it was beyond the scope of this thesis to 
investigate this further. The presence and extent of quantitative differences between the first and 
second injection of USCA is likely to be influenced by several factors and several explanations are 
proposed.  
Microbubbles have a tendency to adhere to the catheter, three-way stopcock and even vessel walls. 
A part of the microbubbles in the first injection may thereby be ‘lost’ for imaging. The second 
injection may cause propagation of these bubbles in the systemic circulation or, alternatively, the 
bulk of subsequent injections may arrive in the circulation since the multiple adherence sites are 
occupied by contrast agent of the first injection.25  
Microbubbles may be captured in capillaries and sinusoids of the organs of the reticuloendothelial 
system as the liver and spleen. Microbubble destruction in-between the injections is believed to 
clean the majority of the captured contrast agent, however it cannot be excluded that some 
microbubbles remain lodged in capillaries. Haers et al. (2012) assumed that remnant microbubbles 
may be propelled into the systemic circulation following the second injection, thereby causing a 
relative increase in the dose of contrast agent for the second injection.22 In mice, short-term 
saturation of the hepatic and splenic sinusoids is described. Consequently, a lower amount of 
microbubbles will be captured by these organs upon the second injection, leaving relatively more 
microbubbles available to circulate.26 However, injection of 1.2 – 1.4 mL USCA in people did not 
cause liver saturation.27 It is unclear if the dose used in this study, 0.15 mL, could cause liver 
saturation in cats.  Similarly, saturation of pulmonary macrophages may occur.28 This would allow 
more microbubbles to pass the lung and finally reach the systemic circulation.  
The composition of the USCA, mainly microbubble shell composition, also affects the degree 
phagocytosis by the reticuloendothelial system.20 Moreover, it is assumed that species- and even 
individual-specific responses to microbubbles exist. The organ studied may be another factor 
influencing the presence and degree of this phenomenon.  
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Because our study proved that quantitative differences were present between the first and second 
injection of contrast agent, the first injection was not used for further analysis in the following 
studies. 
 
3 . Repeatabi l i ty  
 
Contrast ultrasound is known to suffer from an inherent relatively high variability.20 Nevertheless, 
the repeatability of CEUS for the kidney in a clinical setting has not been described, neither in 
human medicine, nor in veterinary medicine. In Chapter  IV  we assessed the repeatability of CEUS 
of the kidneys in 12 healthy cats. To determine and compare the repeatability of the different 
perfusion parameters, the coefficient of variation (CV) was calculated.  
The lowest CV, and thus best repeatability, was present for the time-to-peak (TTP) for the renal 
cortex. This was followed by rise time (RT), fall time (FT) and mean transit time (mTT) for the renal 
cortex. The CV values of these parameters were < 25% and even < 10% for the TTP, this may be 
judged as good to moderate repeatability. The injection technique is crucial for the variation in 
these time-related parameters. The manual bolus injection used in our studies is more susceptible 
to variation compared to controlled injections performed using specialized equipment.20 
Nevertheless, all efforts were made to standardize the injection procedure as the injection was 
always performed by the same person, not only for this study, but also for all studies in this thesis. 
Recently, a commercial bolus-injection system has become available.29 Using this system might 
lead to a further improvement in the repeatability of the TTP, mTT, WiR and WoR, whereas no 
improvement is expected for PE and AUC.29 
Repeatability for the perfusion parameters related to the intensity (and thus concentration of 
contrast agent) and shape of the time-intensity curve was low.  These parameters are susceptible 
to several sources of variation. The first source of variation encountered is the contrast agent. It 
may be assumed that the contrast agent itself is one of the most important sources of variation as 
the CV for PE and AUC was 33-36% in an in vitro study 30, eliminating variation related to the 
patient. The manual shaking of the vials for reconstitution prior to use may already introduce 
significant variations in size and concentration of the USCA. Moreover, significant differences exist 
between the shell compositions of the microbubbles of the same contrast agent, leading to 
different responses to ultrasound waves.20 Further variation is caused by administration and the 
physical and physiological conditions in the immediate environment. Different degrees of 
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sedimentation in the syringe and catheter will result in different microbubbles doses. Patient-
related factors will cause some additional variation. The acoustic window and several 
uncontrollable patient factors such as blood pressure, heart rate, filtration of microbubbles by the 
lungs and phagocytosis by the reticuloendothelial system will influence quantification of CEUS.20  
Normalization of areas of interest with neighboring normal tissue may reduce variation.20 This 
method is extremely useful in the evaluation of abnormal tissue surrounded by normal tissues as 
focal liver lesions. It is more difficult to accomplish in the diagnosis of diffuse renal disease, in 
which the entire kidney is involved. Choosing reference tissue outside the kidney seems most 
appropriate, however this interferes with the imaging of the kidney itself. Obtaining a 
standardized, longitudinal plane of the kidney is of major importance, as suboptimal and 
inconsistent imaging planes will induce extra variation. Therefore, after multiple attempts by 
experienced persons, we decided that combining standardized imaging of the kidney with 
simultaneous imaging of normal reference tissue is not feasible. In several studies we tested 
normalization to the interlobar arteries. However, in Chapter  IV , the variance in PE was higher for 
the interlobar artery compared to the PE for the renal cortex or medulla. Therefore, normalization 
to the interlobar artery did not reduce variation but in contrast, higher CV was found for the 
normalized PE values. Moreover, in Chapter  VI I , significant changes in PE were obtained after 
angiotensin II (AT II) infusion, whereas this difference was no longer seen if the parameters were 
normalized to those of the interlobar artery. Nevertheless, in Chapter  VI I I , a significant decrease 
in normalized PE for the renal medulla was found after treatment for hyperthyroidism, whereas 
the change in PE did not reach significance. Interlobar arteries are tiny structures and are therefore 
very susceptible to motion artifact, resulting in inconsistent imaging and therefore difficult 
placement of regions-of-interest (ROI). Moreover, the flow in the interlobar artery could also be 
influenced by a renal condition. 
For the last patients of the clinical studies described in Chapters  VI ,  and VI I I  an attempt was 
made to use the caudal abdominal aorta as reference tissue. The major drawback was that this was 
accomplished by imaging the aorta separately, thus acquiring an additional clip. Therefore, it could 
not correct for variation induced by the imaging plane. Moreover, an additional injection of USCA is 
subject to its own sources of variability, which may slightly differ from those of the previous 
injections. A proper repeatability study could not be performed on the data normalized to the 
aorta, however the variability seems similar to those obtained after normalization to the interlobar 
artery. 
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Flash-replenishment kinetics may be less susceptible to variation, but no supporting data are 
currently available. Therefore, it would be interesting to test this hypothesis in a prospective, 
randomized crossover study. 
 
4 . Inf luence of  sedation and anesthesia  
 
In Chapter  V  the influence of a commonly used sedative agent and an anesthetic agent on 
quantitative CEUS was assessed. Although CEUS is a relatively short procedure, it is very important 
that the animal remains immobile during the acquisition of the CEUS clip, lasting approximately 90 
s to be able to perform accurate quantification. As this is not possible for all cats, we aimed to 
investigate the influence of 2 commonly used sedative/anesthetic protocols: intramuscular (IM) 
administration of 0.4 mg/kg butorphanol and intravenous (IV) boluses of propofol on effect. This 
was accomplished by enrolling 6 healthy cats in a randomized crossover design. No significant 
effect of butorphanol was observed for any of the perfusion parameters. In contrast, increases in 
TTP and AT, and a decrease in Win, were observed after using propofol, indicating a decrease in 
blood velocity. This is explained by the well-known cardiovascular effects of propofol, namely 
decreased cardiac output and systemic vascular resistance, resulting in depression of the systolic 
and diastolic blood pressure.31   
Therefore, we concluded that butorphanol could be used for CEUS studies, however the sedative 
effect is often inadequate in anxious or nervous cats. Propofol is a favorable anesthetic to use in 
cats: it is safe in older patients and cats with various diseases and induces a superficial anesthesia 
of short duration. However, the CEUS parameters are influenced by the use of propofol, hence 
cannot be compared with those from conscious animals. Consequently, at the start of every study 
we needed to decide whether anesthesia would be used in all patients or in none of them. Propofol 
anesthesia was used in all experimental cats in the studies in Chapter  I I I  and IV  in order to 
reduce stress for the animals and facilitate the ease of performing CEUS. Moreover, we assume that 
the cardiovascular effects of stress could also induce extra variation. Propofol was also used in the 
hyperthyroid cats (Chapter  VI I I ), before and after treatment. Hyperthyroid cats often suffer from 
hyperactivity, stress intolerance and aggressiveness32, justifying the use of anesthesia. Inhalation 
anesthesia was used in the angiotensin-study (Chapter  VI I) because of the longer imaging times 
related to the combination of CEUS and renal scintigraphy. The effects of general anesthesia were 
not investigated in this thesis as it was only used in one study; moreover there was no need to 
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compare these results with those of conscious animals. Beside cardiovascular effects, inhalation 
anesthetics can influence perfusion parameters through their direct effect on the microbubbles. 
The inhaled gasses change the local blood gas concentration and hence gas diffusion between the 
bubbles and environment.18, 20  
For the healthy client-owned cats and the cats suffering from renal disease (Chapters  VI  and 
IX), we decided to perform CEUS on conscious animals. Cat owners are often reluctant to allow 
their cat to participate in a study if sedation or anesthesia is involved. Some cats had to be 
excluded because of uncooperative behavior, however CEUS could be performed relatively easy in 
the majority of the cats.   
 
5 . Inf luence of  aging in  healthy cats  
 
In humans, aging has a degenerative effect on the kidney: both functional and morphological 
changes are present in elderly people.33 The prevalence of feline CKD, increases with age.1, 2 
However, information on age-related variations in feline renal perfusion is currently lacking. 
Therefore, in Chapter  VI , we assessed the influence of age on renal perfusion parameters in 
healthy cats. Forty-three client-owned cats aging from 1 year to 16 years and 6 months were 
enrolled in the study and divided into 4 age groups: group 1: 1-3 years, group 2: 3-6 years, group 3: 
6-10 years and group 4: > 10 years. No significant differences in any of the perfusion parameters 
were observed among the age groups. Still, a tendency towards a lower PE and WiAUC was present 
when comparing cats > 10 years with the cats between 1 and 3 years. This suggests a reduction in 
renal blood volume as ageing progresses. A lower renal plasma flow, measured by para-
aminohippurate (PAH) clearance, has been reported in elderly people.33, 34 Similarly, in a large study 
on 331 people monitoring the transit of radioxenon through the kidney, a significant age-
associated reduction in mean renal blood flow was observed.35 Moreover, the blood flow reduction 
exceeded the reduction in GFR and renal mass, and is hence believed to be primary.35 Age-related 
changes in humans were found to be most prominent in the renal cortex, corresponding to the 
findings in our study in cats.35 
Age-related increase in renal resistance and loss of intrarenal arterial compliance results in higher 
resistive index measured with Doppler in elderly people.36, 37 However, an age-related increase in 
resistive index could not be detected in cats.38 A higher renal resistance is likely to cause changes 
in time-based perfusion parameters and contribute to a lower PE and AUC. However, significant 
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changes in time-based parameters were not observed in this study. It remains unclear if they could 
not be detected with CEUS or if age-related renal changes in cats are less pronounced compared to 
people.  
Several studies report a higher sCr in aging cats.39-41 In dogs, an age-effect on GFR has only been 
reported in small breed dogs, whereas it was not present in large breed dogs.41 Moreover, vascular 
morphological changes as reported in humans (decreased luminal area and hyalinization of 
afferent arterioles, loss of peritubular capillaries) are not detected in dogs.33, 42-44 Therefore, more 
studies should be performed in dogs and cats to clarify the existence and extent of the effect of 
aging on renal morphology and function. 
In this study (Chapter  VI) we have shown that no significant age-effect was present on the renal 
perfusion parameters obtained with CEUS. Moreover, no linear correlation between age and the 
renal perfusion parameters was detected. Nevertheless, a tendency towards lower PE and WiAUC in 
cats > 10 years was present. Therefore, we decided to incorporate age as categorical fixed effect in 
the statistical analysis of the study performed on cats with chronic kidney disease in Chapter  IX .  
  
6 . Perfusion changes induced by angiotensin-I I  infusion 
 
In Chapter  VI I , we performed an exploratory study to determine the ability of CEUS to detect 
changes in renal perfusion and correlated them with perfusion parameters obtained with renal 
scintigraphy. This study makes the link between the studies in healthy cats in Chapters I I I ,  IV ,  V  
and VI  and the studies in cats with naturally occurring renal disease (Chapter  IX) and 
hyperthyroid cats (Chapter  VI I I ).  
CEUS and 99mTc-mercaptoacetyltriglycerine (MAG3) scintigraphy were performed in 11 healthy cats, 
at baseline and during infusion of AT II. AT II is a potent vasoconstrictor that is often upregulated in 
patients with CKD and in cats with hyperthyroidism.45, 46 
AT II-induced perfusion changes could be detected with CEUS, whereas no significant changes were 
detected using renal scintigraphy. Ang-II infusion caused a lower PE and a tendency towards a 
lower WiAUC, corresponding with a decrease in global renal blood volume. Moreover, WiPI and WoR 
for the entire kidney decreased significantly after AT II-infusion, indicating a slower in- and outflow 
of contrast medium and thus slower renal blood velocity. These changes were expected knowing 
the physiologic effects of AT II: AT II is a potent vasoconstrictor, causing systemic but even more 
pronounced renal vasoconstriction, thereby decreasing total and renal blood flow.47, 48 In a human 
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study, a decrease in perfusion index (calculated as renal blood volume divided by mean transit 
time) was detected after AT II infusion. Moreover, the changes in perfusion index paralleled those 
in estimated renal plasma flow. 49 In a similar study in sheep, a very heterogeneous and 
inconsistent response on CEUS parameters was noticed after AT II infusion. Only an increase in 
mean transit time was present after infusion of high dose AT II. CEUS-derived perfusion indices did 
not parallel changes in renal blood flow measured with invasive flow probes.50 In both the sheep 
and the human study, CEUS was performed using a completely different technique compared to the 
one used in this thesis. They used a continuous infusion of contrast agent followed by consecutive 
destruction-refilling sequences (as explained in Chapter  I ). Consequently, other perfusion 
parameters were calculated, thereby strict comparison between our results and the results from 
these 2 studies is not possible.  
We did not observe AT II-induced changes in perfusion parameters of the renal medulla. A variable 
response of the medullary blood flow on AT II has been reported in experimental animals.48, 51, 52 
Moreover, the renal medulla is inherently less sensitive to vasoconstriction compared to the 
cortex.53  
To our knowledge, this is the first study using AT II infusion in cats; therefore it was difficult to 
determine an optimal dose. The aim was to give the lowest dose inducing renal vasoconstriction 
without causing significant systemic effects. We chose to administer 2 ng/kg/min, which is 
intermediate between the low (1 ng/kg/min) and high (3 ng/kg/min) dose used in the human study 
of Schneider et al. (2012).49 This dose was believed safe in cats, by extrapolation from a study using 
boluses of AT II in healthy cats. Boluses between 0.02 ng/kg and 500 ng/kg did not cause important 
side effects and effects were transient. Significant increase in blood pressure were observed for 
boluses > 20 ng/kg.54 The total duration of AT II infusion was about 30 min in our study, thereby 
corresponding to a total dose of 60 ng/kg. However, we expected the effect of a continuous 
infusion to be less pronounced compared to a bolus. It would have been interesting to test several 
dosages of AT II infusion and evaluate the change in response in perfusion parameters.  
 A major problem in this study is the absence of a golden standard to evaluate renal perfusion. To 
validate CEUS as a technique for the evaluation of renal perfusion it would be mandatory to 
compare the results to those of a golden standard. To our knowledge there is currently no 
standardized technique available to measure renal perfusion. Flow probes that are directly 
inserted into renal vascularization are used in experimental settings. However, these probes can 
only assess perfusion in larger vessels and hence do not evaluate microperfusion.48, 50, 51 Moreover, 
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their use has not been described in cats, and would be unethical since their invasiveness. PAH 
clearance techniques are considered the gold standard to evaluate global renal perfusion in 
humans. The technique is poorly described in cats and is not applicable in a clinical setting due to 
the requirement for specific equipment and multiple sampling strategies.55 Additionally, 
comparison between CEUS and PAH clearance cannot be strict since these techniques actually 
compare different parameters, regional microvascularisation and total renal blood flow 
respectively.49 Nevertheless, significant correlations between CEUS parameters and PAH clearance 
have been described in humans.10, 49, 56 In this study, we chose to compare CEUS parameters to 
perfusion parameters obtained with MAG3 scintigraphy. MAG3 has a similar chemical structure to 
PAH and good correlation between MAG3 and PAH clearance has been described in humans and 
dogs, however no information is available in cats.57, 58 One study in people found a significant 
correlation between effective renal plasma flow calculated based on MAG3 and decline ratio 
obtained with CEUS.10 We did not observe a correlation between the CEUS parameters and the 
ratio’s calculated with MAG3. Important differences are present between our study and the human 
study of Hosotani et al. (2002). In the latter study, CEUS was performed using a different technique 
hence resulting in different parameters. Moreover, in humans, formulas are available to calculate 
effective renal plasma flow from data obtained with MAG3, whereas these formulas are not 
validated in cats. Therefore, we used ratios to assess renal perfusion with MAG3. 
This study proved the potential of CEUS to detect renal perfusion changes, thereby encouraging 
further research in patients (Chapters  VI I I  and IX) 
 
7 . Renal  perfusion evaluation in  treatment of  hyperthyroid cats  
 
In Chapter  VI I I  we assessed renal perfusion changes in cats occurring 1 month after radioiodine 
treatment for hyperthyroidism. The complex relationship between the kidney and thyroid gland 
has been extensively described.45, 59, 60 It is known that hyperthyroidism causes an increase in GFR, 
whereas GFR will normalize again 1 month after treatment.61, 62 Changes in renal blood flow are 
believed to underlie the changes in renal function.59, 60 Nevertheless, only 1 study has investigated 
renal perfusion in iatrogenic hyperthyroidism.63 Therefore, a prospective study was performed to 
evaluate renal perfusion in hyperthyroid cats, before and 1 month after treatment of 
hyperthyroidism. The RT, mTT, TTP and FT for the renal cortex significantly increased after 
resolution of the hyperthyroid state. In parallel with these findings, WiR and WoR decreased, and 
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WiAUC, WoAUC and total AUC for the cortex increased. Similarly for the renal medulla, RT and TTP 
increased and WiR decreased. The combination of these findings indicates a slower renal blood 
velocity in both renal cortex and medulla after treatment of hyperthyroidism.  Additionally, a 
decrease in normalized PE was present for the renal medulla, suggesting a decrease in medullary 
blood volume. This was not noticed for the renal cortex. 
Increased total T4 levels will lead to an increased renal blood flow caused by a combination of 
decreased systemic and intrarenal vascular resistance and increased cardiac output.59, 60 
Additionally, a significant decrease in heart rate was noticed post-treatment. As the contrast agent 
relies on the systemic circulation to reach the kidney, changes in cardiovascular parameters may 
influence renal perfusion parameters. Therefore, the post-treatment decrease in heart rate likely 
contributed to the changes in time-based parameters in our study.   
An increased renal blood flow, measured by clearance of 131I-orthoiodohippuric acid, was present in 
one study with iatrogenically induced hyperthyroidism.63 Our study is the first to evaluate the 
response of renal perfusion to treatment of hyperthyroidism. The renal perfusion is expected to 
parallel the changes in GFR and thus decrease 1 month after treatment as noticed in our study.61, 62 
Moreover, as the changes in GFR occur within the first month after treatment, and not anymore 
thereafter, we would expect the same for renal perfusion.61, 62 However, this was not evaluated in 
our study, since only a short follow-up of 1 month was performed. Nevertheless, it would be 
interesting to test this hypothesis in a longer follow-up study.  
An unexpected low number of cats (4.8%) developed post-treatment azotemia in our study. 
Therefore, we were not able to evaluate the predictive value in CEUS for the development of post-
treatment azotemia.  
 
8 . Cats with chronic  k idney disease  
 
Finally in Chapter  IX we aimed to assess renal perfusion in cats diagnosed with CKD. In humans 
and experimental animals, there is increasing evidence that renal hemodynamic changes underlie 
functional and morphological changes in chronic kidney disease.64-67 Loss of peritubular capillaries 
is a prominent feature in CKD and seems to be independent of the underlying cause. Moreover, 
renal capillary rarefaction is considered a central mechanism in the initiation and progression of 
CKD.64, 65 Therefore, evaluation of renal microvascularization might deliver important insights in the 
pathophysiology of CKD, and its diagnosis.  
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CEUS was performed in 14 cats with CKD and 43 healthy control cats. In cats with CKD, a longer TTP 
for the renal cortex, indicating slower blood flow, was present. Moreover, a shorter mTT suggested 
shorter cortical contrast enhancement in CKD cats. In contrast, a shorter TTP and RT, and hence 
higher blood velocity was present for the renal medulla.  
The changes in the renal cortex were expected and are likely to be caused by an increased vascular 
resistance occurring secondary to the loss of peritubular capillaries and activation of the renin-
angiotensin system.66, 67  
Comparison of our results to those obtained in literature is complicated since different CEUS 
methods often used, thereby obtaining other perfusion parameters. The human study of Dong et al. 
2014, had a comparable study design to ours. They performed a bolus injection of Sonovue® in 41 
patients with CKD and 45 healthy controls. A lower AUC, lower PE and lower inflow slope was 
present in people with CKD, a longer TTP was detected but did not reach statistical significance.11 
Another human study used bolus kinetics to study renal perfusion in patients suffering from CKD, a 
different contrast agent was used and different parameters were calculated. A decreased intensity 
and decreased steepness of the time-intensity curve was present in patients with renal disease in 
the latter study.14 In a study using continuous infusion, a lower enhancement was seen in CKD 
patients.10 Delayed arrival time and TTP were seen in humans with early stage diabetic 
nephropathy, PE and AUC only decreased in advanced diabetic nephropathy.68 It is striking that a 
decreased intensity, corresponding to a lower renal blood volume, is a rather consistent finding in 
human studies.  A lower PE was also present in the CKD cats in our study, however no statistical 
significance was reached. As described in Chapter  IV , this parameter suffers from a high degree 
of variability, thereby complicating interpretation.  Nevertheless, Dong et al. (2014) assumed that 
PE has the best diagnostic accuracy in the detection of CKD in people, whereas the opposite is 
proven in both our study in CKD cats (Chapter  IX) and the repeatability study in healthy cats 
(Chapter  IV). The reason for this discrepancy between our study and the human study remains 
unclear, since broad reference intervals and overlap between values of people with renal disease 
and healthy individuals is also present in the human study.11  
The decreased TTP and RT for the renal medulla in CKD cats, where rather unexpected. Medullary 
perfusion is less extensively studied compared to the renal cortex. Only 1 study has described CEUS 
parameters for the renal medulla in people with CKD. In this study, the changes in medullary 
perfusion parameters paralleled those of the renal cortex.14 The renal medulla only receives about 
10% of the total renal blood flow and the medullary circulation diverges from the cortical 
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circulation.53 Nevertheless, it is known that the medullary blood flow is controlled differently 
compared to the cortical blood flow, moreover the medullary circulation is relatively insensitive to 
vasoconstrictive factors.53 In a study using CT angiography to assess renal perfusion in people with 
CKD, medullary blood flow was found to be very variable and did not correlate with GFR.69 More 
studies are necessary to confirm the increased medullary blood velocity in cats with CKD and 
further investigate the underlying pathophysiology. 
 
9 . Future perspect ives 
 
Our results show that CEUS is capable of detecting perfusion changes in cats and thus holds 
promise for further use in the evaluation of renal perfusion in cats, however considerable 
challenges need to be addressed before wider clinical use of quantitative CEUS can be achieved. 
These are largely related to the high degree of variability resulting in diagnostic uncertainty as 
described in Chapter  IV . Continuous development in the areas of contrast agent composition, 
ultrasound systems, transducer design and signal processing may allow more reliable 
quantification of CEUS studies in the future. Moreover, there is a strong need for international 
standards in study design of CEUS procedures. Currently, multiple different experiments set-ups 
are used, resulting in a large variety of perfusion parameters, complicating comparison. Well-
powered (clinical) trials are needed to compare the different experimental designs and assess the 
variability and reliability of the perfusion parameters they deliver. Results of these trials should be 
used to build strong uniform guidelines in performing CEUS studies. Given the diagnostic and even 
therapeutic potential (not discussed in this thesis), we believe CEUS is likely to grow in prominence 
over the coming decade.  
 
Additionally, veterinary science could also follow other pathways in the evaluation of renal 
perfusion. Interesting results have recently been obtained with the use of quantitative CT 
angiography in people and experimental animals.70 In contrast to CEUS, CT angiography has a low 
inter-individual variability. However, the clinical application is currently limited by the potential 
risk of contrast agent nephropathy and use of ionizing radiation. Nevertheless, efforts are made to 
produce iodine free contrast with reduced toxicity and novel reno-protective imaging protocols.69, 70 
Similarly, Blood Oxygen Level Dependency (BOLD) and Diffusion-weighted (DW) MRI techniques, 
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which can be used to study renal perfusion without requiring contrast agent, are likely to develop 
within the next years 71, 72 
 
 
10 . General  conclusion 
 
In this thesis, we have investigated the use of contrast-enhanced ultrasound for the evaluation of 
renal perfusion in cats. Encouraging results were obtained in the study using AT II infusion in 
experimental cats (Chapter  VI I), as well in the clinical studies in CKD cats (Chapter  IX) and cats 
with hyperthyroidism (Chapter  VI I I ). The time-based perfusion parameters, TTP, mTT, RT and FT 
hold the most promise as they showed significant results in the clinical studies in Chapters  VI I I  
and IX , moreover they suffer from the least variability (Chapter  IV). However, PE, an important 
parameter for the blood volume currently suffers from very high variability.   
 
In conclusion, renal perfusion quantification with CEUS has been shown to be a promising but yet 
not validated method. The large variability currently limits the application of CEUS in a clinical 
setting. Despite these limitations, CEUS is still a promising method for renal microvascular 
evaluation and further technical advances are likely to improve repeatability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter X General discussion  
171	
11 . References  
 
1. Lulich JP, Osborne CA, Obrien TD, Polzin DJ. Feline Renal-Failure - Questions, Answers, 
Questions. Compendium on Continuing Education for the Practicing Veterinarian. 1992;14: 127-152. 
2. Marino CL, Lascelles BDX, Vaden SL, Gruen ME, Marks SL. Prevalence and classification of 
chronic kidney disease in cats randomly selected from four age groups and in cats recruited for 
degenerative joint disease studies. Journal of Feline Medicine and Surgery. 2014;16: 465-472. 
3. Polzin JP. Chronic kidney disease. In: Bartges J, Polzin JP (eds): Nephrology and Urology of 
Small Animals. Chichester: Wiley-Backwell, 2011;433-471. 
4. Finco DR, Brown SA, Vaden SL, Ferguson DC. Relationship between plasma creatinine 
concentration and glomerular filtration rate in dogs. Journal of Veterinary Pharmacology and 
Therapeutics. 1995;18: 418-421. 
5. Jepson RE. Current Understanding of the Pathogenesis of Progressive Chronic Kidney 
Disease in Cats. Veterinary Clinics of North America: Small Animal Practice. 2016;46: 1015-1048. 
6. Regan MC, Young LS, Geraghty J, Fitzpatrick JM. Regional renal blood flow in normal and 
disease states. Urological Research. 1995;23: 1-10. 
7. Schmiedt CW, Brainard BM, Hinson W, Brown SA, Brown CA. Unilateral Renal Ischemia as a 
Model of Acute Kidney Injury and Renal Fibrosis in Cats. Veterinary Pathology. 2016;53: 87-101. 
8. Seiler GS, Brown JC, Reetz JA, Taeymans O, Bucknoff M, Rossi F, et al. Safety of contrast-
enhanced ultrasonography in dogs and cats: 488 cases (2002-2011). Journal of the American 
Veterinary Medical Association. 2013;242: 1255-1259. 
9. Dietrich CF, Ignee A, Hocke M, Schreiber-Dietrich D, Greis C. Pitfalls and Artefacts using 
Contrast Enhanced Ultrasound. Zeitschrift Fur Gastroenterologie. 2011;49: 350-356. 
10. Hosotani Y, Takahashi N, Kiyomoto H, Ohmori K, Hitomi H, Fujioka H, et al. A new method 
for evaluation of split renal cortical blood flow with contrast echography. Hypertension Research. 
2002;25: 77-83. 
11. Dong Y, Wang WP, Cao J, Fan P, Lin X. Early assessment of chronic kidney dysfunction using 
contrast-enhanced ultrasound: a pilot study. British Journal of Radiology. 2014;87: 1-7. 
12. Dong Y, Wang WP, Cao JY, Fan PL, Lin XY. Quantitative evaluation of contrast-enhanced 
ultrasonography in the diagnosis of chronic ischemic renal disease in a dog model. Plos One. 
2013;8: e70377. 
Chapter X General discussion  
172	
13. Haers H, Daminet S, Smets PMY, Duchateau L, Aresu L, Saunders JH. Use of quantitative 
contrast-enhanced ultrasonography to detect diffuse renal changes in Beagles with iatrogenic 
hypercortisolism. American Journal of Veterinary Research. 2013;74: 70-77. 
14. Tsuruoka K, Yasuda T, Koitabashi K, Yazawa M, Shimazaki M, Sakurada T, et al. Evaluation of 
renal microcirculation by contrast-enhanced ultrasound with sonazoid (TM) as a contrast agent. 
International Heart Journal. 2010;51: 176-182. 
15. Kinns J, Aronson L, Hauptman J, Seiler G. Contrast-enhanced ultrasound of the feline 
kidney. Veterinary Radiology & Ultrasound. 2010;51: 168-172. 
16. Leinonen MR, Raekallio MR, Vainio OM, Ruohoniemi MO, Biller DS, O'Brien RT. Quantitative 
contrast-enhanced ultrasonographic analysis of perfusion in the kidneys, liver, pancreas, small 
intestine, and mesenteric lymph nodes in healthy cats. American Journal of Veterinary Research. 
2010;71: 1305-1311. 
17. Schweiger H, Ohlerth S, Gerber B. Contrast-enhanced ultrasound of both kidneys in healthy, 
non-anaesthetized cats. Acta Veterinaria Scandinavica. 2015;57: 57-80. 
18. Hyvelin JM, Tardy I, Arbogast C, Costa M, Emmel P, Helbert A, et al. Use of Ultrasound 
Contrast Agent Microbubbles in Preclinical Research Recommendations for Small Animal Imaging. 
Investigative Radiology. 2013;48: 570-583. 
19. Tranquart F, Mercier L, Frinking P, Gaud E, Arditi M. Perfusion Quantification in Contrast-
Enhanced Ultrasound (CEUS) - Ready for Research Projects and Routine Clinical Use. Ultraschall in 
Der Medizin. 2012;33: S31-S38. 
20. Tang MX, Mulvana H, Gauthier T, Lim AKP, Cosgrove DO, Eckersley RJ, et al. Quantitative 
contrast-enhanced ultrasound imaging: a review of sources of variability. Interface Focus. 2011;1: 
520-539. 
21. Budras KD, McCarthy PH, Fricke W, Richter R. Anatomy of the dog. Hannover, Germany: 
Schlütersche, 2007. 
22. Haers H. Contrast-enhanced ultrasonography of canine kidneys. Ghent University, 
Merelbeke, 2012 (thesis). 
23. Pey P, Vignoli M, Haers H, Duchateau L, Rossi F, Saunders JH. Contrast-enhanced 
ultrasonography of the normal canine adrenal gland. Veterinary Radiology & Ultrasound. 2011;52: 
560-567. 
Chapter X General discussion  
173	
24. Salwei RM, O'Brien RT, Matheson JS. Characterization of lymphomatous lymph nodes in 
dogs using contrast harmonic and power Doppler ultrasound. Veterinary Radiology & Ultrasound. 
2005;46: 411-416. 
25. O'Brien R, Seiler G. Clinical applications of contrast ultrasound In: Penninck D, d'Anjou MA 
(eds): Atlas of small animal ultrasonography Oxford, UK: John Wiley and Sons, 2015;481 - 493. 
26. Rix A, Palmowski M, Gremse F, Palmowski K, Lederle W, Kiessling F, et al. Influence of 
Repetitive Contrast Agent Injections on Functional and Molecular Ultrasound Measurements. 
Ultrasound in Medicine and Biology. 2014;40: 2468-2475. 
27. Weskott HP. Emerging roles for contrast-enhanced ultrasound. Clinical Hemorheology and 
Microcirculation. 2008;40: 51-71. 
28. Skrok J. Markedly increased signal enhancement after the second injection of Sonovue 
compared to the first - a quatitative normal volunteer study. 12th European symposium on 
ultrasound contrast imaging. Rotterdam, the Netherlands, 2007. 
29. Dizeux A, Payen T, Barrois G, Le Guillou Buffello D, Bridal SL. Reproducibility of Contrast-
Enhanced Ultrasound in Mice with Controlled Injection. Molecular Imaging Biology. 2016;18: 651-
658. 
30. Gauthier TP, Averkiou MA, Leen EL. Perfusion quantification using dynamic contrast-
enhanced ultrasound: the impact of dynamic range and gain on time-intensity curves. Ultrasonics. 
2011;51: 102-106. 
31. Short CE, Bufalari A. Propofol anesthesia. Veterinary Clinics of North America: Small Animal 
Practice. 1999;29: 747-778. 
32. Scott-Moncrieff JC. Feline hyperthyroidism. In: Feldman EC, Nelson RW, Reusch C, Scott-
Moncrieff JC, Behrend E (eds): Canine and feline endocrinology. St Louis, Missouri, USA: Saunders 
Elsevier, 2015;136-195. 
33. Esposito C, Plati A, Mazzullo T, Fasoli G, De Mauri A, Grosjean F, et al. Renal function and 
functional reserve in healthy elderly individuals. Journal of Nephrology. 2007;20: 617-625. 
34. Fliser D, Zeier M, Nowack R, Ritz E. Renal functional reserve in healthy elderly subjects. 
Journal of the American Society of Nephrology. 1993;3: 1371-1377. 
35. Hollenberg NK, Adams DF, Solomon HS, Rashid A, Abrams HL, Merrill JP. Senescence and the 
renal vasculature in normal man. Circulation Research. 1974;34: 309-316. 
Chapter X General discussion  
174	
36. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, et al. Increased renal 
resistive index in patients with essential hypertension: a marker of target organ damage. 
Nephrology Dialysis Transplantation. 1999;14: 360-365. 
37. Terry JD, Rysavy JA, Frick MP. Intrarenal Doppler: characteristics of aging kidneys. Journal 
of Ultrasound in Medicine. 1992;11: 647-651. 
38. Tipisca V, Murino C, Cortese L, Mennonna G, Auletta L, Vulpe V, et al. Resistive index for 
kidney evaluation in normal and diseased cats. Journal of Feline Medicine and Surgery. 2015;18: 
471-475. 
39. Paepe D, Bavegems V, Combes A, Saunders JH, Daminet S. Prospective evaluation of healthy 
Ragdoll cats for chronic kidney disease by routine laboratory parameters and ultrasonography. 
Journal of Feline Medicine and Surgery. 2013;15: 849-857. 
40. Ghys LF, Paepe D, Duchateau L, Taffin ER, Marynissen S, Delanghe J, et al. Biological 
validation of feline serum cystatin C: The effect of breed, age and sex and establishment of a 
reference interval. Veterinary Journal. 2015;204: 168-173. 
41. Miyagawa Y, Takemura N, Hirose H. Assessments of factors that affect glomerular filtration 
rate and indirect markers of renal function in dogs and cats. Journal of Veterinary Medical Science. 
2010;72: 1129-1136. 
42. Cianciolo RE, Benali SL, Aresu L. Aging in the canine Kidney. Veterinary Pathology. 2016;53: 
299-308. 
43. Yoon HE, Choi BS. The renin-angiotensin system and aging in the kidney. The Korean 
Journal of Internal Medicine. 2014;29: 291-295. 
44. Smets PM, Lefebvre HP, Aresu L, Croubels S, Haers H, Piron K, et al. Renal function and 
morphology in aged Beagle dogs before and after hydrocortisone administration. Plos One. 2012;7: 
e31702. 
45. Langston CE, Reine NJ. Hyperthyroidism and the kidney. Clinical Techniques in Small 
Animal Practice. 2006;21: 17-21. 
46. Klein BG. Cunningham's textbook of veterinary physiology St Louis, Missouri: Elsevier 
Saunders, 2013. 
47. Evans RG, Head GA, Eppel GA, Burke SL, Rajapakse NW. Angiotensin II and neurohumoral 
control of the renal medullary circulation. Clinical and Experimental Pharmacology and Physiology. 
2010;37: e58-69. 
Chapter X General discussion  
175	
48. Badzynska B, Grzelec-Mojzesowicz M, Dobrowolski L, Sadowski J. Differential effect of 
angiotensin II on blood circulation in the renal medulla and cortex of anaesthetised rats. Journal of 
Physiology. 2002;538: 159-166. 
49. Schneider AG, Hofmann L, Wuerzner G, Glatz N, Maillard M, Meuwly JY, et al. Renal 
perfusion evaluation with contrast-enhanced ultrasonography. Nephrology Dialysis 
Transplantation. 2012;27: 674-681. 
50. Schneider AG, Calzavacca P, Schelleman A, Huynh T, Bailey M, May C, et al. Contrast-
enhanced ultrasound evaluation of renal microcirculation in sheep. Intensive Care Medicine 
Experimental. 2014;2: 33. 
51. Nobes MS, Harris PJ, Yamada H, Mendelsohn FAO. Effects of angiotensin on renal cortical 
and papillary blood flows measured by laser-Doppler flowmetry. American Journal of Physiology. 
1991;261: F998-F1006. 
52. Walker LL, Rajaratne AA, Blair-West JR, Harris PJ. The effects of angiotensin II on blood 
perfusion in the rat renal papilla. Journal of Physiology. 1999;519 Pt 1: 273-278. 
53. Evans RG, Eppel GA, Anderson WP, Denton KM. Mechanisms underlying the differential 
control of blood flow in the renal medulla and cortex. Journal of Hypertension. 2004;22: 1439-1451. 
54. Coleman AE, Schmiedt CW, Jenkins TL, Garber ED, Reno LR, Brown SA. Evaluation of a rapid 
pressor response test in healthy cats. American Journal of Veterinary Research. 2013;74: 1392-1399. 
55. Osbaldiston GW, Fuhrman W. The clearance of creatinine, inulin, para-aminohippurate and 
phenosulphothalein in the cat. The Canadian Journal of Comparative Medicine. 1970;34: 138-141. 
56. Kishimoto N, Mori Y, Nishiue T, Nose A, Kijima Y, Tokoro T, et al. Ultrasound evaluation of 
valsartan therapy for renal cortical perfusion. Hypertension Research. 2004;27: 345-349. 
57. Itkin RJ, Krawiec DR, Twardock AR, Gelberg HB, Koritz GD. Evaluation of the Single-Injection 
Plasma Disappearance of Tc-99m Mercaptoacetyltriglycine Method for Determination of Effective 
Renal Plasma-Flow in Dogs with Normal or Abnormal Renal-Function. American Journal of 
Veterinary Research. 1994;55: 1652-1659. 
58. Daniel GB, Mitchell SK, Mawby D, Sackman JE, Schmidt D. Renal nuclear medicine: A review. 
Veterinary Radiology & Ultrasound. 1999;40: 572-587. 
59. van Hoek I, Daminet S. Interactions between thyroid and kidney function in pathological 
conditions of these organ systems: A review. General and Comparative Endocrinology. 2009;160: 
205-215. 
Chapter X General discussion  
176	
60. Vaske HH, Schermerhorn T, Grauer GF. Effects of feline hyperthyroidism on kidney function: 
a review. Journal of Feline Medicine and Surgery. 2015. 
61. van Hoek I, Lefebvre HP, Peremans K, Meyer E, Croubels S, Vandermeulen E, et al. Short- 
and long-term follow-up of glomerular and tubular renal markers of kidney function in 
hyperthyroid cats after treatment with radioiodine. Domestic Animal Endocrinology. 2009;36: 45-
56. 
62. Boag AK, Neiger R, Slater L, Stevens KB, Haller M, Church DB. Changes in the glomerular 
filtration rate of 27 cats with hyperthyroidism after treatment with radioactive iodine. Veterinary 
Record. 2007;161: 711-715. 
63. Adams WH, Daniel GB, Legendre AM. Investigation of the effects of hyperthyroidism on 
renal function in the cat. Canadian Journal of Veterinary Research. 1997;61: 53-56. 
64. Ballermann BJ, Obeidat M. Tipping the balance from angiogenesis to fibrosis in CKD. Kidney 
International Supplements. 2014;4: 45-52. 
65. Babickova J, Klinkhammer BM, Buhl EM, Djudjaj S, Hoss M, Heymann F, et al. Regardless of 
etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular 
capillaries. Kidney International. 2017;91: 70-85. 
66. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-
stage renal failure. Journal of the American Society of Nephrology. 2006;17: 17-25. 
67. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent 
damage to peritubular capillaries and influences long-term function. American Journal of  
Physiology Renal Physiology. 2001;281: F887-899. 
68. Ma F, Cang YQ, Zhao BZ, Liu YY, Wang CQ, Liu B, et al. Contrast-enhanced ultrasound with 
SonoVue could accurately assess the renal microvascular perfusion in diabetic kidney damage. 
Nephrology Dialysis Transplantation. 2012;27: 2891-2898. 
69. von Stillfried S, Apitzsch JC, Ehling J, Penzkofer T, Mahnken AH, Knuchel R, et al. Contrast-
enhanced CT imaging in patients with chronic kidney disease. Angiogenesis. 2016;19: 525-535. 
70. Ehling J, Babickova J, Gremse F, Klinkhammer BM, Baetke S, Knuechel R, et al. Quantitative 
Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. 
Journal of the American Society of Nephrology. 2016;27: 520-532. 
71. Herget-Rosenthal S. Imaging Techniques in the Management of Chronic Kidney Disease: 
Current Developments and Future Perspectives. Seminars in Nephrology. 2011;31: 283-290. 
Chapter X General discussion  
177	
72. Grenier N, Merville P, Combe C. Radiologic imaging of the renal parenchyma structure and 
function. Nature Reviews Nephrology. 2016;12: 348-359. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	178	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	179	
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
180	
Chronic kidney disease (CKD) is a common pathology in elderly cats. Early treatment is important 
as it may improve prognosis and quality of life, nevertheless timely detection remains challenging 
in current veterinary practice. Changes in renal perfusion play an important role in the 
pathophysiology of CKD. Therefore, evaluation of renal perfusion may serve as a sensitive 
diagnostic tool, potentially allowing diagnosis in the first stages of the disease process. Contrast-
enhanced ultrasound (CEUS) is an emerging functional imaging technique allowing non-invasive 
assessment of renal perfusion.  
 
In Chapter I, the anatomy and physiology of the kidneys, focusing on the renal vascularization, are 
explained. A summary on the commonly used medical imaging techniques to visualize the kidneys 
is provided. Radiography and B-mode ultrasonography are often used in clinical practice, however 
both techniques only provide morphological information. Renal scintigraphy, CT angiography and 
MRI may also deliver functional information. However, the practical use of these techniques is 
limited by equipment availability, costs, long imaging times and use of ionizing radiation or 
nephrotoxic contrast agents. CEUS does not suffer from these limitations and is thus a promising 
technique to assess renal perfusion. An overview of the current knowledge of renal CEUS in both 
human and veterinary medicine is provided in Chapter  I . 
 
The scientific aims of this thesis are presented in Chapter II. The final goal of this work was to 
assess the value of CEUS in the diagnosis of diffuse renal diseases in cats. In the first part of this 
thesis, studies on healthy cats were performed to gain more insight in the technique and 
influencing factors. In the second part, the use of CEUS in the evaluation of renal perfusion in cats 
with CKD and hyperthyroid cats was evaluated.  
 
Quantitative differences between the first and second injection of contrast agent were 
investigated in Chapter III. Perfusion parameters of the spleen and the left kidney for the first and 
second injection of SonoVue® were compared in 7 healthy cats. A lower peak enhancement and 
area-under-the-curve were present for the first injection. This was statistically significant for the 
renal cortex and splenic parenchyma, whereas a tendency was present for the renal medulla. The 
time-intensity curve for the renal cortex showed less steep wash-in and wash-out for the first 
injection. The exact mechanism behind this findings remains unclear, however phagocytosis of the 
microbubbles in the reticuolendothelial system is believed to play an important role. The findings 
Summary 
181	
of this study proved that significant quantitative differences were present between the first and 
second injection of contrast agent. Therefore, it is recommended to withdraw the first injection 
from quantitative analysis. 
 
The repeatability of CEUS in feline kidneys was assessed in Chapter IV to determine the most 
reliable perfusion parameters in detecting renal perfusion changes.  CEUS of both kidneys was 
performed in 12 healthy cats at 3 time-points with a 7-days interval. Variability was determined on 
3 levels: (1) within cat variability for repeated measures on the same cat, (2) the extra variation 
added by considering both kidneys, and (3) extra variation added by considering observations of 
different cats. The coefficient of variation (CV) was also determined. The CEUS parameters with the 
lowest variation were time-to-peak (CV 5.7%), rise time (CV 13.1%), fall time (CV 19.0%) and mean 
transit time (CV 24.4%) for the renal cortex. Intensity-related parameters and parameters related 
to the slope of the time intensity curve suffered from high variability (CV 36.6 – 56.0%). For the 
renal medulla, only the time-to-peak (CV 12.9%) and rise time (CV 26.3%) showed reasonable 
variability, whereas high coefficients of variation were present for all other parameters (CV 37.7 – 
83.4%). The extra variation added by studying different kidneys was minimal. The variation added 
by considering different cats was moderate in respect to relatively high within-cat variability. In 
summary, time-related parameters for the renal cortex and, in a lesser extent for the renal 
medulla, show good to moderate repeatability, whereas poor repeatability is present for intensity-
related parameters, and parameters related to the shape of the time-intensity curve. This high 
degree of variability will complicate diagnosis based on CEUS.  
 
In Chapter V, the effect of sedation with butorphanol and propofol-anesthesia on CEUS perfusion 
indices of the kidney was investigated. Six healthy cats were enrolled in a randomized crossover 
design, comparing 3 protocols: (1) awake, (2) butorphanol (0.4 mg/kg IM) and (3) propofol (3.5 – 7.7 
mg/kg IV boluses on effect). There was no difference in the subjective enhancement pattern of the 
kidneys between the 3 protocols. Butorphanol did not cause a significant effect on any of the 
perfusion parameters, however the sedative effect was minimal. In contrast, anesthesia with 
propofol resulted in a significant increase in arrival time and time-to-peak, and a slower wash-in 
phase of the time-intensity curve. These changes indicated a decreased blood velocity, likely 
caused by propofol-induced decrease in blood pressure by a combination of decreased cardiac 
output and systemic vascular resistance. In conclusion, propofol is a favorable anesthetic to use in 
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older cats and cats with CKD, however, its effects on CEUS parameters should be taken into 
consideration and direct comparison of perfusion parameters obtained in anesthetized cats and 
awake cats is not possible.  
 
Chapter VI reports the influence of age on CEUS of the kidneys in healthy cats. Forty-three healthy 
cats, aging 1 to 16.5 years, were included and divided into 4 groups: 1-3 years, 3-6 years, 6-10 years 
and > 10 years. No significant differences in any of the perfusion parameters were observed among 
the age groups. Still, a tendency towards a lower PE and WiAUC was noted for the renal cortex 
when comparing the cats > 10 years to the cats between 1 and 3 years. This corresponds to the 
findings in people, in whom a progressive age-related reduction in renal blood flow is well known. 
In conclusion, ageing in cats did not induce significant differences in CEUS renal perfusion 
parameters. Nevertheless, this study suggests that a mild decreased blood volume might occur in 
elderly cats. 
 
In Chapter VII, we investigated if CEUS was capable of detecting relatively small perfusion changes 
induced by angiotensin II infusion. CEUS and renal scintigraphy using 99mTc-
mercaptoacetyltriglycerine were performed in 11 healthy cats, during infusion of angiotensin II 
(vasoconstriction) and during infusion of 0.9% NaCl (control). Angiotensin II-induced changes were 
noticed on several perfusion parameters for a region-of-interest on the entire kidney: peak 
enhancement, wash-in perfusion index and wash-out rate decreased significantly. No significant 
changes were detected for the medullary or cortical regions of interest. Renal scintigraphy was not 
capable of detecting significant perfusion changes after angiotensin II-infusion. This study showed 
that CEUS was able to detect changes in the renal perfusion, suggesting that it is a promising 
technique for the evaluation of renal perfusion in cats. 
  
After the encouraging results of the angiotensin-study, we aimed to evaluate renal perfusion in 
hyperthyroid cats, before and after radioiodine therapy. Therefore, in Chapter VIII, 42 hyperthyroid 
cats were included and CEUS was performed just before radioiodine treatment and at 1-month 
control. Time-related parameters (time-to-peak and rise time) for the renal cortex and medulla 
were significantly lower before treatment compared to 1-month control. A higher wash-in rate 
(cortex and medulla) and wash-out rate (cortex) were also present before treatment. The 
combination of these findings indicates a higher renal blood velocity during hyperthyroid state. The 
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mean transit time for cortex was lower during hyperthyroidism, indicating a shorter duration of 
contrast-enhancement. Additionally, area-under-the-curve for the renal cortex was lower before 
treatment, resulting from the change in shape of the time-intensity curve due to higher blood 
velocity. Uniquely for the renal medulla, a higher normalized peak enhancement was present 
before treatment, suggesting a higher medullary blood volume.  The changes in CEUS parameters 
can be attributed to the decreased systemic and renal vascular resistance typically present in 
hyperthyroidism. Moreover, higher heart rates in hyperthyroid cats will have reinforced the effect 
on renal blood velocity. In conclusion, CEUS showed a higher blood velocity and higher medullary 
blood volume during hyperthyroid state compared to post-treatment control.  
 
Finally, in Chapter IX, the diagnostic capabilities of CEUS were evaluated in cats with CKD (n=14) 
and compared with healthy control cats (n=43).  In cats with CKD, a longer time-to-peak and 
shorter mean-transit time were observed for the renal cortex. In contrast, a shorter time-to-peak 
and rise time were seen for the renal medulla. The findings for the cortex indicate a slower renal 
blood velocity, likely caused by a higher renal vascular resistance in CKD. A higher blood velocity in 
the renal medulla has not been described before, and may be caused by a different response to 
regulatory factors. It is known that the renal medulla is less susceptible to vasoconstriction. To 
conclude, CEUS was capable of detecting perfusion changes in cats suffering from CKD: slower 
cortical but faster medullary blood velocity were detected.  
 
Chapter X comprises the general discussion and conclusions of this thesis. Throughout the different 
studies in this work, CEUS has been shown to be a favorable technique for the evaluation of renal 
perfusion in cats. The large variability currently causes a high degree of diagnostic uncertainly 
limiting the application of CEUS in a clinical setting.  Despite this limitation, CEUS is still a 
promising method for renal microvascular evaluation and further technical advances may improve 
repeatability.  
 
 184	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	185	
 
 
 
 
 
 
 
 
 
SAMENVATTING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samenvatt ing 
186	
Chronische nierziekte (CNZ) is een vaak voorkomende aandoening bij oudere katten. De prognose 
en levenskwaliteit van de kat kunnen merkelijk verbeteren als de behandeling vroegtijdig 
ingesteld wordt. Tot op heden blijft het echter moeilijk om de diagnose in een vroeg stadium te 
stellen omdat de huidige technieken die in de praktijk gebruikt worden (bloed- en urineonderzoek), 
pas diagnose toelaten wanneer reeds een substantieel deel van de nierfunctie verloren is.  
Veranderingen in de doorbloeding van de nier spelen een belangrijke rol in het ontstaan en de 
progressie van CNZ. Evaluatie van de nierperfusie kan daarom nieuwe inzichten geven en ingezet 
worden voor de vroegtijdige diagnostiek van CNZ. Contrast-echografie (CEUS) is een nieuwe 
functionele beeldvormingstechniek die toelaat om de doorbloeding van een orgaan te bestuderen.  
 
In het eerste hoofdstuk wordt de anatomie en fysiologie van de nier uitgelegd, de focus ligt op de 
doorbloeding van de nier. Dit wordt gevolgd door een samenvatting van de meest gebruikte 
medische beeldvomingstechnieken om de nier in beeld te brengen. Radiografie en klassieke B-
mode echografie zijn de meest gebruikte technieken in praktijk. Beiden geven enkel morfologische 
informatie, maar leren ons niets over de functie van de nier. Scintigrafie, CT angiografie en MRI 
kunnen wel functionele informatie opleveren. De nadelen van deze technieken zijn hun hoge 
kosten, beperkte beschikbaarheid van de apparatuur, langere onderzoeksduur, gebruik van 
ionizerende straling en/of mogelijks nefrotoxische contrast agentia. Contrast echografie is een zeer 
gebruiksvriendelijke techniek die niet onderhevig is aan de bovenvermelde beperkingen, bijgevolg 
lijkt het een zeer veelbelovende methode voor de evaluatie van de nierperfusie. In dit hoofdstuk 
vindt men een overzicht  van de huidige kennis omtrent het gebruik van CEUS voor onderzoek van 
de nieren in de humane geneeskunde en diergeneeskunde. 
 
De doelstellingen van deze thesis worden toegelicht in hoofdstuk II. Het finale doel van dit werk 
was om het potentieel van CEUS voor de diagnose van CNZ bij de kat te onderzoeken. In het eerste 
deel van deze thesis werden studies gedaan bij gezonde katten om inzicht te verkrijgen in de 
techniek en mogelijke factoren die een invloed kunnen hebben op de resultaten. In het tweede deel 
werd het diagnostisch potentieel van CEUS geëvalueerd bij katten met CNZ en katten met 
hyperthyroïdie.  
 
Het voorkomen van kwantitatieve verschillen tussen de eerste en tweede injectie van contrast 
medium werd onderzocht in hoofdstuk III. De perfusieparameters voor de milt en de linker nier 
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voor de eerste en tweede injectie van SonoVue® werden vergeleken voor 7 gezonde katten. De 
piekintensiteit en oppervlakte-onder-de-curve waren lager voor de eerste injectie ten opzichte van 
de tweede. Dit was enkel statistisch significant voor de nierschors en de milt, terwijl er een 
statistische trend was voor het niermerg. De tijd-intensiteitscurve was vlakker voor de eerste 
injectie in de nierschors. Het exacte mechanisme achter deze bevinden blijft voorlopig een 
vraagteken. Er wordt verondersteld dat fagocytose van de ‘microbubbles’ in het contrast medium 
door het reticuloendotheliaal systeem een sleutelrol speelt. De bevindingen van deze studie 
bewijzen dat er significante kwantitatieve verschillen zijn tussen de eerste en tweede injectie van 
contrast medium. Er wordt daarom geadviseerd om de eerste injectie niet te gebruiken voor 
verdere analyses.  
 
De herhaalbaarheid van CEUS voor evaluatie van de nierperfusie bij de kat werd bestudeerd in 
hoofdstuk IV. CEUS van beide nieren werd uitgevoerd bij 12 gezonde katten op 3 tijdstippen met 
telkens 7 dagen tussenperiode. De variabiliteit werd bestudeerd op 3 niveaus: (1)  de variabiliteit 
binnen eenzelfde kat voor herhaalde metingen op eenzelfde nier,  (2) bijkomende variabiliteit 
wanneer beide nieren in beschouwing genomen werden, (3) bijkomende variabiliteit wanneer 
observaties van verschillende katten in beschouwing genomen werden. De coëfficiënt van variatie 
(CV) voor de verschillende perfusie parameters werd eveneens bepaald. De parameters met de 
laagste variatie en dus hoogste herhaalbaarheid waren tijd-tot-piekintensiteit (CV 5,7%) , ‘rise time’ 
(CV 13,1%) , ‘fall time’ (CV 19,0%) en de gemiddelde transit tijd (‘mean transit time’) (CV 24,4%) voor 
de nierschors. De parameters gerelateerd aan de intensiteit en de helling van de tijds-
intensiteitscurve vertoonden een hoge variabiliteit (CV 36,6-56,0%). Voor het niermerg, vertoonden 
enkel de tijd-tot-piek (CV 19,9%) en ‘rise time’ (CV 26,3%) een matige coëfficiënt van variatie, terwijl 
alle andere parameters een hoge coëfficiënt (CV 37,7-83,4%) en dus hoge variabiliteit vertoonden. 
De bijkomende variabiliteit wanneer beide nieren in beschouwing genomen werden, was laag en 
zelfs verwaarloosbaar voor de nierschors. Bijkomende variabiliteit door observaties van 
verschillende katten in rekening te brengen was matig ten opzichte van de hoge variabiliteit 
binnen eenzelfde kat voor herhaalde metingen. Samenvattend kan er gezegd worden dat de tijd 
gerelateerde parameters voor de nierschors en, in mindere mate, voor het niermerg een goede tot 
matige herhaalbaarheid vertonen, terwijl de herhaalbaarheid voor de intensiteit gerelateerde 
parameters, en de parameters gerelateerd aan de vorm van de tijds-intensiteitscurve laag is. De 
hoge mate van variabiliteit bemoeilijkt het stellen van een diagnose op basis van CEUS. 
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In hoofdstuk V werd het effect van sedatie met butorfanol en anesthesie met propofol op de 
perfusie parameters bestudeerd. Zes gezonde katten werden geïncludeerd in een gerandomiseerde 
cross-over studie waarin 3 protocollen vergeleken werden: (1) wakker (geen anesthesie of sedatie) 
, (2) sedatie met butorfanol (0,4 mg/kg IM) en (3) anesthesie met propofol (3,5 – 7,7 mg/kg IV 
bollussen op effect). Er waren geen subjectieve verschillen in het perfusiepatroon tussen de 3 
protocollen. Butorfanol veroorzaakte geen significante verschillen in de perfusieparameters, maar 
het sedatief effect was minimaal. Propofol-anesthesie daarentegen, zorgde voor een significante 
verlenging van de aankomsttijd (‘arrival time’) en tijd-tot-piekintensiteit, bovendien was de eerste 
fase van de tijds-intensiteitscurve minder steil (tragere ‘wash-in’). Deze bevindingen wijzen op een 
tragere bloedsnelheid, meest waarschijnlijk het gevolg van een daling in bloeddruk veroorzaakt 
door propofol. Deze bloeddrukdaling ontstaat typisch door de combinatie van een gedaald 
hartminuutvolume en lagere systemische vasculaire weerstand.  
Concluderend kunnen we stellen dat propofol een goed anestheticum is voor oudere katten en 
katten met CNZ, maar er zijn belangrijke kwantitatieve effecten op CEUS van de nieren bij gezonde 
katten, deze dienen in rekening gebracht te worden. Perfusie parameters bekomen bij wakkere 
katten kunnen niet vergeleken worden met deze bekomen bij katten die onder anesthesie waren. 
 
In hoofdstuk VI werd de invloed van leeftijd op CEUS van de nieren bij gezonde katten onderzocht. 
Drieënveertig gezonde katten met een leeftijd tussen 1 en 16,5 jaar werden geïncludeerd en in 4 
leeftijdscategorieën onderverdeeld: 1-3 jaar, 3-6 jaar, 6-10 jaar en > 10 jaar. Er waren geen 
significante verschillen in de perfusieparameters tussen de verschillende leeftijdscategorieën. Er 
was echter wel een trend tot een lagere piekintensiteit en lagere oppervlakte-onder-de-curve voor 
het eerste deel van de tijd-intensiteitscurve van de nierschors wanneer de katten tussen 1 en 3 jaar 
met de katten van meer dan 10 jaar vergeleken werden. Deze bevindingen komen overeen met 
gegevens bij de mens, waar een progressieve leeftijdgebonden afname in de nierperfusie een goed 
gekend fenomeen is. Deze studie suggereert voor het eerst een milde daling in bloedvolume voor 
de nierschors  bij oudere katten.  
 
In hoofdstuk VII werd er onderzocht of CEUS in de mogelijkheid was om relatief kleine 
perfusieveranderingen veroorzaakt door een angiotenine II-infuus, te detecteren. Elf gezonde 
katten ondergingen CEUS en nierscintigrafie (99mTc-mercaptoacetyltriglycerine) tijdens infusie van 
angiotensine II (vasoconstrictie) en 0.9% NaCl (controle). Perfusieveranderingen geïnduceerd door 
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angiotensine II werden waargenomen in verschillende parameters voor de volledige nier: de 
piekintensiteit, ‘wash-in perfusion index’, en ‘wash-out rate’ daalden significant.  Er waren geen 
significante verschillen tussen controle en angiotensine II-infuus wanneer de nierschors of het 
niermerg afzonderlijk beschouwd werden. Nierscintigrafie was niet in staat om significant 
perfusieveranderingen te detecteren. Deze studie toonde aan dat CEUS een zeer veelbelovende 
techniek is voor de evaluatie van de nierperfusie bij katten, wat verder onderzoek bij patiënten 
sterk aanmoedigt.  
 
Na de veelbelovende resultaten van de angiotensine-studie, was het volgende doel om de 
nierperfusie te bestuderen bij hyperthyroïde katten, vóór en na radiojoodbehandeling. Voor de 
studie in hoofdstuk VIII werden er 42 hyperthyroïde katten geïncludeerd die CEUS ondergingen net 
voor radiojoodbehandeling en tijdens een controlebezoek 1 maand nadien.  Tijd gerelateerde 
parameters (tijd-tot-piekintensiteit en ‘rise time’) voor de nierschors en het niermerg waren 
significant lager vóór behandeling van hyperthyroïdie ten opzichte van het controlebezoek. De 
‘wash-in rate’ (nierschors en medulla) en de ‘wash-out rate’ (nierschors) waren eveneens hoger 
vóór de behandeling (steilere tijd-intensiteitscurve). De combinatie van deze bevindingen wijst op 
een hogere doorbloedingssnelheid ten gevolge van hyperthyroïdie. De gemiddelde transit tijd voor 
de nierschors was lager vóór behandeling, wat wijst op een kortere verblijfsduur van contrast in de 
nier. Bovendien was de oppervlakte-onder-de-curve voor de nierschors ook lager vóór de 
behandeling ten gevolge van de hoger beschreven verandering in vorm van de tijds-
intensiteitscurve. Een hogere genormaliseerde piekintensiteit voorafgaand aan de behandeling 
was een uniek gegeven voor het niermerg, dit suggereert een hoger bloedvolume tijdens de 
hyperthyroïde status van de kat.  De verschillen in CEUS parameters vóór en na de behandeling met 
radioactief jodium, kunnen toegewezen worden aan een gedaalde systemische en renale vasculaire 
weerstand tijdens hyperthyroïdie. Hierbij komt nog dat de hogere hartfrequentie bij hyperthyroïde 
katten het effect of de perfusieparameters van de nier versterkt. Uit deze studie kunnen we 
afleiden dat CEUS een hogere bloedsnelheid in de nierschors en het niermerg en hoger 
bloedvolume voor het niermerg aantoont bij katten met hyperthyroidie, ten opzichte van een 
controle 1 maand na behandeling.  
 
Tot slot werd in hoofdstuk IX het diagnostisch potentieel van CEUS geëvalueerd bij katten met CNZ 
(n=14) ten opzichte van gezonde controle katten (n=43). De tijd-tot-piekintensiteit voor de 
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nierschors was langer en de gemiddelde transit tijd van de nierschors was korter bij katten met 
CNZ.  Voor het niermerg daarentegen was de tijd-tot-piekintensiteit en de ‘rise time’ korter bij 
katten met CNZ. Deze bevindingen tonen aan dat de doorbloedingssnelheid van de nierschors daalt 
bij katten met nierziekte, meest waarschijnlijk veroorzaakt door een hogere vasculaire weerstand 
in aangetaste nieren. De hogere doorbloedingssnelheid voor het niermerg in deze studie, werd nog 
niet eerder gerapporteerd.  Deze wordt mogelijks veroorzaakt door een niermerg-specifieke 
respons van de doorbloeding op bepaalde factoren, bovendien is het reeds langer geweten dan het 
niermerg relatief ongevoelig is aan vasoconstrictie. We kunnen concluderen dat CEUS in staat is om 
perfusieafwijkingen te detecteren bij katten met CKD: er is een tragere bloedsnelheid in de 
nierschors, terwijl de bloedsnelheid in het niermerg toeneemt. 
 
Hoofdstuk X omvat de algemene discussie en de conclusies van dit doctoraatsonderzoek. Doorheen 
de verschillende studies in deze thesis bleek dat CEUS een beloftevolle techniek is voor de 
evaluatie van de nierperfusie bij katten. De hoge variabiliteit en dus lage reproduceerbaarheid 
waarmee de techniek momenteel te kampen heeft, leiden echter tot een grote mate van 
diagnostische onzekerheid wat het gebruik in de praktijk momenteel beperkt. Desondanks deze 
beperking blijft CEUS een veelbelovende techniek om de microvascularisatie van de nier te 
beoordelen, bovendien zal de technologische vooruitgang in de toekomst hoogstwaarschijnlijk 
zorgen voor merkelijke verbeteringen in de herhaalbaarheid. 
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Het einde is in zicht, het is tijd geworden voor het allerlaatste hoofdstuk, waarschijnlijk ook het 
belangrijkste. Enerzijds is het dé kans om iedereen te bedanken die mij geholpen en gesteund 
heeft om dit doctoraat tot een goed einde te brengen, anderzijds is het ook het meest gelezen deel 
van een doctoraat.  
 
In de eerste plaats wil ik mijn promoteren, Prof. Jimmy Saunders en Prof. Katrien Vanderperren, 
bedanken voor alle kansen die ik gekregen heb. Zonder hen was er geen sprake geweest van dit 
doctoraat. Jimmy, Katrien, jullie hebben me begeleid van de eerste beursaanvraag tot het printen 
van dit boekje. Jullie hebben me steeds veel vrijheid gegund, maar op hetzelfde moment hebben 
jullie me bijgestuurd en afgeremd waar nodig. Gelukkig maar, anders was ik nu waarschijnlijk nog 
steeds katjes aan het rekruteren. Katrien, bedankt voor alle steun, het luisterende oor en om mij op 
te peppen als ik het even minder zag zitten. Je hebt mij altijd net dat ene stapje meer laten 
bereiken. Dankzij jou waren er af en toe interessante nevenprojectjes, waar ik steeds met plezier 
aan meegewerkt heb. Ik koester ook goede herinneringen aan de congressen in Rotterdam of het 
congres in Barcelona, waar we de avond steevast afsloten bij de ‘Font màgica’.  
 
Mijn volgende woordje van dank richt ik graag tot de leden van de lees- en examencommissie. 
Bedankt voor alle tijd die jullie in dit werk gestoken hebben, jullie opbouwende commentaar was 
van onschatbare waarde om het finale werk te verbeteren. Prof. Duchateau, bedankt om de taak 
van voorzitter op u te nemen en daarmee alles in goede banen te leiden, net zoals u doorheen mijn 
ganse doctoraat gedaan hebt. U was steeds beschikbaar om een optimaal studiedesign uit te 
werken, om gegevens statistisch te verwerken, en, het allerlastigste, om mij nadien wegwijs te 
maken in die statistiek. Bedankt voor al uw geduld, ik hoop alvast dat ik vandaag geen statistische 
flaters sla. Prof. Paepe, beste Dominique, reeds van voor de start van mijn doctoraat speelde u een 
belangrijke rol. Het begint allemaal in het laatste jaar van mijn studies, met een masterproef 
omtrent idiopathische hypercalcemie bij de kat. U ligt aan de basis van mijn interesse in nierziekte 
bij de kat, tevens heeft u mij aangespoord om mijn eerste artikels te schrijven, het prille begin van 
dit alles. Toen ik later aan mijn doctoraat begon, stond u steeds klaar met goede raad, bovendien 
kon ik altijd op u rekenen als ik hulp nodig had met patiëntjes (je bent kampioen in het 
bloednemen van springerige Ragdolls met kleine bloedvaatjes!). Artikels nalezen (en nog eens 
nalezen), het was u nooit teveel, uw suggesties en correcties waren steeds zeer waardevol. 
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Bedankt voor alles! Prof. Vanhove, bedankt om in de examencommissie te willen zetelen. Een 
eindje geleden, kreeg ik de kans om enkele introductielessen in ‘translational biomedical in vivo 
imaging’ van u te volgen. Een boeiende lessenreeks over beeldvorming in al zijn aspecten.  U leidt 
een fantastische onderzoeksgroep, misschien zit er ooit wel eens een samenwerking in?  Prof. 
Bolen, nous nous sommes rencontrées la première fois en Pologne, pendant les conférences EVDI. 
Nous avons parlé de votre chat, Chaminou, alors hyperthyroïdien. Quelques semaines plus tard, 
Chaminou, est venue à Merelbeke pour un traitement avec l’iode radioactive et a été incluse dans 
mon étude. Un grand merci pour votre confiance et un gros câlin pour Chaminou, elle a été 
formidable.  Dr .  Smets , Pascale, bedankt om met veel enthousiasme mee te stappen in de studie 
met de hyperthyroïde katjes. Het was altijd fijn om op maandagochtend bij u langs te komen voor 
de echocardio’s. Uw enthousiasme in cardiologie werkt aanstekelijk, ik kom binnenkort nog wel 
eens meevolgen. Dr. Broeckx, bedankt voor de gezellige babbels tussendoor, om mij even bij te 
sturen als ik, zelfs na de uitgebreide uitleg van Prof. Duchateau, toch nog wat meer achtergrond 
nodig had bij een of andere statistische analyse. Bedankt ook om mij te introduceren in de 
wondere wereld van de HD screening, ik kijk alvast uit naar meer. Dr. Raes,  Els, bedankt om de 
voorbije jaren zo’n fijne geduldige collega te zijn. Ik kijk naar je op, desondanks je iets wat warrige 
levensstijl, slaag je er toch maar in om alles te combineren. Die diplomate-titel is meer dan 
verdiend. Binnenkort kom ik jullie nog af en toe eens vergezellen op paard, ik kan zoveel van je 
leren. Nu Frits en Nova toch beslist hebben om vriendjes te worden, zullen we elkaar ook tijdens de 
middag wel eens vergezellen voor een wandelingetje.  
 
Prof. Daminet, uw bijdrage aan dit doctoraat is groot. U heeft geholpen in de uitwerking van de 
protocollen van de klinische studies en u stond steeds klaar met advies. Bedankt dat ik u steeds 
mocht lastigvallen voor vragen ivm ‘de hyperthyroïdjes’. Uw endocrinologische kennis is 
onuitputtelijk. Bedankt ook om de artikels steeds met zorg te lezen en altijd opnieuw naar een 
hoger niveau te tillen.  
 
Hendrik, ook zonder jou was dit doctoraat er niet geweest. Je bent wat op de achtergrond geraakt, 
ontrecht! Jouw doctoraat was het eerste doctoraat dat ik ooit bijgewoond heb, wat een introductie 
in ‘het universitaire wereldje’! Ik probeer mijn verdediging iets korter te houden (al is het een 
efficiënte manier om te vragenronde in te korten), maar om aan jouw kennis van microbubbles en 
contrast-echografie te geraken, zal ik serieus mijn best moeten doen. Je hebt mij de basis van 
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contrast-echografie bijgebracht, geholpen met het opstellen van protocols, en geleerd hoe je een 
goede contrast-echografie van een nier doet. Het was altijd aangenaam werken met jou, het 
filosoferen achteraf niet te vergeten. Onze gans is momenteel aan het broeden, hopelijk zijn er 
binnenkort kleintjes, dan kunnen we een ruil organiseren (een gansje tegen een kalkoentje?). Als je 
eens in de buurt van Melden bent, ben je zeker welkom. Dan kan je ‘onzen hof’ eens inspecteren en 
tips geven.  
 
‘De mensen van de farmacie’, Ine en Heleen, ik ben blij dat ik jullie tijdens mijn doctoraat heb 
mogen ontmoeten. Jullie zijn fanastische madammen. Dankzij jullie heb ik een geheel andere kant 
van het microbubble onderzoek leren kennen. Bedankt ook om ons te introduceren op het 
microbubble symposium in Rotterdam. Hopelijk mogen er nog heel wat gemeenschappelijke 
projecten volgen. 
 
During the last years, the faculty has been my second home. I would like to thank all the colleagues 
for creating a nice working environment. The colleagues of the medical imaging department, 
thanks for all your help and patience with me and my patients (the first one is probably the worst). 
I’m sorry for my impatience in the ultrasound room when I wanted to ‘steal’ the machine for a 
contrast-ultrasound while you were very busy running the clinic. Laure, I’m so happy you are 
staying some more months with us, thanks for teaching me; you make me a better imager. 
Blandine, Olivia, Tibor, Lise, Mileva, you are a great team of residents, I’m so lucky to be part of that. 
Good luck with everything in the future. Elke, thank you for guiding and teaching me. I hope you 
can finalize your own PhD soon. Kim, a small talk with you can cheer up my day. Thanks for 
listening when I needed someone. The equine department wouldn’t be the same without you. I’m 
looking forward to spent some more time at equine imaging soon.  Veerle and Ines, you both left 
the faculty, nevertheless you kept on supporting me form the UK and Swiss. I’ve greatly enjoyed 
working with you; you’ve thought me so much.  We keep in touch and we’ll meet again. Many other 
current and previous colleagues,  Caroline, Olga, Eva, Kaatje, Walter, Daisy, Annemie, Aqui, Ingrid, 
Prof. van Bree, Prof. Dik, Kathelijne, Robrecht, Marnix, Claudine, Sandra, less words, but not less 
gratitude for you.  
The orthopaedics team, Prof. Van Ryssen, Yves, Evelien dB en B, Eva, Tine, Stijn, thanks for being 
who you are, contributing to a nice working environment. Special thanks (woef!) to Vita, Wilson, 
Soda and Isa for being friends with my little monster, Fritske.  
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The team of the small animal department thanks for contributing each in your own way. The 
internal medicine team, Lisa, Eva, Gonçalo, Femke, Sofie, Annelies,  thanks for the nice collaboration 
in clinics and your professional advice on some of the patients in my study. Eva, a special word for 
you, thanks for your contribution in the hyperthyroid study. We spent several Sundays together 
performing GFR’s, I think we can say, we are a superb cat-GFR team by now. The cardiology team, 
Veronique, Dominique, Valérie, Iris, thanks for all the help with the hyperthyroid cats. I have 
enjoyed attending the echocardiography exams and the small talks in-between; it felt like a nice 
refreshing break in the Monday morning rush. The people from anaesthesia, you are a top-team, 
thanks for your help. Prof. de Rooster, Sophie, Eline and Laetitia, I’m so happy our research topics 
crossed at some point. I have always enjoyed working with you. Several teams of cheerful interns 
have passed by during my PhD, thanks for assisting me with patients in the weekends. Nausikaa, 
thanks to Juno and Frits we started our (almost) daily walks around the faculty, you have become 
a friend in that period. Thanks for listing to me, for the small breaks in-between, it makes the 
working day so much more fun.  
 
De mensen van diervoeding, Prof. Hesta, Veerle Vandendriesche, Amy en Isolde, bedankt voor jullie 
bijdrage aan de studies met proefkatjes.  
 
Alle katjes, katteneigenaars en doorverwijzende dierenartsen, zonder jullie was dit uiteraard niet 
mogelijk geweest. Bedankt voor jullie enthousiasme om deel te nemen aan mijn studies. Jullie 
kunnen niet geloven hoeveel plezier de mailtjes met updates en foto’s mij doen.  
 
Gelukkig waren er naast het werk ook vr ienden om de weekends en avonden op te fleuren. 
Bedankt voor de leuke intermezzo’s, maar even naar mijn werk gerelateerde verzuchtingen te 
luisteren en het dan moeiteloos over een andere, vrolijke boeg te gooien. Zonder jullie steun was 
dit niet haalbaar geweest. Ine en Kristof,  ik kijk al uit naar onze volgende ‘date’, bowlen, een 
etentje, bootje varen of één of andere workshop, zolang we elkaar maar af en toe eens zien. Ik kijk 
toch wel uit naar het moment dat jullie terug wat dichter komen wonen, misschien kunnen we 
onze squash-avonden dan weer opnemen? Hanne en Wim, bedankt om alle voorbije bbq’tjes op 
jullie te nemen, binnenkort nemen wij terug over (beloofd!). Hanne, je wordt nog een echte 
kippendierenarts. Ken en Astrid, jullie hebben een prachtig gezinnetje. Ik sta er altijd van versteld 
hoe jullie alles voor elkaar krijgen. Een bezoekje bij jullie is altijd gezellig . Lieze en Gwij, het spijt 
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me verschrikkelijk dat ik jullie meermaals heb laten zitten met de ingredienten voor Tajine. Ik 
beloof dat ik het binnenkort goed maak.  Rebecca, dinsdag is onze vaste afspraak geworden. Je 
bent altijd welkom, ook als we binnenkort wat verder wonen. De fantastische bende van Stal ten 
Legenbos, allemaal totaal verschillend maar samen de gezelligste stal van het land. Ik ben altijd 
blij als ik zie dat er auto’s staan als ik ’s avonds laat nog langskom: samen poetsen, babbelen 
tijdens het instappen, … een uurtje op stal, en ik kan terug alles aan. Peter en Hilde, jullie verdienen 
toch een speciaal woordje van dank om zo goed voor ons mannetje te zorgen. Het is ongelooflijk 
wat jullie allemaal doen voor de paarden en de baasjes, chapeau!  
Als ons huisje binnenkort voorzien is van alle comfort (lees: ramen, deuren, elektriceit en water), 
zijn jullie allemaal welkom! 
 
Mama, papa, bedankt om mij alle kansen te geven om te studeren en om me te ondersteunen in 
alles wat ik doe. Papa, op het moment dat ik dit aan het schrijven ben, is het onduidelijk of je er zal 
kunnen bij zijn vandaag. Hou de moed erin, binnenkort heb je een nieuwe aorta en nieuwe klep, dan 
zal het ongetwijfeld beter gaan dan ooit tevoren. Mama, bedankt om er altijd te zijn voor mij, om 
mij de kans te geven naar Admiral te gaan als ik wil, maar even goed voor hem te zorgen als het te 
druk is. Bomma, bompa, oma en opa, jullie zijn er niet meer, maar ik ben zeker dat jullie trots 
zouden geweest zijn. Je ziet maar, het heeft geloond om mijn West-Vlaams accent te proberen 
‘afleren’ en mij te stimuleren om flink te studeren, ik ben toch op ‘den unif’ geraakt.  
Mama en papa van Roel, Yves en Daniëlla, jullie zijn mijn 2de ouders geworden. Het is jullie nooit te 
veel om de was of strijk te doen, of te helpen bij de verbouwingen. Moeke, Peter, Marleen en Jan, 
Lore, Janne, Lien en Kris, bedankt om mij in de familie op te nemen. Ik probeer om in de toekomst 
wat meer familiefeestjes en etentjes bij de wonen. Broertje en Tara, jullie zijn een prachtig koppel. 
Jullie trouwfeest was het beste ooit, zo wil ik ook wel trouwen… Bedankt voor de leuke babbels. Ik 
zal het toch wat missen als je binnenkort ietsje verder wonen. Veel succes in alles wat jullie doen, 
er staat jullie nog zoveels moois te wachten.  
 
Mijn mannen, Admiral, Frits, Florian en Gaudi (om alle verwarring te vermijden: paard, hond en 
katten respectievelijk), jullie maken alles zoveel mooier. Admiraltje, je bent mijn mateke, bedankt 
om je energie af en toe wat te temperen als ik op je rug zit, het wordt geapprecieerd. Ik probeer 
binnenkort wat meer tijd voor je te maken. Fritske, jouw werkvreugde valt in een aparte categorie, 
je bent al uitzinnig van blijdschap als de faculteit vanaf het rondpunt in zicht komt. De korte 
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wandelingetjes zijn vaak een deugdoende verfrissing tussendoor, bovendien heeft het gezorgd dat 
collega’s, vrienden zijn geworden. Florian en Gaudi, voor jullie toch een kleine opmerking: jullie 
hebben niet willen deelnemen aan mijn studie (foei). Toegegeven, het was het veiligste voor 
iedereen. Thuis zijn jullie wel , gelukkig, de allerliefste en allerschattigste katjes.  
 
Roel, woorden schieten te kort om jou te bedanken. Je hebt mij altijd gesteund, hoe onhaalbaar 
mijn plannen ook leken, jij stond altijd achter mij. Je hebt jezelf dikwijls weggecijferd zodat ik mijn 
dromen kon waarmaken. Zonder jou was dit allemaal niet gelukt. Ik zie je graag! Ik kijk uit naar 
onze toekomst samen.  
 
 
Emmelie 
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Emmelie Stock werd geboren op 23 oktober 1988 te Kortrijk. Na het behalen van het diploma hoger 
secondair onderwijs, richting wetenschappen-wiskunde aan het Koninklijk Atheneum te Kortrijk, 
startte ze in 2006 met de studies Diergeneeskunde aan de universiteit Gent. In 2012 behaalde ze 
het diploma van Master in de diergeneeskunde, afstudeerrichting gezelschapsdieren, met grote 
onderscheiding.  
 
Aansluitend startte ze een internship bij de dienst medische beeldvorming van de vakgroep 
Medische beeldvorming van de huisdieren en Orthopedie van de kleine huisdieren, faculteit 
diergeneeskunde van de universiteit Gent. Geboeid door de mogelijkheden die het 
wetenschappelijk onderzoek kan bieden voor de kliniek, startte ze in 2013 een doctoraatsstudie 
naar contrast-echografie voor de evaluatie van de nierperfusie bij katten. Dit onderzoek werd 
gefinancierd door het Bijzonder Onderzoeksfonds van de universiteit Gent. Tevens vervolledigde ze 
het trainingsprogramma van de Doctoral School of Life Science and Medicine van de Universiteit 
Gent.  
 
Emmelie Stock is auteur en medeauteur van verschillende wetenschappelijke publicaties en nam 
actief deel aan verschillende nationale en internationale congressen.  
 
 
 
 
 
 
 
 
 
	201	
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibl iography 
202	
Publ icat ions in  peer-reviewed scientif ic  journals  
 
Stock E . , Paepe D., Daminet S., Duchateau L., Saunders J.H.*, Vanderperren K.* Influence of ageing 
on quantitative contrast-enhanced ultrasound of the kidneys in healthy cats. Veterinary Record, 
under revision. (* shared senior authorship) 
 
Stock E . , Daminet S., Paepe D., Buresova E., Vandermeulen E., Smets P., Duchateau L., Saunders J.H.*,  
Vanderperren K.* Evaluation of renal perfusion in hyperthyroid cats before and after radioiodine 
treatment. Journal of Veterinary Internal Medicine, under revision. (* shared senior authorship) 
 
Stock E ., Paepe D., Daminet S., Vandermeulen E., Duchateau L., Saunders J.H.*, Vanderperren K.* 
Contrast-enhanced ultrasound for the assessment of renal perfusion in cats with chronic kidney 
disease. Journal of Veterinary Internal Medicine, under revision. (* shared senior authorship) 
 
Stock E ., Duchateau L. Volckaert V., Polis I., Saunders J.H.*, Vanderperren K.* Repeatability of 
contrast-enhanced ultrasonography of the kidneys in healthy cats. Ultrasound in Medicine and 
Biology, under revision. (* shared senior authorship) 
 
Broeckx B.J.G., Vezzoni A., Bogaerts E., Bertal M., Stock E ., Deforce D., Peelman L., Saunders J.H. 
Comparison of three methods to quantify laxity in the canine hip joint. Veterinary Comparative 
Orthopaedics and Traumatology, under revision. 
 
Van Hoof K.J.M., Van der Vekens E., Samoy Y., de Bakker E., Stock E . Fysaire dysplasia van de 
femurkop bij een jonge Golden Retriever.Vlaams diergeneeskundig tijdschrift 2017; 86: 35-39. 
 
Vanderperren K., Stock E ., Pardon B., Saunders J. Contrast-enhanced ultrasound in sheep. Small 
Ruminant Research 2017. In press 
 
Stock E ., Vanderperren K., Haers H., Duchateau L., Hesta M., Saunders J. Quantitative differences 
between the first and second injection of contrast agent in contrast-enhanced ultrasonography of 
feline kidneys and spleen. Ultrasound in Medicine and Biology 2017; 43: 500-504.  
 
Bibl iography 
203	
Ciccelero L, Denies S., Vanderperren K., Stock E ., Van Brantegem L., de Rooster H., Sanders N. 
Immunological, anti-angiogenic and clinical effects of intratumoar interleukin 12 electrogene 
therapy combined with metronomic cyclophosphamine in dogs with spontaneous cancer: a pilot 
study. Cancer Letters 2016; S0304-3835: 1-14.  
 
Rossi F.*, Fina C.*, Stock E ., Vanderperren K., Duchateau L., Saunders J.H. Effect of sedation on 
contrast-enhanced ultrasonography of the spleen in healthy dogs. Veterinary Radiology and 
Ultrasound 2016; 57: 276-81. (*Contributed equally) 
 
Cicchelero L., Denies S., Haers H., Vanderperren K., Stock E ., Van Brantegem L., de Rooster H.*, 
Sanders N.N*. Intratumoral interleukin 12-gene therapy stimulates the immune system and 
decreases angiogenesis in dogs with spontaneous cancer. Veterinary and Comparative Oncology 
2016. 
 
Stammeleer L., de Bakker E., Stock E ., Dehuisser V., Gielen I., Van Ryssen B. Flexorenthesopathie bij 
een Italiaanse Cane Corso: diagnostische bevindingen en resultaat na behandeling. Vlaams 
diergeneeskundig tijdschrift 2016; 85: 215-20. 
 
Stock E ., Vanderperren K., Bosmans T., Dobbeleir A., Hesta M., Lybaert L., Peremans K., 
Vandermeulen E., Saunders J. Evaluation of feline renal perfusion with contrast-enhanced 
ultrasonography and scintigraphy. Plos One 2016; 11: e0164488. 
 
Dewitte H, Vanderperren K, Haers H, Stock E , Duchateau L, Hesta M, Saunders JH, De Smedt SC, 
Lentacker I. Theranostic mRNA-loaded Microbubbles in the Lymphatics of Dogs: Implications for 
Drug Delivery. Theranostics 2015; 5: 97-109.  
 
Abma E., Kitshoff A., Vandenabeele S., Bosmans T., Stock E ., de Rooster H. Treatment of necrotizing 
fasciitis using negative wound therapy in a puppy. Vlaams diergeneeskundig tijdschrift 2015; 84: 
147-153.  
 
Bibl iography 
204	
Stock E . , Vanderperren K., Van der Vekens E., Haers H., Duchateau L., Polis I., Hesta M., Saunders J.H. 
The effect of anaesthesia with propofol and sedation with butorphanol on quantitative contrast-
enhanced ultrasonography of the healthy feline kidney. Veterinary Journal 2014; 202: 637-639. 
  
Vanderperren, K., Haers, H., Van der Vekens, E., Stock ,  E ., Paepe, D., Daminet, S., Saunders, J.H. 
Description of the use of contrast-enhanced ultrasonography in 4 dogs with pancreatic tumors. 
Journal of Small Animal Practice 2014; 55: 164–169.  
 
Combes A., Stock E ., Van der Vekens E., Duchateau L., Van Ryssen B., Saunders J. Ultrasonographical 
examination of feline adrenal glands: intra- and inter-observer variability. Journal of Feline 
Medicine and Surgery 2014; 16: 937-42.  
 
Raes E., Bergman E., Vanderperren K., Stock E ., Van Ryssen B., Saunders J. Computed tomographic 
features of lesions detected in horses with tarsal lameness. Equine Veterinary Journal 2014; 46: 
189-93.  
 
Stock E ., Paepe D., Daminet S. Clinical approach of feline hypercalcemia. Vlaams diergeneeskundig 
tijdschrift 2013; 82: 3-10.  
 
Stock E ., Paepe D., Verhaert L., Van de Maele I., Daminet S. Casereport – Idiopathic hypercalcemia in 
a Persian cat. Vlaams diergeneeskundig tijdschrift 2013; 82: 11-16.  
 
Abma E., Vandenabeele S., Campos M., Bosmans T., Stock E ., de Rooster H. Necrotizing fasciitis: a 
case report in a dog. Vlaams diergeneeskundig tijdschrift 2013; 82:  134-42. 
 
Research communications/abstracts  presented during scientif ic  meetings  
 
Stock E ., Daminet S., Vanderperren K., Paepe D., Saunders J.H. Contrast-echografie voor de 
diagnose van difuse nieraandoeningen bij de kat. SAVAB najaarsmeeting: work in progress, 10 
december, 2016, Gijzenzele (Belgium). Oral presentation. 
 
Bibl iography 
205	
Stock E ., Vanderperren K., Bosmans T., Duchateau L., Hesta M., Lybaert L., Vandermeulen E., 
Saunders J. Evaluation of feline renal perfusion using contrast-enhanced ultrasound and 
scintigraphy. ECVDI Annual congress, August 31 – September 3, 2016, Wroclaw (Poland). Oral 
presentation. 
 
Vanderperren K., Stock E ., Van der Vekens E., de Rooster H., Duchateau L., Saunders J. Contrast-
enhanced ultrasound of normal canine mammary glands during the estrus cycle. ECVDI Annual 
congress, August 31 – September 3, 2016, Wroclaw (Poland). Oral presentation. 
 
Dewitte H., Van Lint S., Vanderperren K., Stock E ., De Smedt S.C., Breckpot K., Lentacker I. 
Microbubbles as magic bullets in cancer immunotherapy. LKI Symposium “Tumor Immunology & 
Immunotherapy: harnessing the immune system to fight cancer”, September 12-14, 2016, Leuven 
(Belgium). Poster presentation. 
 
Stock E ., Vanderperren K., Haers H., Duchateau L., Hesta M., Saunders J. Quantitative differences are 
present between the first and second injection of contrast agent in contrast-enhanced 
ultrasonography of feline kidneys. Ultrasound contrast imaging symposium, January 21-22, 2016, 
Rotterdam (the Netherlands). Oral poster presentation. 
 
Cicchelero L., Vanderperren K., Denies S., Stock E ., Haers H., Van Brantegem L., de Rooster H., 
Sanders N. Contrast-enhanced ultrasound imaging of the anti-angiogenitic effects of interleukin-12 
in pet dogs with spontaneous malignant tumors. Ultrasound contrast imaging symposium, January 
21-22, 2016, Rotterdam (the Netherlands). Oral presentation. 
 
Stock E ., Vanderperren K., Van der Vekens E., Haers H., Duchateau L., Polis I., Hesta M., Saunders J. 
Assessment of the influence of propofol and butorphanol on contrast-enhanced ultrasonography of 
the feline kidney. Ultrasound contrast imaging symposium, January 22-23, 2015, Rotterdam (the 
Netherlands). Oral presentation. 
 
Stock E ., Vanderperren K., Van der Vekens E., Haers H., Duchateau L., Polis I., Hesta M., Saunders J. 
Assessment of the influence of propofol and butorphanol on contrast-enhanced ultrasonography of 
Bibl iography 
206	
the feline kidney. Southern European Veterinary Conference, October 16-18, 2014, Barcelona (Spain). 
Poster presentation. 
 
Stock E ., Vanderperren K., Moeremans I., Van der Vekens E., de Rooster H.,  Hermans K., Saunders J. 
Use of contrast-enhanced ultrasonography in the diagnosis of liver lobe torsion in a rabbit: case 
report. Southern European Veterinary Conference, October 16-18, 2014, Barcelona (Spain). Poster 
presentation. 
Fina C., Rossi F., Stock E ., Vanderperren K., Duchateau L., Saunders J. Effect of sedation on contrast-
enhanced ultrasonography of the spleen in healthy dogs. ECVDI Annual congress, August 27-30, 
2014, Utrecht (the Netherlands). Oral presentation. 
 
Stock E ., Vanderperren K., Van der Vekens E., Haers H., Duchateau L., Polis I., Hesta M., Saunders. The 
effect of anesthesia and sedation on contrast-enhanced ultrasound of the feline kidney. European 
Veterinary Conference: Voorjaardsdagen, April 17-19, 2014, Amsterdam (the Netherlands). Oral 
presentation. Awarded with the 2nd prize in the Boehringer research award. 
 
Vanderperren K., Cool S., Haers H., Stock E ., Fina C., Sanders N., Saunders J. The use of unloaded 
self-made microbubbles for contrast-enhanced ultrasound imaging in dogs: potential for image-
guided drug delivery in vivo. Annual scientific meeting of the British Medical Ultrasound Society, 
Decmber 9-11, 2013, Gateshead (United Kingdom). Poster presentation.  
 
Stock E ., Quist-Rybachuk G., Paes G., Hesta M. Treatment of canine acute renal failure with omega-
3 fatty acids and fermentable fiber supplementation of commercial adult diet. AAVN Clinical 
Nutrition and Research Annual Symposium, May 30, 2012, New Orleans (United States of America). 
Abstract. Awarded with the 1st prize in the AAVN case writing contest.AAVN  
 
 
 
 
 
	207	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	208	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
